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ABSTRACT 
 
Each year, millions of patients undergo reconstructive surgery to treat injuries 
caused by trauma, deformities, or tumor resection. Repair of these defects often requires 
the use of tissue grafts to promote healing. Current treatment options rely on a limited 
supply of donor tissue or synthetic materials that lack bioactivity and have a high rate of 
revision treatments. Tissue engineered grafts provide a temporary matrix that supports 
tissue regeneration and circumvents complications associated with traditional treatment 
options. In addition to biodegradable and biocompatible requirements, an injectable 
scaffold would offer the advantage of space-filling irregular defects without the need for 
expensive fabrication to shape or custom-build devices. To this end, we have utilized 
emulsion templating to create injectable polyHIPE scaffolds that are biodegradable, 
highly porous, polymerize at body temperature, and possess appropriate and tunable 
mechanical properties for tissue regeneration.  
 PolyHIPE grafts developed for this purpose exhibited tunable pore sizes (5 µm to 
1 mm) and a wide range of mechanical properties (modulus = 50 kPa-50 MPa). The 
biodegradable macromers used in these polyHIPEs were designed to polymerize at body 
temperature and have a low viscosity prior to cure, eliminating the use of toxic solvents 
common in fabricating biodegradable polyHIPEs. New methodology was developed to 
permit the rational selection of macromers based on prediction of molecular 
hydrophobicity and structural analysis of surfactant chemical structure in contrast to the 
traditional trial-and-error approach. Redox initiation was also studied as a means to 
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decrease polyHIPE cure times from hours to minutes, comparable to current bone 
cements used currently in the clinic. This new initiation method also improved 
mechanical properties and had minimal effects on pore structure. The use of a double-
barrel syringe also allowed emulsions to be stored for up to 6 months prior to cure with 
no negative effects on pore structure.  
 Finally, these polyHIPEs were used to make porous microspheres, via a double-
emulsion technique, to improve scaffold bioactivity. These microspheres successfully 
incorporated rhBMP-2 growth factor, a potent osteoinductive agent used in many bone 
graft procedures. Current rhBMP-2 delivery methods are expensive and pose safety risks 
due to the excessive amounts of growth factor used. These microspheres offer a means to 
gradually deliver site-specific dosages of rhBMP-2 directly in the polyHIPE scaffolds, 
potentially improving tissue regeneration. 
 In summary, we have developed a library of injectable porous materials that can 
be used to improve tissue regeneration. Furthermore, the emulsion structure-property 
relationships explored here can be used in designing future polyHIPEs for tissue 
engineering or other applications. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Critical Sized Bone Defects 
Bone is a nanocomposite of a stiff mineralized hydroxyapatite matrix and elastic 
collagen fibrils. The matrix gives it great strength in compression, while the collagen 
resists tensile loads. The combination of the two further improves mechanical properties, 
especially resisting bending forces and fracture. These characteristics, plus bone’s 
microstructure make it the most robust tissue in the body, capable of supporting several 
times a patient’s body weight.1-4 Bone can be divided into two types: cortical and 
cancellous. Cortical bone is dense with porosities from 5-30%, and makes up the 
diaphysis of long bones (Figure 1.1).
5
 While cortical bone is primarily used for load 
bearing, cancellous bone is much more porous (30-90%) and houses bone marrow which 
produces blood cells.  
The compressive modulus of cortical bone is 17 GPa and strength of 220 MPa, 
with tensile properties about 20% weaker.
1, 6-8
 Cancellous bone is much weaker, with a 
modulus equal to 50-100 MPa, and strength 5-10 MPa.
2, 9-17
 Taylor et al. stated that the 
highest stresses occurred at the femur midshaft with an average strain between 1200-
1500 µstrain for walking and 2000-3000 for running.
8, 18, 19
 Assuming an elastic modulus 
of 17 GPa, this equates to physiological stresses only between 20.4 and 51 MPa which is 
very similar to in vivo loads in other large mammals (40-80 MPa).
6
 One method to 
assess bone quality is fracture toughness, which can be determined with tensile testing or 
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nanoindentation. An accepted toughness for cortical bone is 5 MPa√ .
1
 Fatigue strength 
is also important, and Taylor et al. estimated that human long bones are loaded 
approximately 2 million times per year.
8
 The study found bone fatigue strengths as low 
as 23 MPa, indicating failure after 10
5
 cycles and concluding that most bone tissue 
would fail every 6 months in the absence of natural repair processes. 
 
 
 
Figure 1.1. Physiology of compact bone. Adapted from reference 5. 
 
 
This constant state of repair is a result of a balance between osteoclasts and 
osteoblasts. Osteoclasts, once activated, break down bone that is either damaged or 
unnecessary. Osteoblasts follow the osteoclasts and begin replacing the osseous tissue 
with stronger new material. Once repaired, some osteoblasts change their role to become 
osteocytes (bone cells) and continue to lay down mineralized bone matrix. However, 
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larger injuries, termed critical size bone defects, fail to heal naturally and often require 
reconstructive surgery.
20, 21
 These defects are typically a result of traumatic injury, tumor 
resection, or congenital deformities. Tissue grafts promote healing at the defect site by 
providing a template to guide regeneration. In 2004 alone, there were approximately 1.1 
million grafting procedures at an estimated cost of $5 billion.
22
  
 
1.2 Soft Tissue Regeneration 
The majority of bodily tissues can be classified as “soft” tissue, and each tissue in 
the human body has properties specific to its function, e.g. epithelial, adipose, 
connective, and musculoskeletal tissue. These functions include  maintaining body 
contours, body locomotion, and providing mechanical cushioning.
23
 Tissue mechanical 
properties vary between phenotypes, for example muscle has elastic properties to 
facilitate movement
24
 whereas cartilage is designed to lubricate joints and resist wear. A 
common property of these tissues is their elasticity and their ability to withstand cyclic 
loading while maintaining their function. Examples of tissues and their properties can 
been seen in Table 1.1. 
 
Table 1.1. Tensile properties of selected soft tissues. 
Tissue Young’s Modulus, MPa Ultimate Strain, % Ref. 
Anterior Cruciate Ligament 113 ± 45 28 ± 7 
25
 
Smooth Muscle: Relaxed 0.006 300 
24
 
Smooth Muscle: Contracted 0.010 300 
24
 
Articular Cartilage 0.9-20  
26
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Loss of soft tissue can result from trauma, burns, tumor resection, congenital 
deformities, or disease. While some tissues can be replaced with autologous grafts (e.g. 
skin, ligaments) others are commonly replaced with prosthetics (cartilage). 
 
1.3 Treatment Options 
1.3.1 Current Treatments Current treatment options for replacing damaged or 
missing tissue have their respective strengths and weaknesses but none are perfect 
solutions for restoring function. These treatments can be classified into three categories: 
autografts, allografts, and alloplasts. Tissue engineering has the potential to create new 
treatments with the best strengths and no shortcomings of the current options. 
1.3.2 Autografts and Allografts Autologous grafts are tissues harvested from 
elsewhere on the patient’s body, examples of bone autografts are the iliac crest or ribs. 
These grafts are considered the gold standard of current treatments because they contain 
the patient’s native cells, mature microstructures, vascularized tissue, and no risk of 
rejection. This allows the graft to quickly replace the function of the damaged bone, 
tendon, or muscle. Typical success rates are high, between 70-100% in vertebral fusions 
one of the most common uses for autografts.
27
 Although autografts have the highest 
potential for growth, remodeling, and their ability to osseointegrate, they have 
limitations. First, the amount of donor tissue per patient is relatively low. Second, 
retrieval of donor tissue usually results in donor site pain and morbidity.
27, 28
 
Allografts are more available than autografts, with similar success rates.
27
 Bone 
allografts are typically harvested from cadavers and ground up into a powder or paste, 
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allowing them to be used in a variety of applications. Ligament allografts can be used 
successfully, but have similar limitations to bone. These grafts have high regenerative 
capabilities, but carry an inherent risk of disease transmission, which can be mitigated by 
decellularizing the material. However, this process decreases the mechanical properties 
of allografts.  
A common problem of both auto and allografts is reliability. The quality of the 
procedure is highly dependent on graft quality which varies greatly from patient to 
patient. This causes a problem for surgeons because a procedure that works for one 
person may not work for another, and it is difficult to predict this beforehand resulting in 
costly revision surgeries and a decreased quality of life.  
1.3.3 Alloplastic Grafts A wide variety of alloplastic materials have also been 
utilized including stainless steel, titanium, methylmethacrylate resins, polyethylene, 
silicone elastomers, and hydroxyapatite ceramics.
2, 9, 15, 29-33
 Some advantages of 
alloplasts are the tunable mechanical properties, repeatable results, and their high 
availability. Drawbacks and complications inherent in the use of current alloplastic 
materials include inadequate tissue integration, limited biodegradability, and stress 
shielding. 
The first materials used for bone replacement were high strength metals such as 
steel and titanium. However, these materials are orders of magnitude stiffer than bone 
which shields the bone from carrying loads. This causes the bone remodeling process to 
favor resorption instead of rebuilding. Most recipients of metal implants have been 
elderly patients that are less active, but people are living longer now than ever before. 
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This results in more active seniors which puts increased stresses on metal implants with 
weaker bone, thus more failures and revisions.  
Polymeric biomaterials were developed because of their tunable properties that 
are similar to different body tissues. Poly(methylmethacrylate) was the first polymer 
used as bone cement for metal implants. This polymer is mixed in the operating suite 
and poured into the bone before the implant is inserted. The polymerization is extremely 
exothermic, requiring large amounts of ice to keep the surrounding tissue from burning 
up.
34-38
 Another problem with PMMA is that it is not biodegradable in vivo. Poly(lactic-
co-glycolic acid) (PLGA) polymers have been used to fabricate biodegradable tissue 
grafts for bone. The biodegradability and mechanical properties of this polymer is highly 
controllable by varying the components. Other biodegradable polyesters that can be 
formed in situ such as polycaprolactone (PCL) and poly(propylene fumarate) (PPF) have 
been developed and used for soft and hard tissue grafts.
17, 38-48
 Although biodegradable 
and injectable, these materials lack the porosity necessary to repair critical size defects. 
In situ curing hydrogels have improved mass transport properties for soft tissue repair 
but lack the mechanical strength necessary for orthopaedic applications.
49
 A scaffold 
fabrication method that is injectable and porous, with tunable mechanical properties 
would provide a significant improvement over current methods.  
 
1.4 Tissue Engineered Grafts  
1.4.1 Tissue Engineering Strategies In contrast to current treatments, tissue 
engineering strategies promote tissue regeneration by seeding living cells on or attracting 
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endogenous cells to a biomaterial scaffold and delivering appropriate bioactive cues to 
aid in cell differentiation and tissue growth.
50
 As such, tissue engineered grafts combine 
the remodeling of autografts with the availability and tunable properties of synthetic 
grafts, thus limiting the complications associated with each of these traditional 
implants.
15, 51
 These grafts could temporarily replace the function of the damaged tissue 
while regenerating and transferring loads to the developing tissue gradually. 
1.4.2 Tissue Engineering Scaffold Requirements Tissue engineering scaffolds 
typically consist of biodegradable materials that slowly erode at a rate complementary to 
tissue growth and facilitate full integration of the de novo tissue with the host tissue.
50
 In 
addition to the choice of a suitable biomaterial, the success of tissue engineered 
constructs depends on the three-dimensional scaffold architecture. An interconnected 
porous structure enables cellular ingrowth and proliferation, vascularization, and nutrient 
and metabolic waste transport.
2, 9, 10, 16, 30
 Orthopaedic applications also require scaffolds 
with adequate mechanical properties to withstand physiological loading and restore 
tissue function without causing deleterious stress-shielding effects.
2, 15, 16, 29, 52-66
 As 
noted earlier, maximum in vivo loads are estimated between 20-51 MPa.
8
 While neat 
polymers can surpass this mark
17, 66, 67
, only a few polymeric scaffolds have approached 
the lower limit.
68
 It should be noted that this is the maximum physiological stress, and 
researchers have speculated that scaffold’s minimum properties should approximate 
cancellous bone with a modulus equal to 50-100 MPa, and strength 5-10 MPa.
2, 9-17
 
TE grafts can also utilize the patient’s own cells or use suitable donor cells to 
minimize rejection, avoiding lifetime use of anti-rejection drugs and the decreased 
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immune response they cause. Finally, the ability to match the irregular geometries of 
these types of bone defects is necessary to promote osseointegration and full healing. 
Injectable grafts that cure in situ are preferable in this aspect to more costly and time-
consuming computer-aided design molds.
38, 45, 69, 70
 In summary, the advancement of 
bone tissue engineering strategies is strongly dependent on the development of high-
porosity scaffolds that meet these key requirements.  
1.4.3 Scaffold Pore Size and Porosity Tissue engineered scaffolds must be 
porous to allow for cells to proliferate and develop into tissue. A large number of porous 
scaffolds’ ability to support cells/tissues have been evaluated both in vitro and in vivo. 
Several studies have tried to determine the ideal pore size for tissue engineered scaffolds 
by measuring in vivo and in vitro results. The majority of studies showed that porosities 
between 57 and 75% with 80-500 µm pores regenerated tissue similarly but there were 
some differences, discussed briefly here.
71-83
  
Akay et al.(2004) found that although pore size didn’t effect cell depth, 40 µm 
pores had an increased number of osteoblasts whereas larger pores had faster migration 
of cells through the scaffold.
54
 Other researchers failed to find any correlation between 
these properties and cell response. In carbonate apatite scaffolds, Itoh et al. found no 
difference in fibroblast proliferation with 49-79% porosity.
82
 Similarly, Takahashi et al. 
found cell proliferation had no clear dependence on pore size in their woven scaffolds.
72
 
However, they found that proliferation increased with porosity due to the increased 
amount of space and improved nutrient transport
72
 and Lewandrowski et al. observed the 
same results with increased porosity.
71
 However, Chu et al. did not find a correlation 
 9 
 
between porosity and bone ingrowth in hydroxyapatite scaffolds with 400 µm channels 
and instead they insist that channel orientation can influence bone formation.
83
 Clearly, 
there are many complex phenomena in effect which has led to this confusion and 
disagreement. Kruyt et al. compared two scaffolds and found that scaffolds with 60% 
porosity and 400µm (60/400) pores had greater goat MSC DNA than the 70/800 
scaffolds, but the 70/800 grafts grew more bone in vivo.
81
 This study highlights why no 
single test is indicative of graft success, and that caution must be taken before comparing 
in vivo and in vitro results. Similar results were also seen in studies by Kujala et al. and 
Fisher et al.
79, 80
  
Hulbert et al. has stated that the minimum pore size is 100 µm for bone 
regeneration (Table 1.2).
78, 84
 However, a study by the Ratner group showed that 30-40 
µm pores with 15 µm interconnects best regenerated bone and induced angiogenesis, a 
critical aspect of large tissue repair.
85
 Liu et al. observed that increasing pore size from 
34 to 45.7 µm also increased bone formation, which agrees with Ratner’s findings.75, 85 
Furthermore, no maximum or optimal pore size has been discovered, as evidenced by the 
following studies. Roy et al. fabricated β-tricalcium phosphate scaffolds with 125-150 
µm pores and 80-88%, and their results supported Takahashi et al.’s findings.86 They 
observed that tissue ingrowth and bone formation increased with porosity, in rabbit 
cranial defects.
86
 Two studies of porous HA scaffolds with various pore sizes (106-600 
µm) observed increased alkaline phosphatase, osteocalcin, and bone formation with 300-
400 µm pores.
76, 77
 They also observed capillary formation at pore sizes above this 
mark.
76, 77
 Kujala et al. found that 505 µm pores elicited more fibrosis than scaffolds 
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with 209 µm pores.
80
 And other studies found seemingly contradictory results with 
smaller pores (90 µm) causing earlier chondrogenesis and larger pores (120 µm) 
skipping right to osteogenesis.
73, 74, 77
 While Fisher et al. found no difference in bone 
formation for PPF scaffolds with different porosities or pore sizes.
79
  
Due to the complex nature of tissue regeneration, no single best option has been 
found. Further studies are needed to truly guide graft design but until then graft materials 
must be tunable to meet the changing demands and theories about tissue regeneration. 
 
Table 1.2. Type of tissue formed in vivo vs interconnect size. 
Tissue Interconnect Size, µm Ref 
Fibrous 5-15 
84
 
Osteoid 40-100 
84
 
Mineralized Bone 100 
84
 
 
 
1.4.4 Scaffold Fabrication Strategies Tissue engineers have developed 
numerous fabrication strategies to create 3D bone grafts to meet the various 
requirements outlined above.
12, 14, 16, 17
 The selected fabrication process dictates scaffold 
architecture which is a critical design feature given the effect of architecture on construct 
mechanical properties, degradation rate, and cellular response. In particular, generation 
of a scaffold with high porosity that retains sufficient mechanical strength for 
orthopaedic applications remains challenging. The most common techniques to produce 
porous scaffolds include particulate leaching, gas foaming, thermal induced phase 
separation, and fiber bonding.
38, 45
 Several of these strategies provide exceptional 
architectural control; however, matching construct geometry to the contours of the defect 
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is generally limited to the mold used in fabrication or post-fabrication shaping. In situ 
forming scaffolds can fill irregular shaped defects, improve contact between the scaffold 
and surrounding tissue, and eliminate the need for costly molding techniques.
87
 
Electrospinning allows for the generation of highly porous fibrous meshes.
14, 88
 
these meshes are typically in the form of tubes or sheets, ideal for regenerating skin or 
vascular tissue. While they have tunable tensile properties, electrospun meshes cannot be 
loaded in compression. Also, the flat meshes are not ideal for the complex geometries 
needed to regenerate bone. Finally, electrospun meshes will never be injectable since 
they require the use of solvents and a grounded collector. 
Gas foaming is the process whereby pores are generated in a polymer melt by the 
production of gas from either chemical or physical means.
12
 These foams can be 
controlled to possess a wide range of pore sizes 190-400 µm and interconnected 
porosities.
12, 13
 Scaffolds produced in this manner could be formed in a mold to generate 
complex shapes. However, these foams usually have a non-porous skin which needs to 
be removed prior to implantation.
12
 Also, the high temperatures and pressures typically 
required to generate the pores prevent them from being formed in situ. 
Thermal induced phase separation (TIPS) creates porous polymer scaffolds by 
quickly quenching a polymer melt. This changes the solubility of the solvent causing it 
to separate out of the polymer phase, and form droplets. Freeze-drying the foams 
removes the solvent, leaving a porous polymeric scaffold. The process can be controlled 
in such a way to create long aligned pores or spherical pores.
44, 89
 These scaffolds can be 
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shaped to fit any defect, but the solvent and low temperatures prevent them from being 
injectable. 
Porogen leaching is a very simple method to produce scaffolds. The porogen, 
typically a salt, is mixed with a liquid polymer melt, cured, and then the salt is dissolved 
out
16, 17
 and sintering the porogen can create open porous structures. These scaffolds can 
be injectable and biodegradable if the proper salt and polymer are chosen.
85, 90, 91
 
However, the pores left by salt crystals have sharp corners which act as stress 
concentrators and lower the mechanical properties of salt leached scaffolds limiting their 
use in load-bearing applications.
17, 45, 46, 92
 
Hydrogels have become very popular with soft tissue engineering because of 
their ease of fabrication and resultant physical properties.
38, 47, 85, 91, 93-98
 Their 
mechanical properties can be tuned to match most soft tissues in the human body. PEG 
hydrogels are useful because cells do not naturally bind to them, but this can be 
controlled by incorporating motifs such as RGD peptides. Recent studies have utilized 
injectable hydrogels for bone regeneration;
38
 however, their low mechanical strength 
does not permit defect stabilization and requires additional fixation.  
Shape memory polymers have the ability retain a temporary geometry and later 
return to their original dimensions upon exposure to external stimuli such as heat.
99
 
These materials have garnered interest in the biomedical field for use in minimally 
invasive surgeries because they can be compressed to a small size and then actuate to 
their functional shape in situ. Recently, shape memory polymers have also been 
investigated as space-filling scaffolds to match irregular defects and overcome 
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shortcomings of current treatments.
100-103
 Their mechanical properties typically 
approximate soft-tissues
102
, making them a viable alternative to injectable scaffolds.
101
 
However, it is not clear if cells could be encapsulated into the foams and survive the 
shear forces and temperatures associated with shape programming, and non-uniform 
expansion in irregular defects may change material characteristics such as pore size and 
mechanical properties. 
 
1.5 Polymerized High Internal Phase Emulsions (PolyHIPEs) 
Polymerization of high internal phase emulsions (polyHIPEs) is a relatively new 
method to produce high porosity scaffolds.
53, 104
 High internal phase emulsions (HIPEs) 
are characterized by an internal droplet phase volume fraction greater than 74%. 
Polymerizing the HIPE’s continuous phase locks in the emulsion geometry at the gel 
point to generate a high porosity monolith or polyHIPE, Figure 1.2.
53-66, 105
 A wide 
range of porosities (75-99%), pore sizes (1-100 µm), compressive moduli (2 kPa-60 
MPa) and morphologies (open- vs. closed-pore) can be produced by varying the HIPE 
composition and processing variables.
11, 49, 54, 55, 106, 107
 The spherical pores also eliminate 
stress concentrators, like those seen in salt leached scaffolds, increasing mechanical 
properties. A unique feature of the polyHIPE system is that the HIPE retains a viscosity 
that is suitable for injection prior to cure. An injectable polyHIPE system requires 1) 
biodegradable macromers with low viscosities for emulsion formation and 2) reaction 
thermodynamics that allow for HIPE polymerization at physiological conditions. 
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Figure 1.2. Comparison of polyHIPE structure to cancellous bone. PolyHIPE scaffold 
on the left and bone tissue on the right, from reference 56. 
 
 
Previous research on the development of polyHIPE bone grafts has focused on 
styrene-based or unsaturated polyester-based macromers.
56, 65, 108, 109
 Several research 
groups have developed methods to control PS/DVB polyHIPE pore architecture such as 
surfactant concentration, and aqueous addition rate.
53, 54, 56, 63, 67, 110-112
 These scaffolds 
were fabricated with 5-100 µm and interconnects from 0.6-30 µm, see Table 1.3.
54, 67, 113
 
Although these styrene-based systems had controllable pore morphology, they were non-
biodegradable which limited their use as tissue engineered scaffolds. Biodegradability 
was achieved by substituting in unsaturated polyesters such as PCL and polyfumarates; 
however, the macromers studied were often too viscous to form HIPEs without the use 
of toxic diluents, such as toluene. 
17, 35, 36, 45, 71
 These biodegradable polyHIPEs had much 
larger pore sizes (5-3000 µm) but smaller interconnects than their vinyl counterparts.
56, 
109, 114-116
 This increase in pore size is hypothesized to result from decreased emulsion 
stability with the addition of PCL macromer.
11, 56, 109, 115, 116
 An exception to this is the 
polyHIPE fabricated by David et al., where the macrospores were formed by CO2 gas, a 
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product of urea formation between isocyanate functional groups in the presence of 
water.
109
 
 
 
Table 1.3. Selected polyHIPE compositions and pore sizes. 
Materials Surfactant 
Pore Diameter 
(µm) 
Interconnect 
Size (µm) 
Ref 
PS, DVB Span 80 73-90 16-26 
110
 
  40-100 15-30 
54
 
  35-104 11-26 
117
 
  20-45 1-16 
65
 
  5-100 NR 
67
 
PS, DVB, THF Span 80 5-100 1-5 
55
 
PS, DVB, Toluene Span 80 10 NR 
118
 
DVB, EVB Span 80 20-30 0.65-2.55 
113
 
PS, PMMA, PLA Span 80 
 Span 85 
 Tween 85 
Synperonic PE 
L121 
5-20 NR 
11
 
PCL-vinyl Span 80 
Span 85 
Tween 80 
Synperonic PE 
L121 
5-100 NR 
56
 
PCL, tBA, DVB Span 80 5-3000 0.2-2 
115
 
PCL-triol, HDI, THF PGPR 4125 5-100, CO2=1000 0.1-10 
109
 
HA polyHIPE NR NR NR 
106
 
PPF, PFDA, Toluene Span 80 10-400, >500 2-5 
114
 
Semi-IPN 
PCL-diols and vinyls 
Span 80 60-285 0.1-1 
116
 
IPN, Semi-IPN  
PS,DVB, dodecanediol 
Span 80 
PGPR 90 
0.61-2.83 ~0.2 
108
 
Hydrogel—polyHIPE 
Hydroxyapatite 
Span 80 100 NR 
94
 
 
 
 
Despite the different researchers and properties, the surfactant choice is very 
consistent. Span 80 was chosen for all but a handful of previous polyHIPE studies, and 
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every PS-DVB composition.
54, 55, 67, 108, 110, 113, 117, 118
 Utilizing new surfactants like 
Tween 80, Synperonics, and PGPR, allowed for PCL-based polyHIPEs to be fabricated 
successfully.
11, 56, 109
 Further use of new surfactants could facilitate the use of new 
biodegradable polymers and pore structures. 
 
1.6 Tailoring Polymer Mechanical Properties 
This large range in pore sizes with positive in vivo results allows researchers to 
focus on other properties (e.g. compressive strength) with confidence that resultant pore 
sizes will be sufficient for tissue regeneration.
40, 90, 119-124
 Tissue graft mechanical 
properties are influenced by many factors, including: bulk material properties, pore size, 
and porosity. Increasing the porosity and pore size of a scaffold may increase tissue 
regeneration but usually decreases mechanical properties as well. Understanding how 
one affects the other is important for scaffold design. As described below, sometimes the 
easiest way to improve the construct’s strength is to change the material’s properties. 
1.6.1 Effect of Porosity on Mechanical Properties Mechanical properties of 
scaffolds are inversely related to porosity, but the connection is less clear with pore size. 
Barralet et al., Lin et al., Burdick et al., Fisher et al., and Porter et al. all observed a drop 
in mechanical properties with an increase in porosity, for a variety of scaffold 
materials.
40, 90, 119, 122, 123
 Burdick and Fisher’s studies state that 80% porosity is the 
critical point, above which properties deteriorate.
40, 122
 Porter et al. report that only 
elastic bending modulus was unchanged by increased porosity.
119
 Barralet further states 
that increased pore size decreased mechanical strength and modulus
90
, but this was not 
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seen in other studies. A study by Borden et al. increased pore size from 72-164 µm, 
without changing porosity, and found a decrease in modulus from 297 to 232 MPa.
124
 
Burdick et al. increased pore size from 45 to 300 µm and found an increase in modulus 
with no change in yield strength
122
, contradicting Borden et al.
124
 
1.6.2 Tuning Polymer Chemistry Polymer physical properties are strongly 
influenced by their chain/network structure. Higher molecular weight polymers have 
increased modulus and toughness over low molecular weight materials.
120
 This is due to 
chain entanglements resisting deformation of the polymer. However, networked 
polymers behave differently. In this case, crosslink density is a key determinant in 
mechanical properties. The lower the molecular weight between crosslinks, the higher 
the crosslink density and the higher the modulus. Materials may also become brittle if 
crosslink density gets too high. Although counterintuitive, the network may be so 
tightly-woven that it stearically hinders interchain crosslinking resulting in many highly 
crosslinked but separate networks instead of one giant network throughout the whole 
material. This behavior is seen most frequently in low molecular weight multi-functional 
monomers, such as EGDMA. 
1.6.3 Composite Materials with Improved Mechanical Properties Composites 
are a combination of multiple components to yield materials with new and unique 
properties not seen in either individual component. These materials may have increased 
strength or reduced weight, some examples are reinforced concrete or cortical bone. 
Because cortical bone is made up of rigid hydroxyapatite matrix and elastic collagen, 
researchers have attempted to make similar materials. Porter et al. created composites of 
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β-tricalcium phosphate and PPF and found that increasing the ratio of rigid β-TCP 
enhanced all mechanical properties.
119
 
Another way to tailor the scaffold mechanical properties is by creating 
polyHIPEs with interpenetrating polymer networks (IPNs) or semi-IPNs. IPNs are 
defined by multiple crosslinked networks that are not covalently bonded together but 
cannot be separated without breaking chemical bonds, whereas semi-IPNs contain only 
one crosslinked network intertwined by separate polymer chains. IPNs are useful 
because they combine the properties of their component networks to yield a material 
with new and unique attributes, e.g., raising the Tg
125, 126
, or increasing elasticity
48, 116, 
127
. Polyurethane-polystyrene (PU-PS) IPNs have been made numerous times to toughen 
the brittle PS.
108, 125, 126
 
 
1.7 Permeability in Porous Scaffolds 
Pore interconnectivity is necessary to facilitate mass transport through the graft, 
and can be quantified via Darcy’s permeability constant, K.91, 128 At low flow rates, such 
as those seen in permeability tests, K can be solved using Darcy’s law (Equation 1). In 
this form, v0 is the superficial velocity and is defined as the number of cubic meters of 
fluid passing through a square meter of the porous medium every second.
128
 Fluid 
viscosity, µ, length of the scaffold, ∂x, and the pressure differential, ∂P, are the other 
variables. Permeability has been mathematically linked to pore size, porosity, and 
tortuosity, τ. Tortuosity is a unit-less measure of the fluid path length through the porous 
medium, which is also determined experimentally.  
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(1.1)        
  
  
 
Several researchers have studied permeability in tissue engineered scaffolds to 
find relationships between pore structures and cell/tissue viability.
129
 Botchwey et al. 
developed a 1-dimensional model to compare glucose diffusion in scaffolds resulting 
from different types of bioreactors.
129
 Their study found that internal flow rates 
increased with increased pore size or a decreased tortuosity.
129
 For the scaffolds tested, a 
minimum flow of 7.4 x 10
-5
 m/s was required for glucose to fully permeate the graft 
(thickness = 2.5 mm).
129
  
Permeability can be related to solute diffusion
129
 and cell viability, but no 
required values have been stated. The goal of researchers has been to increase porosity 
with the assumption that this will increase permeability and diffusion. The higher the 
diffusion coefficient, the better the mass transport and the larger the graft can be. 
Cancellous and cortical bones have K values between 4.45x10
-8 
and 1.1x10
-13 
m
2
,
130, 131
 
similar to reported permeabilities of several porous scaffolds.
132, 133
 
 
1.8 Summary and Future Directions 
Tissue engineered grafts have the potential to regenerate large tissue defects as 
well or better than current treatments. Research efforts have focused on how materials, 
scaffold fabrication, and scaffold properties affect tissue regeneration but there is still 
more to be understood. Creation of an injectable and biodegradable scaffold for tissue 
engineered grafts would allow the grafts to fill complex shapes easily and completely, 
improving tissue integration and regeneration. These grafts must have tunable properties 
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that match a variety of native tissues and allow use for hard or soft tissue reconstruction. 
For the grafts to be successful, attention must be paid to scaffold degradation, porosity, 
pore size, mechanical properties, and permeability.  
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CHAPTER II  
INJECTABLE POLYHIPES AS HIGH POROSITY BONE GRAFTS
*
 
 
2.1 Introduction 
Large bone defects resulting from traumatic injury, tumor resection, or 
congenital deformities fail to heal naturally and often require reconstructive surgery. 
Bone grafts promote healing at the defect site by providing a template to guide new 
tissue formation. Tissue engineering strategies promote bone regeneration by seeding 
living cells on or attracting endogenous cells to a biomaterial scaffold and delivering 
appropriate bioactive cues to aid in cell differentiation and tissue growth.
50
 As such, 
tissue engineered bone grafts combine the osseointegration and remodeling of autografts 
with the availability and tunability of synthetic grafts, thus limiting the complications 
associated with each of these traditional implants.
15, 51
  
Tissue engineering scaffolds typically consist of biodegradable materials that 
slowly erode at a rate complementary to tissue growth and facilitate full integration of 
the de novo tissue with the host tissue.
50
 In addition to the choice of a suitable 
biomaterial, the success of tissue engineered constructs depends on the three-
dimensional architecture of the scaffold. An interconnected porous structure enables 
cellular ingrowth and proliferation, vascularization, and the transport of nutrients and 
metabolic waste. 
2, 9, 10, 16, 30
 Orthopaedic applications also require scaffolds with 
                                                 
*
 Reprinted with permission from “Injectable PolyHIPEs as High-Porosity Bone Grafts,” by Robert S. 
Moglia, Jennifer L. Holm, Nicholas A. Sears, Caitlin J. Wilson, Dawn M. Harrison, and Elizabeth 
Cosgriff-Hernandez, Biomacromolecules 2011, 12 (10), 3621-3628. Copyright (2011) American Chemical 
Society. 
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adequate mechanical properties to withstand physiological loading and restore tissue 
function without causing deleterious stress-shielding effects.
2, 15, 16, 29, 52
 Finally, the 
ability to match the irregular geometries of these types of bone defects is necessary to 
promote osseointegration and full healing. Injectable grafts that cure in situ are 
preferable in this aspect to more costly and time-consuming computer-aided design 
molds. In summary, the advancement of bone tissue engineering strategies is strongly 
dependent on the development of high-porosity scaffolds that meet these key 
requirements.  
Tissue engineers have developed numerous fabrication strategies to create 3D 
bone grafts.
2, 9-17
 The selected fabrication process dictates scaffold architecture which is 
a critical design feature given the effect of architecture on construct mechanical 
properties, degradation rate, and cellular response. In particular, generation of a scaffold 
with high porosity that retains sufficient mechanical strength for orthopaedic 
applications remains challenging. The most common techniques to produce porous 
scaffolds include particulate leaching, gas foaming, thermal induced phase separation, 
and fiber bonding.
12, 14, 16, 17
 Many of these strategies provide exceptional architecture 
control; however, control of the construct geometry (e.g. to match the contours of the 
defect) is generally limited to the mold used in fabrication or post-fabrication shaping. In 
situ forming scaffolds can fill irregular shaped defects, improve contact between the 
scaffold and surrounding tissue, and eliminate the need for costly molding techniques.
38, 
45
 Poly(methyl methacrylate) (PMMA) bone cements are perhaps the most widely used 
injectable material in orthopaedics; however, PMMA is non-degradable which may 
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impede bone healing.
38
 Recently, investigators have developed highly crosslinked, 
degradable networks such as poly(propylene fumarates) and polyanhydrides that can be 
formed in situ using either thermal or photoinitiated crosslinking.
34-37
 Although 
biodegradable and injectable, these materials lack the porosity necessary to repair critical 
size defects. In contrast, in situ curing hydrogels have sufficient mass transport 
properties but lack the mechanical strength necessary for orthopaedic applications. A 
scaffold fabrication method that is injectable and porous, yet retains high mechanical 
strength would provide a significant improvement over current methods.  
Polymerization of high internal phase emulsions (polyHIPEs) is a method for the 
production of high porosity scaffolds.
114
 High internal phase emulsions (HIPEs) are 
characterized by an internal droplet phase volume fraction greater than 74%. 
Polymerization of the HIPE’s continuous phase locks in the emulsion geometry at the 
gel point to generate a high porosity monolith or polyHIPE.
53, 104
 A wide range of 
porosities (75-99%), pore sizes (1-100 µm), compressive moduli (2 kPa-60 MPa) and 
morphologies (open- vs. closed-pore) can be produced by varying the HIPE composition 
and processing variables.
53-66
 A unique feature of the polyHIPE system is that the HIPE 
retains a viscosity that is suitable for injection prior to cure. An injectable polyHIPE 
system requires 1) biodegradable macromers with suitable viscosities for emulsion 
formation and 2) reaction thermodynamics that allow for HIPE polymerization at 
physiological conditions. Previous research on the development of polyHIPE bone grafts 
has focused on styrene-based or unsaturated polyester-based macromers.
11, 54, 55, 106, 107, 
114
 Although past styrene-based systems had excellent pore morphology, they were non-
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biodegradable which limited their use as tissue engineered scaffolds. Biodegradability 
was achieved by substituting in unsaturated polyesters; however, the macromers studied 
were often too viscous to form HIPEs without the use of a toxic diluent, such as toluene. 
56, 65, 108, 109
  
We have developed a biodegradable and injectable polyHIPE system based on 
propylene fumarate dimethacrylate (PFDMA) macromers.  The viscosity of PFDMA is 
suitable for HIPE formation and reactive methacrylate end groups enable in situ 
crosslinking into rigid monoliths at 37˚C. Furthermore, fumarate-based polymers have 
shown great promise as bone grafts with established osteoconductivity in vivo.
35, 36, 134
 
PFDMA polyHIPEs exhibited ~75% porosity, pore sizes ranging from 4 to 29 µm, and 
an average compressive modulus and strength of 33 and 5 MPa, respectively. The ability 
to synthesize a fully biodegradable polyHIPE without a toxic diluent that can also cure at 
physiological temperatures is an important adaptation of emulsion templating. These 
new polyHIPEs have potential application as an injectable, tissue engineered bone graft. 
 
2.2 Materials and Methods 
2.2.1 Materials Polyglycerol polyricinoleate (PGPR 4125) was donated by 
Paalsgard and PEG 600 dilaurate was donated from Unitex Chemical. All other 
chemicals were purchased from Sigma Aldrich. All chemicals were used as received. 
2.2.2 PFDMA Synthesis PFDMA was synthesized in a two-step process adapted 
from Timmer et.al.
41
 First, propylene oxide was added dropwise to a solution of fumaric 
acid and pyridine in 2-butanone (2.75:1.0:0.033 mol). The reaction was refluxed at 80˚C 
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until the fumaric acid completely reacted, approximately 19 hours. Residual propylene 
oxide and 2-butanone were then removed in two distillations steps and the product 
redissolved in dichloromethane. The solution was then washed in 0.2 M NaOH/brine 
(6:4 v/v) until basic to remove residual acidic byproducts, washed with brine, and stirred 
over anhydrous sodium sulfate to remove residual water. Dichloromethane was removed 
using rotary evaporation to yield the diester bis (1,2 hydroxypropyl) fumarate product as 
a colorless liquid. The diester was then end-capped with methacrylate groups in an 
addition process with triethylamine and methacryloyl chloride. Hydroquinone was added 
to inhibit crosslinking during the synthesis. The molar ratios of the diester, methacryloyl 
chloride, triethylamine, and hydroquinone were 1:2.1:2.1:0.016, respectively. The 
reaction was maintained below -10˚C to reduce undesirable side reactions and stirred 
vigorously overnight under a nitrogen blanket. The macromer was filtered to remove 
triethylamine salt and neutralized overnight in 2 M potassium carbonate. The solution 
was washed in 0.1 M NaOH/brine (6:4 v/v) to remove residual byproducts, washed with 
brine, and stirred over anhydrous sodium sulfate to remove residual water. The 
dichloromethane was removed by rotary evaporation and the PFDMA structure 
confirmed using 1H NMR (300 MHz, CdCl3) δ 1.33 (dd, 3H, CH3), 1.92 (s, 3H, CH3), 
4.20 (m, 2H, -CH2-), 5.30 (m, 1H, -CH-), 5.58 (s, 1H, -C=CH2), 6.10 (s, 1H, -C=CH2), 
6.84 (m, 2H, -CH=CH-). The final product was a low viscosity liquid with a pale yellow 
to amber appearance. 
2.2.3 Surfactant Study Sorbitan monooleate (Span 80), PEG 600 dilaurate, 
Tween 80, and PGPR 4125 were studied to observe their effect on PFDMA HIPE 
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formation. Each surfactant had different hydrophilic-lipophilic balance (HLB) values 
and different hydrogen bond donor sites (Table 2.1). PFDMA, surfactant, and DI water 
(2, 0.4, 8g, respectively) were vortexed for 5 minutes. The mixture qualified as a HIPE if 
all of the water incorporated and it had a high viscosity similar to mayonnaise. The 
scouting compositions which resulted in HIPEs were fabricated full-scale to investigate 
the effect of surfactant structure on pore architecture.  
 
Table 2.1. The effect of hydrogen bond donor site location and HLB value on HIPE 
formation. 
Hydrogen Bond Donor Site Location 
Surfactant Polar Head Hydrophobic Tail HLB value HIPE Formed 
Span 85 1 0 1.8 no 
Span 80 3 0 4.3 no 
PGPR 4125 0 3 4.7 yes 
PEG 600 Dilaurate 0 0 11.7 no 
Tween 80 3 0 15 no 
 
 
2.2.4 HIPE Fabrication HIPEs were prepared using the FlackTek Speedmixer 
DAC 150 FVZ-K. Briefly, PFDMA was mixed with the surfactant PGPR in the 
Speedmixer cup prior to emulsification. The PGPR concentrations used in this study 
were 5, 10, 15, and 20 wt%. Once thoroughly mixed, the aqueous solution of calcium 
chloride (1% v/v), ammonium persulfate (5 wt %) and deionized water was then added 
to the organic phase in the speedmixer cup. The calcium chloride was used to prevent 
Ostwald ripening while the ammonium persulfate initiated radical crosslinking of the 
macromer chains. HIPEs were then transferred to a 37°C aluminum bead bath for 12 
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hours to facilitate cross-linking. The resulting polyHIPE foams were placed under 
vacuum for 24 hrs to remove water prior to characterization. 
2.2.5 Gravimetric Analysis PolyHIPE porosity was measured gravimetrically. 
Briefly, dried HIPE samples were cut into cubic sections (9 x 9 x 3 mm) and weighed.  
Following equation 1, the HIPE porosity can be calculated by comparing HIPE density 
(ρH) with the bulk polymer’s density (ρP).  Reported values are an average of nine 
sections per polyHIPE composition. 
(2.1)  Porosity     
ρH
ρP
 
2.2.6 SEM Analysis Scanning electron microscopy (SEM) was utilized to 
characterize the polyHIPEs pore architecture. Circular specimens were sectioned into 
quarters, fractured at the center of the quarter, sputter-coated with gold, and imaged 
using FE-SEM (JEOL JSM-7500F). Images at 250x were utilized to determine the 
average pore size when the pores were 25-100 µm. Higher magnification (500x, 1000x) 
images were utilized to determine the average pore size when the pores were less than 
25µm. Each section was imaged in a rastor pattern yielding five images. Measurements 
were made on the first 10 pores along the image median to minimize user bias. Averages 
pore sizes for each polyHIPE composition are reported (n=150). A statistical correction 
was calculated to account for non-perfect spherical pores,            where R is the 
void diameter’s equatorial value, r is the diameter value measured from the micrograph, 
and h is the distance from the center. The average diameter values were multiplied by 
this correction factor resulting in a more accurate description of pore diameter. 
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2.2.7 In vitro Cell Proliferation Investigation of 3T3 fibroblast viability was 
done to assess polyHIPE cytocompatibility. Cell viability was determined using the 
Live/Dead Viability/Cytotoxicity Kit (Molecular Probes). NIH/3T3 Swiss mouse 
fibroblast were purchased (ATCC-CCL92) and cultured in vitro with Dulbecco’s 
Modified Eagle Medium (DMEM), Glutamax, high glucose supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) and 1% Penicillin-Strepotomycin solution 
(Gibco). The polyHIPE sample comprised of 5 wt% PGPR, 75/25 volume fraction, and 
mixed at 500 rpm was chosen for cytocompatibility testing because it possessed the 
largest pore sizes and contained the least amount of surfactant which could potentially 
disrupt the cell membrane. PolyHIPE foams were prepared for cell seeding as follows: 
UV irradiation (1 hour per side), ethanol wetting ladder and progressive solvent 
extraction, and overnight media incubation supplemented with 40 v/v% FBS in DMEM. 
Following overnight incubation in 37°C, 5% CO2, medium was removed, specimens 
were dried in the hood for 30min, washed 1x with PBS and pre-conditioned with growth 
medium for 15 min. Cells were seeded into wells at 10,000 cells/cm
2
. Live/Dead staining 
was conducted at 24 hours and images taken using fluorescence microscope (Nikon 
Eclipse TE2000-S).  
2.2.8 Mechanical Testing The foams mechanical properties were all tested with 
an Instron 3300, equipped with a 1000-N load cell. Three specimens were taken from 
each sample. The test specimens were cut into flat rectangular shapes (9 x 9 x 3 mm) and 
compressed at 50 µm/s.
92
 The calculations in ASTM method D1621-04a 
135
 were used to 
determine the compressive modulus. Briefly, a straight edge and computer software were 
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used to determine the linear region of the stress-strain curve by extending a line from the 
steepest slope of the curve to the zero-load axis.  The point at which this line crossed the 
axis was determined to be where strain equaled zero and all data points were shifted 
accordingly.  The elastic modulus was equal to the slope of the line in the linear region, 
as outlined in the ASTM method. Reported moduli data was an average of the three 
sections for each sample tested (n=9).  
2.2.9 Statistical Analysis The data are displayed as mean ± standard deviation for 
each composition. A Student’s t-test was performed to determine any statistically 
significant differences between compositions. All tests were carried out at a 95% 
confidence interval (P<0.05). 
 
2.3 Results and Discussion 
2.3.1 PFDMA Synthesis and Analysis PFDMA was synthesized by the two-step 
reaction described previously. The first step produced a diester intermediate, bis-(1,2-
hydroxypropyl) fumarate, which was then functionalized with methacrylate endgroups, 
Figure 2.1.  Following purification, the structure of the resulting PFDMA product was 
confirmed with 1H NMR. The integration ratio of methacryloyl protons to fumarate 
protons in the
 
1H NMR spectra, Figure 2.2, confirmed the structure of PFDMA as a 
single fumarate unit with two terminal methacrylate groups. The average 
functionalization was calculated to be ~83%. The methacrylate and fumarate groups 
provided sites for radical crosslinking of the macromer to permit cure of the HIPE at 
physiological temperatures. Furthermore, fumarate-based bone grafts have shown 
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promising osteoconductivity results in vivo.
35, 36, 134
 The resulting macromer had a 
sufficiently low viscosity (125 cP) and hydrophobicity to permit HIPE formation.  
 
 
 
Figure 2.1. Molecular structure of (A) bis (1,2 hydroxypropyl) fumarate and (B) 
PFDMA. 
 
 
 
Figure 2.2. Nuclear magnetic resonance spectrum of PFDMA. 
 
 31 
 
Model predictions of the octanol-water partition coefficients (LogP) were used in 
these studies as a means of comparing molecular hydrophobicity.
136
 LogP values are a 
measure of the differential solubility of a compound between two immiscible solvents, 
typically water and a hydrophobic solvent such as octanol. Log P values range from 
negative to positive where a negative value corresponds to a hydrophilic molecule and a 
positive value a hydrophobic one. The method used in these studies for LogP prediction 
was developed at Molinspiration (miLogP2.2 – November 2005). The LogP value of 
each compound was calculated from the sum of its non-overlapping molecular 
fragments. The group contributions were obtained by fitting calculated LogP with 
experimental LogP for a training set of more than twelve thousand molecules. The LogP 
value of PFDMA (3.4) was comparable to macromers that have previously formed stable 
HIPEs, Table 2.2. 
 
Table 2.2. Estimated octanol-water partition coefficients. 
Molecule LogP 
a
 
Styrene 2.8 
Divinyl benzene 3.6 
PFDA 2.3 
PFDMA 3.4 
PPF (n = 5) 2.4 
PPF (n = 6) 3.1 
a
Octanol-water diffusion coefficient calculated with the Molinspiration miLogP model 
based on  molecular structures. 
 
 
2.3.2 Selection of HIPE Surfactant Surfactant choice and concentration play a 
large role in emulsion stability and successful HIPE formation.
53, 56, 63, 67
  Selection of 
HIPE surfactants has largely been based on trial and error and historical precedence. One 
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method of characterizing surfactants is their hydrophilic-lipophilic balance (HLB) 
classification. Typically, empirical testing is used to ascertain what HLB values are 
suitable for each application with an HLB range of 2-6 designated for water-in-oil 
emulsions.
111
 Although several investigators have indicated the limitations of the HLB 
approach, in this study, we attempt to identify structural features and predictors that may 
be used to rationally select surfactants for new HIPE macromers. It was hypothesized 
that a relationship between surfactant HLB and organic phase hydrophobicity may exist 
which could then be used to select appropriate surfactants for the PFDMA HIPE. Log P 
values were utilized as a comparison between established HIPE macromers/monomers 
and PFDMA, Table 2.2. The most widely studied polyHIPE system is styrene and 
divinylbenzene with LogP values ranging from 2.8 - 3.6. The surfactant Span 80 (HLB = 
4.3) is typically used to stabilize styrene-based HIPEs. Therefore, it was hypothesized 
that PFDMA HIPEs with a log P of 3.4 should also form stable emulsions with Span 80. 
Surprisingly, Span 80 did not stabilize PFDMA emulsions despite the similarity between 
LogP and HLB values.  Additional surfactants and combinations of surfactants with 
similar structures as Span 80 but a range of HLB values from 1.8-15 were investigated, 
Table 2.1, but these too failed to form stable HIPEs with PFDMA. These studies 
indicate that HLB alone is insufficient as a selection criteria for stable HIPE formation. 
Surfactant structures were compared to determine differences that might affect 
PFDMA emulsification. It was determined that all of the surfactants tested had hydrogen 
bond donor sites in the polar head, Figure 2.3. PFDMA has multiple hydrogen bond 
acceptor sites in its backbone that could interact with the polar head of the surfactant. It 
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was hypothesized that this hydrogen bonding could prevent the polar head of the 
surfactant from interacting with the aqueous phase of the emulsion, thereby attenuating 
its ability to stabilize the organic/water interface. Previous fumarate and ester-based 
systems that were effectively stabilized with Span 80 utilized a non-polar solvent (e.g. 
toluene) which may have interrupted the hydrogen bonding.
11, 56, 114, 137
  To avoid using a 
toxic diluent, a surfactant without hydrogen bond donor sites in the polar head was 
needed with the appropriate HLB value. The organic soluble emulsifier, polyglycerol 
polyricinoleate (PGPR), was selected to test this theory based on its comparable HLB 
(~4.7) and lack of hydrogen bond donor sites in its polar region. This surfactant has also 
been used to generate water-in-oil HIPEs with ester-based macromers.
108, 109, 138
 
Successful formation of PFDMA HIPEs resulted with the addition of PGPR suggests 
that hydrogen bonding does indeed play a critical role in surfactant stabilization of high 
internal phase emulsions. Further investigation of surfactants that lack donor sites in 
their polar head could expand the number of biodegradable polymers utilized in 
emulsion templating given that many biodegradable polymers (e.g. polyesters) have 
hydrogen bond acceptor sites in their backbone.  
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Figure 2.3. Comparison of hydrogen bond donor sites in two common surfactants. (A) 
Span 80 has 3 in the polar head, whereas (B) PGPR 4125 has 3 in the hydrophobic tail. 
 
 
2.3.3 Injectable Porous Scaffolds Stable PFDMA HIPEs were incubated at 37°C 
to initiate radical crosslinking of the unsaturated double bond of the methacrylate 
groups. The resulting polyHIPE monoliths exhibited ~75% porosity and an average 
compressive modulus and strength of 33 and 5 MPa, respectively. SEM analysis was 
utilized to determine pore size and morphology. Polymerization of the continuous phase 
of the HIPE locked in the emulsion geometry resulting in a high-porosity foam with a 
closed-pore morphology and average pore size ranging from 4 – 29 µm, Figure 2.4. 
These studies represent an important milestone in the development of an injectable bone 
graft. Specifically, these polyHIPEs utilize a biodegradable and osteoconductive 
polymer, have a suitable pre-cure viscosity for injection; and cure at physiological 
temperatures to a rigid, high-porosity monolith. The potential utility of this new 
polyHIPE system as an injectable bone graft is illustrated in Figure 2.4. 
Cytocompatibility analysis of 5 wt% PGPR specimens yielded good viability of 3T3 
fibroblasts after 24 hours as illustrated in Figure 2.5. 
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Figure 2.4. Injectable PFDMA polyHIPEs can be used in situ to space fill complex 
defects without the need for expensive CAD software. 
 
 
An open-pore morphology is a common design goal for tissue engineering 
applications to facilitate tissue ingrowth and nutrient/waste transport. Previous studies 
have investigated the mechanisms that govern pore opening in the polyHIPE system.
53, 
63, 114
 Interconnect formation in HIPE systems has been attributed to shrinkage of the thin 
polymer film separating droplets that occurs as monomer is converted to higher density 
polymer. If this film between droplets is sufficiently thin, shrinkage results in a window 
opening and expanding. Therefore, whether a HIPE forms an open- or closed-pore 
morphology upon polymerization is related to both initial film thickness between 
droplets and densification during polymerization which initiates pore opening.
53, 56
 Film 
thickness is dictated by the aqueous phase volume and droplet size; whereas, 
densification is related to structural features of the polymer. Current studies are 
underway to investigate these two mechanisms with the goal of generating open-pore, 
fumarate-based polyHIPEs.  
 
1. Inject HIPE to fill 
irregular defects
2. Polymerizes at body temperature, 
forming a high porosity bone graft 
37°C
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Figure 2.5. 24 hour 3T3 live/dead analysis of 5 wt% PGPR polyHIPEs. 
(A) Fluorescent image (green = live, red = dead) (B) Comparison of viable cells on 
tissue culture polystyrene and HIPE. No significant difference was observed between the 
polystyrene and HIPE demonstrating the potential cytocompatibility of the system. 
 
 
2.3.4 Effect of PGPR Concentration on Pore Architecture Given that the 
polyHIPE architecture is dictated by the emulsion geometry prior to cure, modulation of 
emulsion stability may be used to tune the resulting polyHIPE architecture. This requires 
a brief review of the thermodynamics involved in both emulsion formation and phase 
separation. The increase in surface energy of an emulsion compared to the non-
emulsified components (ΔW) is a product of both the interfacial energy (σ) and the 
change in surface area (ΔA) upon emulsification.  
(2.2)         
ΔW is the free energy of the interface and corresponds to the reversible work 
brought into the system during emulsification. The magnitude of ΔW can be considered 
a measure of the thermodynamic instability of the emulsion and drives phase separation 
as a means to decrease ΔA. From this relationship, it is evident that ultimate stability 
against coalescence processes is only achieved if σ approaches zero. The surfactant’s 
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role during emulsification is to reduce this interfacial tension and form a barrier between 
the two phases.  
Two relationships relevant to polyHIPE architecture can be inferred from this 
discussion: 1) an increase in interfacial tension (↑ σ) will increase the rate of droplet 
coalescence due to an increase in ΔW; 2) an increase in interfacial tension (↑ σ) will 
correspond to larger initial droplet sizes (↓ ΔA) for a given ΔW.  It follows that the 
surfactant which directly impacts interfacial tension can be used to tune pore sizes by 
changing the initial droplet size and/or the rate of droplet coalescence prior to cure. To 
this end, Williams et al. studied the effect of surfactant concentration on both pore size 
and wall thickness between droplets.
67
 It was reported that a reduction in surfactant 
concentration could be used to increase pore size by destabilizing the HIPE. In addition, 
an increase in surfactant concentration was found to decrease wall thickness and induce 
pore opening upon polymerization. We hypothesized that HIPE stability could be 
modulated by changing the surfactant concentration to achieve a range of polyHIPE pore 
sizes and an open-pore morphology. PGPR concentrations from 5 to 40 wt% were 
utilized to investigate the effect of surfactant concentration on polyHIPE pore 
architecture. SEM analysis of polyHIPE monoliths was conducted to quantify pore and 
interconnect size using the 10.7 pixels/µm ratio at 1000x, Table 2.3. Decreasing the 
concentration of PGPR from 20 to 5 wt% was found to increase average pore diameter in 
PFDMA polyHIPEs (6 to 29 µm), Figure 2.6. A narrowing of pore size distributions 
with increasing surfactant concentration was also observed, Figure 2.7.  
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Table 2.3. The effect of surfactant concentration on polyHIPE architecture. 
Surfactant (wt%) Porosity (%) Average Pore Diameter (µm) 
5 75.1 ± 0.4 29 ± 19 
10 75.1 ± 0.3 21 ± 11 
15 75.1 ± 0.1 14 ±   8 
20 74.1 ± 0.1  4 ±   2 
Gravimetric porosity, N = 3, average ± standard deviation. Average pore 
measurements from image analysis of scanning electron micrographs, N = 150, 
average ± standard deviation. 
 
 
 
 
Figure 2.6. Scanning electron micrographs (A,B,C,D) of PFDMA polyHIPEs with 
increasing surfactant concentrations. It can be seen that pore sizes decrease as PGPR 
concentration increases from 5-20 wt%. 
 
 
 
 
Figure 2.7. Distribution of pore sizes for 75/25 polyHIPEs with varied PGPR 
concentrations, mixed at 500 rpm. (A) 10 wt%, (B) 15 wt%, and (C) 20 wt%. Pore sizes 
become more uniform as PGPR content increases. 
 
 
The decreased pore size observed at higher surfactant concentration was 
attributed to a decrease in interfacial tension with a corollary decrease in droplet size, as 
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discussed above. Assuming conservation of organic phase volume, this increase in 
surface area also decreases the film thickness between droplets;
111
 however, this wall 
thinning was insufficient to lead to pore opening in this system. Based on these 
preliminary results, it was hypothesized that increased densification in combination with 
decreasing film thickness would be needed to generate open-pore polyHIPEs. This is the 
subject of current investigation using alternative fumarate-based macromers. A 
narrowing of the pore size histograms also indicated that a higher surfactant 
concentration resulted in a more uniform pore size, Figure 2.7. Williams et al. reported 
that increased pore size homogeneity was observed with increased surfactant due to a 
reduction in droplet coalescence.
67
 However, the droplet coalescence observed in these 
studies was characterized by a few large pores surrounded by many smaller pores. As 
illustrated in Figure 2.7, there was a continuum of pore sizes observed rather than the 
more bimodal distribution reported by Williams et al.
67
 Ostwald ripening has also been 
reported to increase the pore size distribution of polyHIPEs. In this process, diffusion of 
water from smaller droplets to larger droplets causes a more gradual broadening of the 
pore size distribution.
117
 Both of these processes are affected by the nature and 
concentration of surfactant; however, it is unclear whether droplet coalescence or 
Ostwald ripening is responsible for the observed difference in pore size distribution. 
Based on the histograms alone, it appears that Ostwald ripening may be more 
significant; however, additional studies are needed to make a stronger claim on this 
front. 
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2.3.5 Effect of Mixing Speed on Pore Architecture Processing parameters such 
as mixing speed can also be utilized to tune the pore architecture through manipulation 
of the emulsion geometry prior to cure. Revisiting the thermodynamic stability of the 
system yields mechanistic answers for the effect altered mixing speed has on pore size 
and homogeneity. Varying the mixing speed directly affects the difference in surface 
energy of the emulsion relative to the non-emulsified components. By adding 
mechanical energy into the system through mixing, the surface energy of the emulsion is 
increased yielding a larger change relative to the non-emulsified components (∆W). This 
causes an increase in the surface area (∆A) of the droplets upon emulsification, assuming 
low interfacial tension due to surfactant (σ). This increase in surface area corresponds 
with decreased droplet sizes. We hypothesized that pore size and homogeneity can be 
modulated by altering the free energy of the system resulting in decreased pore 
diameters and increased homogeneity with an increase in mixing speed. 
Mixing speeds of 500, 1000, and 2000 rpm on the FlackTek Speedmixer™ were 
tested to investigate the effect on pore architecture. Initially, HIPEs with 20 wt% PGPR 
were utilized resulting in minimal change in pore size with an increase in mixing speed 
as seen in Table 2.4. We hypothesized that destabilizing the emulsion with a lower 
concentration of PGPR would result in a larger pore size distribution, thereby clearly 
illustrating the effect of mixing speed. Scanning electron micrographs of both 10 and 20 
wt% PGPR compositions at varying mixing speeds are found in Figure 2.8. A decrease 
in pore size was observed with both 10 and 20 wt% PGPR specimens as mixing speed 
was increased (500 to 2000 rpm). As discussed, the trend was more evident with the 10 
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wt% PGPR specimens, Table 2.4, and further illustrates the effect of surfactant on 
emulsion stability and pore architecture. The narrowing of the histograms in Figure 2.9 
from 500 to 2000 rpm indicates a more homogeneous pore size distribution which is 
illustrated in the SEM images. As stated previously, increased surfactant produced an 
increase in pore homogeneity due to decreased surface energy. Combining both mixing 
speed and surfactant had a large effect on pore size homogeneity as observed in Figure 
2.9 by increasing the surface area of the emulsion and decreasing the interfacial energy 
of the droplets, respectively, to reduce droplet size and coalescence.  
 
Table 2.4. The effect of mixing speed on polyHIPE pore structure with a constant 
volume fraction (75/25) and varied surfactant concentration (10 and 20 wt% PGPR). 
Mixing Speed (rpm) [PGPR] Average Pore Diameter (µm) 
500 
10 wt% 21 ± 11 
20 wt% 4 ± 2 
1000 
10 wt% 8 ± 4 
20 wt% 3 ± 2 
2000 
10 wt% 4 ± 3 
20 wt% 2 ± 1 
Average pore measurements from image analysis of scanning electron micrographs, N = 
150, average ± standard deviation. 
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Figure 2.8. Scanning electron micrographs of PFDMA polyHIPEs fabricated at 
increasing mixing speeds. (A-C) 10 wt% PGPR (A) 500 rpm (B) 1000 rpm (C) 2000 
rpm, (D-F) 20 wt% PGPR (D) 500 rpm (E) 1000 rpm (F) 2000 rpm. A decrease in pore 
size is seen with an increase in mixing speed. 
 
 
 
 
Figure 2.9. Distribution of pore sizes for 75/25 polyHIPEs fabricated with 10 (black) 
and 20 wt% PGPR (blue) at 500, 1000, and 2000 rpm. 
 
 
 
2.4 Conclusions 
The application of emulsion templating in the development of tissue engineering 
scaffolds is a relatively new area of orthopedic research.  In this study, polyHIPEs were 
fabricated without toxic solvents or monomers at cure temperatures appropriate for in 
D F
Figure 4. Scanning electron micrographs of PFDMA polyHIPEs fabricated at increasing mixing speeds: (A-C) 10 wt% PGPR (A) 
500 rpm (B) 1000 rpm (C) 2000 rpm, (D-F) 20 wt% PGPR (D) 500 rpm (E) 1000 rpm (F) 2000 rpm
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situ deployment. These new polyHIPEs have potential application as an injectable, tissue 
engineered bone graft. Injectable grafts that are also biodegradable and porous offer 
unique advantages over current alternatives in terms of deployment and tissue 
integration. In addition, investigation of the effect of surfactant structure on HIPE 
stability elucidated additional structural features that can be used to rationally select 
surfactants for new polyHIPE compositions. This transition from a time-intensive trial 
and error method of selecting surfactants will facilitate additional biodegradable 
polyHIPE formulations with utility in a wide range of tissue engineering applications. 
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CHAPTER III 
INJECTABLE POLYMIPE SCAFFOLDS FOR SOFT TISSUE REGENERATION
†
 
 
3.1 Introduction 
Injury caused by trauma, burns, surgery, or disease often results in soft tissue 
loss, most commonly skin, muscle, adipose, and cartilage.
139
 These tissues have unique 
properties that drive various functions such as: supporting vasculature, body locomotion, 
and impact protection.
23, 139
 The lack of viable donor tissue to treat these injuries often 
results in scarring and impaired function. Tissue engineering aims to improve on current 
options through the use of a porous scaffold combined with stem cells and bioactive 
factors that are designed to regenerate the damaged tissue. Scaffolds have been 
fabricated using a variety of polymers to restore the function and regenerate these 
tissues; however, clinical success is often limited by poor graft properties.
23-26, 75, 140, 141
  
Soft tissue scaffolds are often designed to have tunable moduli and strengths 
comparable to the target tissue.
4, 142-144
 A common feature of soft tissue that is often 
poorly replicated in scaffolds is elasticity and an ability to withstand repeated loading 
without loss of function.
8, 24, 26, 145
 Improved biomaterial scaffolds should be designed to 
match tissue modulus and strength while also retaining desired elastomeric and fatigue-
resistant properties. In addition, these materials need to support cells and growing tissue, 
typically with an interconnected porous structure and biodegradable chemistry.
44, 146-148
 
                                                 
†
 Reprinted with permission from “Injectable PolyMIPE Scaffolds for Soft Tissue Regeneration,” by 
Robert S. Moglia, Jennifer L. Robinson, Andrea D. Muschenborn, Tyler J. Touchet, Duncan J. Maitland, 
and Elizabeth Cosgriff-Hernandez, Polymer 2014, 55 (1), 426-434. Copyright (2014) Elsevier. 
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Of particular design importance is the interconnected porous structure of the scaffold, 
which facilitates mass transport. This is especially true for newly implanted scaffolds 
that lack vasculature to support tissue and cells. The size of a tissue engineered construct 
is constrained by the diffusion limit of nutrients to cells at the center of the construct.
129, 
149
 Porosity and pore size need to be easily modulated in a tissue engineered scaffold to 
allow for increased fluid permeability, and thus nutrient flux, in order to enable larger 
defects to be regenerated.
129
 
Tissue engineers have developed numerous fabrication strategies to create 3D 
scaffolds that meet these various requirements.
12, 14, 16, 17, 44, 109, 146, 147, 150, 151
 The 
fabrication process dictates scaffold architecture and the resultant mechanical properties, 
degradation rate, and cellular response. These methods often utilize toxic solvents and 
high temperatures or pressures during fabrication.
56, 65, 108, 109
 The scaffolds must then be 
purified and shaped to fit the defect, commonly with the use of computer generated 
molds made from clinical imaging techniques.
38, 45, 152
 Molds are reliant upon the 
accuracy of the images, increase cost, and delay patient treatment. Research has shown 
that in situ forming scaffolds can better fill irregularly shaped defects, thus improving 
contact with surrounding tissue and eliminating the need for costly molding 
techniques.
87
 An elastomeric, biodegradable, and porous scaffold that can be fabricated 
at body temperature without the use of toxic components could be injected into the 
defect without the need for extensive imaging or mold casting and can potentially 
improve tissue regeneration beyond current methods. Hydrogel scaffolds have been 
studied as injectable scaffolds because their mechanical properties approximate soft 
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tissues, but they typically have 10-100 nm mesh sizes that limit cellular infiltration and 
migration to the rate of scaffold degradation.
153
 Hydrogels with larger pores have also 
been fabricated, but are commonly non-biodegradable or non-injectable.
154
 Polyurethane 
foams have recently been formed in situ by injecting isocyanates and polyols which react 
rapidly to conform to the defect.
155
 In animal studies, this material successfully 
regenerated bone tissue without notable toxicity or inflammation in the surrounding 
tissue despite injecting isocyanates directly into the defect site.
155
 Other researchers have 
conducted animal studies of injectable two-component polyurethane foams and found 
mild short-term side effects.
156
 
Emulsion templating can be used to generate an injectable graft that cures to a 
porous foam in situ. Emulsions with water volumes between 40-74% are termed medium 
internal phase emulsions (MIPEs), the polymerized form is termed a polyMIPE. Prior to 
curing, the emulsion has a mayonnaise-like consistency capable of flow through a 
syringe and space-filling irregularly shaped defects.
157
 Historically this technique 
required the use of toxic solvents to control macromer viscosity or high cure 
temperatures.
35, 36, 45, 71, 134
 Our lab recently fabricated emulsion templated scaffolds 
without solvent that cure at body temperature and are biodegradable.
157
  Successful 
deployment through a syringe with microscale integration in a bone defect was also 
demonstrated.
158
 The properties of these injectable foams can be tuned by altering pore 
size, porosity, composition, and macromer/polymer chemistry.  
This study details the fabrication and characterization of poly(ester urethane 
urea) based polyMIPEs as candidates for soft tissue scaffolds. The compositional effects 
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on polyMIPE pore architecture and mechanical properties were determined to illustrate 
the range and control of scaffold properties. The porous media properties, permeability 
and form factor, were also measured in order to better compare pore interconnectivity of 
several compositions. Finally, human mesenchymal stem cell (hMSC) viability and 
morphology was studied as an early indicator of whether these scaffolds can support 
tissue regeneration.  
 
3.2 Materials and Methods 
3.2.1 Materials Polyglycerol polyricinoleate (PGPR 4125) was donated by 
Paalsgard. All other chemicals were purchased from Sigma-Aldrich and used as 
received. 
3.2.2 PCL-Isocyanate Synthesis Isocyanate functionalized prepolymers were 
synthesized in bulk. Briefly, polycaprolactone (PCL) diol or triol (530, 900 Mn 
respectively) was heated with 50°C air and added dropwise to a reaction flask charged 
with hexamethylene diisocyanate (HDI, 2.02 x mol diol, 9.00 x mol triol), Figure 3.1. 
The reaction was heated to 80 °C for 90-120 minutes and reaction progress was 
monitored with FTIR spectroscopy every 30 minutes until complete. The product was 
washed with hexane to remove excess HDI and dried under vacuum overnight. The final 
products were colorless liquids with a viscosity similar to honey. The prepolymer 
structure was confirmed using 
1
H NMR (300 MHz, CdCl3): PCL-diisocyanate (PCL-DI) 
δ 1.33-1.47 (m, 8H), 1.52 (q, 4H), 1.60-1.75 (m, 8H), 2.30-2.40 (m, 4H), 3.18 (s, 2H), 
3.33 (q, 2H), 3.70-3.73 (m, 2H), 4.09 (t, 4H), 4.24-4.27 (m, 2H), 4.77 (s, 1H). PCL-
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triisocyanate (PCL-TI) δ 0.91(t, 3H), 1.33-1.52 (m, 8H), 1.60-1.75 (m, 8H), 2.31-2.38 
(m, 4H), 3.18 (s, 2H), 3.33 (m, 2H), 4.04-4.11 (m, 4H), 4.74 (s, 1H).  
 
 
 
Figure 3.1. Chemical structures of PCL-isocyanate polyurethane prepolymers. PCL-
polyols are functionalized with HDI in bulk to synthesize isocyanate terminated 
macromers. (A) PCL-diisocyanate (PCL-DI) and (B) PCL-triisocyanate (PCL-TI). 
 
 
3.2.3 MIPE Fabrication PCL-DI and –TI were mixed with the surfactant PGPR 
in a 3-necked round bottom flask prior to emulsification. This mixture was stirred with a 
glass stirring rod fitted with a D-shaped PTFE paddle connected to an overhead stirrer 
motor for 10 minutes. The aqueous solution, comprised of varied amounts of 1,4-
diazabicyclo[2.2.2]octane (DABCO) and calcium chloride (1% v/v) in reverse osmosis 
water, was added at a rate of 1 mL/min using a syringe until it totaled 50% v/v, while 
constant stirring at 300 rpm was maintained. The emulsion was stirred for 10 additional 
minutes to ensure emulsion homogeneity. The MIPE was then transferred to a 50 mL 
polypropylene tube and immersed in a bead bath at 37 °C for 48 h. All specimens were 
dried in vacuo at room temperature for 24 h prior to characterization, Figure 3.2. 
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Figure 3.2. PolyMIPE fabrication scheme. (A) The isocyanate macromers were mixed 
with surfactant while water was added to form medium internal phase emulsions. The 
MIPEs viscosity allows them to be injected through a syringe prior to polymerizing in 
the body. (B) The isocyanates react with water to produce primary amines and carbon 
dioxide, increasing porosity beyond the aqueous volume fraction, a limiting factor for 
typical styrene-based polyMIPEs. 
 
 
3.2.4 Gravimetric Analysis PolyMIPE porosity was measured gravimetrically. 
Briefly, dried MIPE samples were cut into cubic sections (9 × 9 × 3 mm) and weighed. 
Following eq (1), the MIPE porosity can be calculated by comparing MIPE density (ρM) 
with the neat polymer density (ρP). Neat polymer density was assumed to equal 1 g/cm
3
, 
a reasonable value for polymers. Reported values are an average of nine sections per 
polyMIPE composition.  
(3.1) 
P
MPorosity


1  
3.2.5 Characterization of Scaffold Architecture Scanning electron microscopy 
(SEM) was utilized to characterize polyMIPE pore architecture. Circular specimens were 
sectioned into quarters, fractured at the center of the quarter, sputter-coated with gold, 
and imaged using SEM (JEOL NeoScope JCM-5000). Images at 20× were utilized to 
determine the average void diameter and 50x to measure water template pores, Figure 
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3.3. Three specimens of each composition were generated and then three sections were 
cut from each monolith. Three horizontal lines were drawn across the image, dissecting 
it into four equal rectangles. Starting with the topmost mark, measurements were made 
on the first 10 voids crossed by the lines to minimize user bias. Averages void sizes for 
each polyMIPE composition are reported (n = 90). Water pores/interconnects were 
measured similarly except that 30 pores/openings were measured per image, average 
interconnects per composition are reported (n = 270). A statistical correction was 
calculated to account for the random fracture plane through spherical voids and pores, 2/
3 .
159
 The average diameter values were multiplied by this correction factor resulting in 
a more accurate description of pore diameter. 
 
 
 
Figure 3.3. SEM comparing voids and pores observed in polyMIPE scaffolds. 
 
 
3.2.6 Compression Testing The foams were tested in compression with an RSA 
III (TA, Delaware) dynamic mechanical analyzer, equipped with a 30 N load cell. Four 
Void
Pore
500 μm
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specimens were taken from each sample. The test specimens were cut into flat 
rectangular shapes (10 × 10 × 4 mm) and compressed at 50 μm/s. Tangent modulus was 
calculated at 5% strain and strength at 20%. Reported moduli data were an average of 
the three sections for each sample tested (n = 12). 
3.2.7 Cyclic Loading and Strain Recovery Samples were subjected to three 
compressive loading–unloading cycles from 0 to 50% strain and back to 0% at 50 µm/s 
(~1 %/s). The dimensions (diameter and height) of the samples were measured with 
calipers after each cycle to ensure that the stress–strain curves always started from the 
new unloaded specimen height. The samples rested for 2-3 minutes between cycles as 
dimensions were measured and samples re-positioned on the compression platen. New 
sample height was divided by the previous cycle height to calculate strain recovery. 
3.2.8 Permeability Testing Scaffold interconnectivity was characterized by 
measuring their respective intrinsic/Darcy’s permeability using the Forchheimer-Hazen-
Dupuit-Darcy equation:  
(3.2) 
2
00 

C
Kx
P



  
where x
P



 is the pressure gradient along the sample in the direction of flow (Pa/m),   
is the dynamic viscosity of the fluid (Pa·s), K is the intrinsic permeability of the 
(scaffold, sample) (m
2
), v0 is the Darcy velocity (flow rate divided by cross-sectional 
area of the (scaffold, sample)) (m/s),   is the density of the fluid (kg/m
3
), and C is the 
form factor of the (scaffold, sample) (m
-1
). The experimental details for measuring the 
permeability and form factor of porous polymers have been described elsewhere by 
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Muschenborn et al.; briefly, MIPEs were polymerized inside 3D printed sample holders 
(inner diameter = 15.1 mm, outer diameter = 18.9 mm) containing three 4 × 4 mm 
pressure port openings, 15 mm apart from one another.
160
  The sample holders had o-
rings to isolate each pressure port.  Each sample holder was then inserted into a custom-
built measuring chamber, and two pressure transducers (PX429-2.5G5V, Omegadyne 
Inc) were connected at the upstream and downstream pressure port locations. Water flow 
at room temperature was enabled via a gear pump (Chemsteel R106, Oberdorfer), a 
servo motor (750 W M-series, Applied Motion Products), and a motor controller 
(BLuAC5-Q, Applied Motion Products).  The output voltage of the pressure transducers 
was recorded at 1 Hz through a data acquisition system (USB6251, National 
Instruments) for 120 seconds. The flow rate was measured by hand using a stop watch 
and a graduated cylinder. A second-order least squares fit to the data of pressure gradient 
plotted against Darcy velocity was implemented for nine values to calculate the samples’ 
porous media properties, permeability and form factor.
160
 The Reynolds number at each 
velocity point was calculated as the ratio of the second term to the first term on the right 
side of Equation 3.2.
161
 
3.2.9 Cytocompatibility Initial hMSC viability and morphology studies were 
conducted on 2:1 PCL-DI:PCL-TI films and 50% PCL-DI : 50% PCL-TI polyMIPEs to 
assess cytocompatibility. Cell viability was determined using the Live/Dead 
Viability/Cytotoxicity Kit (Molecular Probes) and morphology accessed by imaging 
cells stained with CellTracker™ Orange (Molecular Probes). The hMSCs were obtained 
from the Center for the Preparation and Distribution of Adult Stem Cells at Texas A&M 
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Health Science Center College of Medicine and cultured in vitro with Minimal Essential 
Medium α (MEM α, Gibco) supplemented with 16.5% heat-inactivated fetal bovine 
serum (FBS, Atlanta Biologicals), and 1% L-Glutamine (200 mM, Gibco). Cells were 
cultured to 80% confluency and utilized at Passages 4-5. Samples were prepared for cell 
seeding as follows: 3 hour 70% ethanol sterilization, ethanol wetting ladder and 
progressive solvent extraction, and overnight media incubation supplemented with 40% 
v/v FBS in MEM α. Following overnight incubation in 37 °C, 5% CO2, medium was 
removed, specimens were dried in the hood for 15 min, washed 1× with PBS, and 
preconditioned with growth medium for 15 min. Cells were seeded at 5,000 cells/film 
and 100,000 cells/foam. Live/Dead staining was conducted at 3, 24, and 72 hours and 
cell adhesion and morphology on foams was assessed at 3 and 24 hours. For viability 
analysis, images of each of the four specimens were obtained through Raster patterning 
(n = 20) for each timepoint using a fluorescence microscope (Nikon Eclipse TE2000-S). 
Observation of hMSC morphology was completed with one sample imaged with rastor 
patterning (n = 5) at each timepoint. 
3.2.10 Statistical Analysis The data are displayed as mean ± standard deviation 
for each composition. A Student’s t test was performed to determine any statistically 
significant differences between compositions. All tests were carried out at a 95% 
confidence interval (p < 0.05). 
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Figure 3.4. Scanning electron micrographs of the polyMIPE scaffolds indicated an 
open-pore interconnected structure. A bimodal pore distribution was also observed due 
to the difference in pores formed by (A,B,C) carbon dioxide generation and those 
resulting from (D,E,F) water templating. 
 
 
3.3 Results and Discussion 
3.3.1 Pore Architecture All of the scaffolds exhibited a bimodal pore structure 
composed of discrete 1-2 mm voids surrounded by 30-400 µm pores, Figure 3.4 and 
Figure 3.5. The pore size remained relatively unchanged despite large differences in 
void diameter between compositions. Increased PCL-TI concentration significantly 
increased void size once it exceeded 50%, from 1 to 1.3 mm. This phenomena was 
observed by David and Silverstein in a similar system and hypothesized to be caused by 
side products of urea formation.
109
 Briefly, the isocyanate functional groups react with 
the encapsulated water to form amine end groups with the liberation of carbon dioxide. 
These amine end groups react rapidly with remaining isocyanates to form urea linkages 
100% DI : 0% TI 50% DI : 50% TI 0% DI : 100% TI
1mm1mm 1mm
100 µm 100 µm 100 µm
A)
D)
B) C)
E) F)
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in the resulting polymer network. David and Silverstein determined that the large pores 
were caused by carbon dioxide and the smaller pores formed by water droplets.
109
 They 
hypothesized that carbon dioxide would separate from both the organic and aqueous 
phases, merge, and form the observed voids.
109
 This is consistent with the present study, 
except the water-templated pores are not as clearly defined. Instead, the walls of the 
voids are porous with irregular interconnects between them, Figure 3.4 D,E,F. The 
oblong shapes of these interconnects indicate that the emulsion is relatively unstable and 
is undergoing droplet coalescence, whereas stable emulsions would result in spherical 
pores.
56, 109
 Additionally, some interconnects appear to be torn open. This is most likely 
the result of carbon dioxide escaping from the polymerizing emulsion after the pore 
walls had mostly gelled. 
The effect of catalyst concentration on pore structure was also evaluated and the 
results summarized in Table 3.1. Void size decreased from ~ 0.9 to 0.7 mm with 
increased DABCO concentration. The increased cure rate from higher DABCO amounts 
was hypothesized to cause rapid polymer wall strengthening that better resisted 
expansion from carbon dioxide production and forced the gas to find existing exit paths 
and thus form smaller voids. Foaming in polyurethane foams has long been studied for 
industrial and commercial uses. Anti-foamers (or pore openers) have been used to 
prevent or control foam cell production and size.
162-164
 The Guelcher group has used 
calcium stearate pore openers in their injectable bone grafts to form interconnects and 
tune pore size.
70, 162, 163, 165
 Although it was not studied here, a biocompatible pore opener 
could potentially be used to homogenize void sizes in this injectable system. 
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Figure 3.5. (A) Average CO2 void diameters, (B) average pore diameters, and (C) 
average porosities of polyMIPEs with varied PCL-DI : PCL-TI ratio and constant water 
volume fraction. 
 
 
The effect of catalyst concentration on pore structure was also evaluated and the 
results summarized in Table 3.1. Void size decreased from ~ 0.9 to 0.7 mm with 
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increased DABCO concentration. The increased cure rate from higher DABCO amounts 
was hypothesized to cause rapid polymer wall strengthening that better resisted 
expansion from carbon dioxide production and forced the gas to find existing exit paths 
and thus form smaller voids. Foaming in polyurethane foams has long been studied for 
industrial and commercial uses. Anti-foamers (or pore openers) have been used to 
prevent or control foam cell production and size.
162-164
 The Guelcher group has used 
calcium stearate pore openers in their injectable bone grafts to form interconnects and 
tune pore size.
70, 162, 163, 165
 Although it was not studied here, a biocompatible pore opener 
could potentially be used to homogenize void sizes in this injectable system. 
 
Table 3.1. Effect of catalyst and PCL-TI crosslinker on cure time, pore sizes, and 
porosity. 
DABCO 
(wt %) 
PCL-DI 
(wt %) 
PCL-TI 
(wt %) 
Tack 
Free 
Time 
(hours) 
Void Size 
(µm) 
Water Pore 
Size (µm) 
Porosity 
(%) 
0 75 25 5.5 1021 ± 583 ° 181 ± 230      70 ± 6 ° 
0 50 50 5.0 881 ± 454    101 ± 60      70 ± 2     
0 25 75 5.5 919 ± 386    131 ± 99     73 ± 4     
0.1 50 50 4.5 1086 ± 454  ° 62 ± 28    ° 67 ± 2   ° 
1 50 50 4.0 721 ± 264      127 ± 71     64 ± 2      
* : p < 0.05 compared to 75% PCL-DI, 0% DABCO 
  : p < 0.05 compared to 50% PCL-DI, 0% DABCO 
  : p < 0.05 compared to 25% PCL-DI, 0% DABCO 
  : p < 0.05 compared to 50% PCL-DI, 0.1% DABCO 
° : p < 0.05 compared to 50% PCL-DI, 1% DABCO 
 
 
3.3.2 Scaffold Porosity A benefit of the carbon dioxide blowing process is 
increased porosity, as evidenced by polyMIPE expansion during polymerization. In 
traditional emulsion templating, porosity is limited by the template volume fraction, 50% 
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in this study. However, due to foaming, these polyMIPE porosities ranged from 64-76%, 
Figure 5C, while higher porosity scaffolds could be fabricated they often exhibited poor 
mechanical properties. Porosity increased with PCL-TI content due to the increase in 
total isocyanate groups, and decreased with increased catalyst concentration. For 
example, a MIPE with 100% PCL-TI would have approximately 1.25x the number of 
isocyanates of a 100% PCL-DI emulsion. Increasing catalyst concentration, from 0 to 1 
wt%, for a 50% PCL-TI polyMIPE decreased porosity from 70 to 64%. This 
corresponded with a decrease in void size from approximately 881 µm to 721 µm while 
water pore size did not follow any trend. This decrease in porosity was not attributed to 
reduced carbon dioxide generation given that the total number of isocyanates was 
constant which indicates that the carbon dioxide generation was most likely unchanged. 
The increase in catalyst was hypothesized to increase polymer film strength more 
rapidly, thus resisting carbon dioxide void expansion and decreasing total porosity. 
These results indicate that changing isocyanate content or reaction rate with catalyst 
could be used to modulate scaffold porosity and expansion in situ through control of the 
carbon dioxide blowing mechanism. Researchers have shown that increasing scaffold 
porosity increases cell viability and growth.
71, 72, 75, 77, 79, 80, 83
 Also, the expansion could 
help the graft “space fill” the defect, improving tissue integration.35, 38, 45, 70, 157, 163 There 
is concern over the safety of carbon dioxide blowing in vivo resulting from reacting 
isocyanates into the human body. Recently, researchers have safely injected foaming 
isocyanate-functionalized prepolymers for a variety of applications and no deleterious 
side effects were noted in relation to the presence of free-isocyanates or the blowing 
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process.
155, 156, 162, 165
 Similar to pore size, porosity of polyurethane foams has been 
studied extensively and can be further controlled using methods beyond the scope of this 
study.
164
 
 
 
Figure 3.6. (A) Compressive modulus and (B) strength of polyMIPEs with increasing 
PCL-TI content (0.1 wt% DABCO). (C) Compressive modulus and (D) strength of 
polyMIPEs without DABCO. 
 
 
3.3.3 Mechanical Properties PolyMIPE compressive modulus and strength 
decreased with decreasing PCL-DI content. The 100 and 75% PCL-DI with 0.1 wt% 
DABCO were the stiffest and strongest compositions tested, with a modulus and strength 
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approximately 215 and 55 kPa, respectively (Figure 3.6). These values decreased 
steadily to 48 and 8 kPa as PCL-TI was increased to 100%. The greatest change 
occurred when 75% TI was reached, afterwards modulus and strength decreased by 
nearly half of the 50% TI values. Catalyst concentration did not have a significant effect 
on the properties of the 25, 50, and 75% PCL-TI scaffolds, with the 0 (Figure 3.6C and 
Figure 3.6D) and 0.1% (Figure 3.6A and Figure 3.6B) compositions behaving near 
identically. However, the uncatalyzed 25% PCL-TI polyMIPEs were less consistent than 
their catalyzed counterparts, as evidenced by the large standard deviation. Furthermore, 
the 100% PCL-TI and 100% PCL-DI polyMIPEs were too macroporous to make 
mechanical specimens, represented by ‘X’ in Figure 3.6.  
The reductions in compressive modulus and strength with increasing PCL-TI 
content was not anticipated given the increase in crosslink density that is typically 
observed with higher macromer functionality. The observed trend corresponded with 
increases in pore size and porosity. However, the difference between the strongest and 
weakest scaffolds was a five-fold change with only a 13% increase in porosity. 
Therefore, the change in porosity is unlikely to be solely responsible for the reduction in 
compressive properties. It was hypothesized that the PCL-TI disrupted secondary chain 
interactions within the polymer network, specifically changes in crystallinity and 
hydrogen bonding. The PCL-diol and –triol are semicrystalline with melting 
temperatures of 7 (37% crystalline) and 21 °C (29% crystalline), respectively, as 
determined with differential scanning calorimetry. Upon endcapping the macromers with 
isocyanate groups, PCL-DI becomes more crystalline as evidenced by increased 
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viscosity and opacity, whereas the PCL-TI displayed a reduction in crystallinity 
becoming less viscous and transparent. Hydrogen bonding between the newly formed 
urethane linkage is also more favorable in the linear PCL-DI.
166
 The steric hindrance of 
the branched PCL-TI structure most likely prevents intra-chain hydrogen bonding and 
impedes inter-chain hydrogen bonding and crystal formation. Additional physical 
crosslinking occurs after polymerization due to the formation of urea linkages that can 
undergo bidentate hydrogen bonding.
146
 Bidentate bonds form between the two active 
hydrogens and the nitrogen of the urea linkages and thus result in stronger hydrogen 
bonding when compared to urethane linkages with only one active site. This hypothesis 
was supported by FTIR spectral analysis of hydrogen bonding of the urethane and urea 
carbonyls of the polyMIPE scaffolds. Peaks assigned to the free, hydrogen bonded, and 
bidentate hydrogen-bonded urea carbonyls (1680, 1654, 1625 cm
-1
 respectively) were 
used to assess relative levels of hydrogen bonding. PCL-TI rich polyMIPEs displayed a 
reduction of 1625 cm
-1
 peak indicating a reduced level of hydrogen bonding. 
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Figure 3.7. Representative loading-unloading curves for (A) 0%, (B) 50%, and (C) 
100% PCL-TI polyMIPEs with 0.1 wt% DABCO. 
 
 
Initial strain recovery increased with PCL-TI content, and approached 100% 
upon subsequent loading, Figure 3.7. These properties allowed the scaffolds to recover 
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from large strains, as can be seen in the video file included with supplementary 
information. The 100% PCL-DI samples exhibited the lowest initial recovery of the 
catalyzed scaffolds, approximately 90%, and the highest recovery was found with the 
50% PCL-DI scaffolds, approximately 95%. All initial strain recoveries were equal to or 
greater than 90% for all scaffolds tested. Subsequent strain recoveries were always 
higher than the initial values, commonly approaching 100%. Subsequent recovery, like 
initial recovery, improved with increased PCL-TI content. Likewise, hysteresis between 
the loading and unloading curves decreased with subsequent loading and PCL-TI 
content. This behavior is similar to conditioning seen in other polyurethane materials and 
characteristic of the “Mullin’s effect”.167-170 
The observed decrease in hysteresis and increased strain recovery after the first 
cycle is most likely due to chain reorganization during compression. Strain first breaks 
physical crosslinks in the network, predominantly hydrogen bonding between urethane 
and ureas in these foams, prior to loss of chemical crosslinks. In a series of loading 
cycles, the first conditioning cycles generates a new network with permanent set 
associated with the loss of these physical bonds. Subsequent cycles do not exceed the 
strain needed to cause further loss of netpoints and therefore have a high level of strain 
recovery. Similar phenomena have been observed in polyurethanes under tensile 
strain.
167, 170-172
 This behavior was most pronounced in the PCL-DI rich compositions, 
which exhibited the lowest initial strain recovery and largest hysteresis, due to the 
increased hydrogen bonding observed in these chains. PCL-TI also exhibited this 
behavior to a lesser extent, with almost no hysteresis, due to the increase in covalent 
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crosslinking and reduced hydrogen bonding of the PCL-TI network. Overall, these 
properties are similar to many soft tissues in the body and can be tuned to closely match 
them by changing the ratio of branched crosslinkers to linear chain extenders.
24, 173
 
Furthermore, these properties mimic those of injectable hydrogels with the advantage of 
being porous and elastomeric.
23, 24, 141, 152, 174
 
3.3.4 Scaffold Permeability Several researchers have attempted to determine the 
ideal pore size for tissue engineered scaffolds by comparing scaffold properties with in 
vivo and in vitro studies. The majority found that porosities between 57 and 75% with 
80-500 µm pores regenerated tissue in vivo.
71-83
 However, results are often contradictory 
and may be specific to cell type. For example, a more metabolically active cell may need 
a higher nutrient flux that corresponds with a more permeable scaffold. As such, 
researchers have been maximizing porosity with the assumption that fluid permeability 
and nutrient flux will increase beyond the limits of diffusion and allow larger defects to 
be treated. Pore interconnectivity and fluid permeability are inherently linked and can be 
quantified in many ways, including Darcy’s permeability constant.91, 128 Permeability is 
mathematically related to pore size, porosity, and tortuosity. Tortuosity is a unit-less 
measure of the fluid path length through the porous medium relative to the end-to-end 
path length, with lower values correlating to an increase in pore interconnectivity.
175
 
Several researchers have studied permeability in tissue engineered scaffolds to find 
relationships between pore structures and cell/tissue viability.
129
 Darcy’s permeability 
constant can be related to solute diffusion, and thus cell viability for similar scaffold 
geometries and types.
91, 128, 129
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Permeability and form factor are constitutive geometrical parameters of the 
porous medium and depend on the energy losses that arise when a fluid flows through 
it.
176-178
 These losses are due to viscous forces and inertial drag that result from the 
fluid’s resistance to motion and friction as it flows over the porous scaffold.  Thus, 
permeability is inversely proportional to the surface area of contact between the solid 
and the fluid, and form factor is proportional to the projected cross-sectional area of the 
obstructing solid perpendicular to the direction of the flow. Consequently, a scaffold 
with highly interconnected pores would have higher permeability and a lower form 
factor. 
In this study, the Reynolds numbers ranged between 0.088 and 1.250, but were 
mostly below 1,  indicating that flow was primarily in the Darcian regime.
177
  The 
Darcian regime is dominated by viscous energy losses, which are inversely proportional 
to permeability. Permeability increased four-fold with PCL-TI content, and form factor 
decreased by an order of magnitude, Figure 3.8. These changes are most likely due to 
the void, pore, and porosity differences noted earlier. The 100, 75, and 50% PCL-DI 
compositions have similar pore sizes and porosities, therefore it follows that their 
permeabilities are almost equal (~1.60 × 10
-10
 m
2
). Permeability begins to increase with 
the 25 and 0% PCL-DI polyMIPEs to 3 and 4 × 10
-10
 m
2
 respectively, which had 
significantly higher average pore diameters and porosities than the lower concentrations. 
Overall, these results confirm that all of the tested compositions possess interconnected 
porous networks, despite having emulsion volume fractions of only 50%. The blowing 
process of the isocyanate reaction with water allows these materials to not only increase 
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their porosity above volume fraction but is also hypothesized to drive interconnect 
formation as carbon dioxide tries to escape the scaffold. 
 
 
Figure 3.8. Darcy permeability “K” and form factor “C” of polyMIPEs with varied 
PCL-DI : PCL-TI ratio and constant water volume fraction. 
 
 
 
Figure 3.9. (A) Cell viability of neat PUU films and (B) micrograph of hMSCs spread 
on polyMIPE scaffold. 
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3.3.5 Cytocompatibility As an initial test of cytocompatibility, percent cell 
viability was tested on neat polymer films of similar composition to the porous scaffold 
but without any catalyst or surfactant. These films exhibited greater than 95% viability 
after 72 hours with no significant difference to the tissue culture polystyrene (TCPS) 
control at any time point. These results indicate that the polymer chemistry is 
cytocompatible and support the use of this system for biomedical applications, Figure 
3.9. Neat films were used to isolate the effect of polymer chemistry on cell viability and 
due to the complications associated with testing viability on porous specimens. 
Subsequent analysis of hMSCs seeded on polyMIPE specimens (75% PCL-DI: 25% 
PCL-TI, 0.1 wt% DABCO) indicated that hMSCs were able to adhere and spread on the 
foam as characterized by the numerous pseudopodia extending from the bright red cell 
nuclei. The results indicate that the cells thrived for up to 24 hours on the polyMIPE 
despite the presence of DABCO (0.1 wt%). Of the handful of catalysts typically used in 
polyurethane and polyurea syntheses, DABCO is considered the most cytocompatible 
but still regarded as a health hazard by many.
179
 Tanzi et al. found the IC50 of DABCO 
in solution to be 0.013 and 0.071 wt% for human endothelial cells and Swiss 3T3 
fibroblasts after 72 hours, respectively.
179
 A key difference between the studies is how 
the cells were exposed to the catalyst. In Tanzi et al., the cells were cultured in solutions 
containing DABCO, but in this study DABCO had to leach out of the scaffold before 
contacting cells.
179
 This leaching mechanism could explain the cell spreading at 24 hours 
when very little DABCO had escaped the polymer, but longer time points need to be 
investigated before any conclusions on cytocompatibility can be drawn. The isocyanate 
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chemistry of this system is advantageous in this regard, since the presence of water will 
result in conversion to amines that react with remaining isocyanates, without catalyst.  
Utilizing these reactions could allow for certain polyMIPEs to retain their 
biocompatibility, be injected into patients, and cured in situ with similar final properties 
to their catalyzed counterparts. Previously, isocyanates had been found to be 
carcinogenic but those harmful isocyanates were very low-molecular weight aromatic 
monomers. Novel injectable polyurethane foams have been safely deployed in animal 
studies without serious adverse reactions.
155, 156, 162, 165
 The improved biocompatibilitiy 
was hypothetically linked to the increased molecular weights of the isocyanate 
prepolymers and are similar to the macromers described here.
70, 155, 162, 165
 Therefore, 
these macromers are not expected to cause adverse reactions in vivo. Additionally, the 
surfactant layer is hypothesized to act as a barrier between the prepolymers and cells, 
further mitigating potential side effects prior to polymerization. Future studies will 
examine the effects of catalyst concentration and polyMIPE composition on cell viability 
and spreading, as well as test the cytocompatibility of unpolymerized PCL-isocyanate 
macromers. 
 
3.4 Conclusions 
Emulsion templating of tissue engineering scaffolds is a relatively new area of 
research that can be used to generate injectable foams with tunable mechanical 
properties. In this study, elastomeric polyMIPEs were fabricated at body temperature 
without toxic solvents and with viscosities appropriate for in situ deployment through a 
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syringe. In addition to the porosity generated from the water droplet phase of the 
emulsion, a chemical blowing mechanism generated additional porosity through carbon 
dioxide generation. The interconnected porous structure of the resulting foams yielded 
high graft permeability that is expected to enable improved mass transport and 
regeneration in vivo. Finally, initial human mesenchymal stem cell (hMSC) 
cytocompatibility testing supported the use of these candidate scaffolds in regenerative 
applications. Overall, these new scaffolds have potential application as biodegradable 
and injectable tissue engineered grafts for soft tissue regeneration and offer unique 
advantages in deployment and tissue integration over current methods. 
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CHAPTER IV 
INJECTABLE POLYHIPES WITH RAPID IN SITU CURING 
 
4.1 Introduction 
Emerging fields like tissue engineering are driving the development of novel 
materials with specialized properties to serve as temporary 3D matrices to regenerate 
complex tissues.
180
 Material chemistry and physical architecture are critical to guiding 
regeneration. An interconnected porous structure is needed to encourage cell growth, 
nutrient and metabolic waste transport, and neovascularization.
2
 Bone and other 
structural tissues also require that these porous scaffolds have adequate mechanical 
properties to withstand physiological loading until tissue function is restored.
180, 181
 Great 
effort has been spent developing materials and fabrication strategies to meet these design 
criteria; however, matching the constraints of tissue regeneration and sufficient 
mechanical properties to restore function remains challenging given that many of these 
properties are inversely related to each other. For example, high porosity enhances mass 
transport to support cell viability but typically reduces mechanical properties. 
Polymerized high internal phase emulsions (polyHIPEs) are a more recent scaffold 
fabrication technique that offers unique advantages in meeting these diverse criteria.
54
 
PolyHIPEs have been investigated as tissue engineered scaffolds due to their 
tunable mechanical properties and pore architectures appropriate for tissue 
regeneration.
54, 157, 158
 A unique advantage of the polyHIPEs developed in our lab is their 
solvent-free fabrication and low cure temperature that permits their use as an injectable 
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scaffold that cures to rigid foams in the body. This injectability allows these scaffolds to 
match irregular defect geometries and thus eliminate gaps and micromotion, which could 
reduce graft failure and revision surgeries.
158, 180, 181
 An injectable graft that cures in situ 
would also reduce cost and time associated with computer-aided design and fabrication 
methods.
182
 Finally, the solvent-free fabrication method permits incorporation of 
bioactive cues to facilitate cell differentiation and promote new tissue growth.
2, 182
  
While these scaffolds offer many advantages over alternative bone grafts, current 
biodegradable formulations require roughly 2 hours to cure at body temperature.
157, 158
 
Clinicians prefer fast-curing materials that reduce surgical times, lower the patient’s risk 
of infection, and rapidly stabilize defects.
181
 Poly(methyl methacrylate) (PMMA) bone 
cement cures in just 15 minutes and is the most common injectable system used 
clinically to stabilize orthopedic implants. Although PMMA bone cements are fast and 
direct, it does not facilitate tissue regeneration because it is highly exothermic, non-
degradable, and non-porous. In contrast, an injectable polyHIPE that cures within 15 
minutes would be advantageous because it can stabilize the defect and be loaded with 
cells prior to injection to provide a temporary matrix that supports tissue regeneration. In 
addition to a rapid cure times, off-the-shelf grafts are preferred to allow use in both 
emergency and scheduled procedures.
181
 Thus, polyHIPE grafts must remain stable in 
storage for a minimum of 6 months and then cure rapidly after injection to facilitate 
clinical translation.  
Previous iterations of injectable polyHIPE scaffolds relied on thermal initiation, 
the rate of which increases exponentially with temperature. A graft that cures in situ is 
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constrained to a physiological cure temperature of 37 °C, well below the typical use 
temperatures of most thermal initiators. In this study, thermal initiation was replaced 
with a redox initiator system to decrease the set time of the HIPEs. Previous redox-cured 
polyHIPEs displayed enhanced cure rates but were not designed for biomedical use and 
often contained toxic or non-degradable components.
183, 184
 Here, a method is described 
that allows for the fabrication of injectable polyHIPEs from biodegradable macromers 
that can be stored for months at a time and then rapidly cures in situ. This proposed 
method involves making two separate but near-identical HIPEs: the first with an 
oxidizing initiator and the second with a reducing agent. Redox-paired initiators allow 
for the rapid polymerization at low temperatures while the use of a double-barrel syringe 
keeps the components separate and unpolymerized until the two components are mixed 
upon injection via a static mixing head. By carefully selecting initiator concentrations, 
this system has the potential to permit stable storage of the uncured emulsion and rapid 
curing after injection into the defect. To this end, we investigated the effect of redox 
initiator concentration on polyHIPE properties for three materials: ethylene glycol 
dimethacrylate (EGDMA), butanediol dimethacrylate (BDMA), and propylene fumarate 
dimethacrylate (PFDMA). The effects of redox concentration and ratio on cure time, 
pore architecture, and compressive modulus and strength were evaluated in relation to 
use in orthopedic applications. Overall, these studies demonstrate the potential of this 
new method of fabricating rapid-curing polyHIPEs with long shelf-lives for utility as 
tissue engineered bone grafts. 
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4.2 Materials and Methods 
4.2.1 Materials Polyglycerol polyricinoleate (PGPR 4125) was donated by 
Paalsgard. All other chemicals were purchased and used as received from Sigma Aldrich 
unless otherwise noted. 
4.2.2 PFDMA Synthesis PFDMA was synthesized in a two-step process adapted 
from Timmer et al.
185
 First, propylene oxide was added dropwise to a solution of fumaric 
acid and pyridine in 2-butanone (2.3:1.0:0.033 mol) and refluxed at 75°C for 18 hours. 
Residual propylene oxide and 2-butatone were removed by distillation and the product 
redissolved in dichloromethane. Residual acidic byproducts and water were removed 
with washing, and the product dried under vacuum to yield the diester bis (1,2 
hydroxypropyl) fumarate product. The diester was then endcapped with methacrylate 
groups using methacryloyl chloride in the presence of triethylamine. The molar ratios of 
the diester, methacryloyl chloride, and triethylamine were 1:2.1:2.1, respectively. 
Hydroquinone was added to the diester to inhibit crosslinking during synthesis at a molar 
ratio of 0.008:1. The reaction was maintained below -10˚C to reduce undesirable side 
reactions and stirred vigorously under a nitrogen blanket. The macromer was neutralized 
overnight with 2 M potassium carbonate. Residual triethylamine and methacrylic acid 
were removed with an aluminum oxide column (7 Al2O3:1 TEA). The integration ratio 
of methacrylate protons to fumarate protons in the
 1
H NMR spectra was used to confirm 
> 90% functionalization for all macromers prior to polyHIPE fabrication. (300 MHz, 
CdCl3) δ 1.33 (dd, 3H, CH3), 1.92 (s, 3H, CH3), 4.20 (m, 2H, -CH2-), 5.30 (m, 1H, -
CH-), 5.58 (s, 1H, -C=CH2), 6.10 (s, 1H, -C=CH2), 6.84 (m, 2H, -CH=CH-).  
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4.2.3 EGDMA and BDMA Inhibitor Removal EGDMA and BDMA purchased 
from Sigma Aldrich were purified to remove inhibitors prior to use. The macromers 
were filtered through an aluminum oxide column to remove monomethyl ether 
hydroquinone. The purified products were stored at 4 °C under a nitrogen blanket until 
used for HIPE fabrication. 
4.2.4 PolyHIPE Fabrication HIPEs were fabricated using a FlackTek 
Speedmixer DAC 150 FVZ-K according to a protocol adapted from Moglia et al.
157
 
Briefly, macromer was mixed with 10 wt% PGPR 4125 and a varied amount of benzoyl 
peroxide (0.5-5.0 wt%) prior to emulsification. A second mixture consisting of 
macromer, 10 wt% PGPR, and a varied amount of trimethylaniline (TMA, 0.5-5.0 wt%) 
was also combined prior to emulsification. Once both were thoroughly mixed, an 
aqueous solution of calcium chloride (1 wt%) was then added to the organic phases 
(75% v) in 3 additions and mixed at 500 rpm for 2.5 minutes each. HIPEs were placed in 
double barrel syringe and the two components mixed upon injection using a static 
mixing head (5 mL syringe with 3 cm straight mixer, Sulzer Mixpac K-System). HIPEs 
were then placed in a 37°C bath to initiate polymerization (Figure 4.1). 
 
Figure 4.1. Schematic of the double-barrel syringe system. 
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4.2.5 Rheological Analysis PolyHIPE cure time was characterized using an 
Anton Paar MCR 301 rheometer based on a process adapted from Foudazi et al.
186
 
HIPEs were injected through a mixing head to facilitate redox initiation directly onto the 
37 °C plate. Storage and loss moduli were measured every 15 s using a parallel-plate 
configuration with a 1 mm gap and 0.5% strain. Work time is presented as the onset of 
increasing storage modulus and set time is presented as the tan δ minimum, which 
corresponds to storage modulus yielding. 
4.2.6 Scanning Electron Microscopy PolyHIPEs were dried in vacuo for 24 hr to 
remove water prior to characterization of pore architecture. Average pore and 
interconnect size of each composition was determined using scanning electron 
microscopy (SEM, JEOL 6500). Circular specimens from three separate polyHIPE 
specimens were sectioned into quarters and fractured at the center. Each specimen was 
coated with gold and imaged in a rastor pattern yielding five images. Pore size 
measurements were completed on the first ten pores that crossed the median of each 
500x magnification micrograph. Average pore sizes for each polyHIPE composition are 
reported (n=450). A statistical correction was calculated to account for the random 
fracture plane through spherical voids and pores, 2/ .
159
 Average diameter values were 
multiplied by this correction factor resulting in a more accurate pore diameter 
description.  
4.2.7 Mechanical Testing PolyHIPE compressive properties were measured 
using an Instron 3300 equipped with a 1000-N load cell. ASTM D1621-04a was utilized 
to determine the compressive modulus and strength of the polyHIPEs.
135
 Each polyHIPE 
3
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specimen was sectioned into three discs (15mm diameter, 5 mm thick) using an Isomet® 
saw and compressed at a strain rate of 50 µm/s. The compressive modulus was 
calculated from the slope of the linear region after correcting for zero strain and the 
compressive strength was identified as the stress at the yield point or 10% strain, 
whichever occurred first. Reported moduli and strength data were averages of 9 
specimens for each composition tested. 
4.2.8 Gel Fraction Gel fraction was measured gravimetrically to evaluate the 
extent of network formation. After curing for 24 hr, polyHIPE samples were sectioned 
into 15mm by 1 mm discs. Mass was recorded for each specimen after vacuum drying 
for 48 hr, incubating in 100X dichloromethane at 20 °C for 48 hr, and vacuum drying 
again until a constant mass was achieved. The final weight divided by the initial weight 
was assessed as the gel fraction. 
4.2.9 Long Term Storage Uncured PFDMA HIPEs were stored at 4°C for up to 
six months and sampled each month to determine the impact of storage on polyHIPE 
architecture and mechanical properties. After a sample was removed, it was thawed for 
60 minutes then injected through a syringe and cured for 48 hours prior to 
characterization, as described above. 
 
4.3 Results and Discussion 
4.3.1 Effect of Redox Initiator Concentration on Work and Set Time Prior to 
curing, all HIPEs flowed like viscous fluids but were rheologically similar to gels (E’ > 
E”), as is expected for HIPEs.186, 187 Their moduli remained relatively constant before 
 77 
 
curing began, indicating that the emulsions were stable without significant phase 
separation.
186
 Work time is defined by ISO1997 as the “period of time, measured from 
the start of mixing, during which it is possible to manipulate a dental material without an 
adverse effect on its properties” and set time is accepted as the point at which a polymer 
network is formed.
186
 Previously, we reported a cure time for PFDMA of approximately 
2 hours (5 wt% BPO)
157
; whereas, both EGDMA and BDMA require over 10 hours to 
set with thermal initiation alone. Utilization of the reducing agent TMA in combination 
with BPO dramatically reduced work and set time for all materials from hours to 
minutes. This corresponded to an order of magnitude increase in rate over thermal 
initiation alone.
157
 Increasing total redox initiator concentration from 0.5 wt% to 5 wt% 
also decreased both work and set times for all materials, Figure 4.2. For EGDMA, redox 
initiation with 0.5 wt% decreased work time to 3.5 minutes and set time to 5 minutes. 
Increasing initiator concentration to 1 wt% further decreased work time to 30 seconds 
and set time to 1 minute. BDMA displayed a slower set and work times than EGDMA 
under the same conditions. At 0.5 wt%, BDMA’s work time and set time was 5 and 7.5 
minutes, respectively, with a further decrease to 1 and 2 minutes at 1.0 wt%. PFDMA 
had similar work and set times to BDMA with (0.1 wt%: 6 and 7 minutes, 1 wt%: 1 and 
1.3 minutes). All of the 5 wt% compositions cured before measurements could be taken 
with the rheometer (< 30 seconds).  
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Figure 4.2. Rheological analysis of redox polyHIPEs during polymerization. Storage 
and loss moduli during EGDMA (A), BDMA (C), and PFDMA (E) polyHIPE 
polymerization and work and set times for EGDMA (B), BDMA (D), and PFDMA (F) 
polyHIPEs at 37 °C with 1.0 TMA:1.0 BPO ratio. 
 
PMMA bone cement is one of the most prevalent injectable biomaterials in 
orthopedic applications because it transitions from a low viscosity liquid to a rigid solid 
within 15 minutes.
188-191
 The PMMA physical transition allows surgeons to work with 
either a liquid or puddy to best suite their procedure and is a contributing factor in 
PMMA’s widespread use.190 The findings from this study demonstrate the utility of the 
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redox system to increase the cure rate of the polyHIPEs to ranges comparable to PMMA 
bone cements. We also demonstrated that the cure rate can be further modulated from 
<30s to 10 minutes by changing the redox initiator concentration. In contrast to PMMA 
which is non-porous, non-biodegradable, and highly exothermic with peak temperatures 
reaching 110°C,
192
 these polyHIPEs cure to porous and degradable materials with a 
maximum exotherm of only 42 °C. This low exotherm would be critical if the scaffolds 
are to be used synergistically with stem cells or growth factors.  
4.3.2 Effect of Redox Initiator Concentration on Network Formation 
Additional rheological and gel fraction data was analyzed to investigate the impact of 
redox initiation concentration on the network formation in candidate polyHIPEs. In each 
material, an induction period was evident prior to an increase in modulus that was 
dependent on macromer chemistry (EGDMA<BDMA<PFDMA) that was primarily 
responsible for the difference in cure times, Figure 4.2. It was hypothesized that reduced 
radical diffusion and steric hindrances associated with increased macromer molecular 
weight resulted in longer induction periods, especially in the low initiator concentration 
compositions.
193
 PFDMA, BDMA, and EGDMA have molecular masses of ~362, 226, 
and 198 g/mol, respectively. HIPE viscosity trended with macromer molecular weight 
with PFDMA almost 30 times more than EGDMA. The increased viscosity likely 
inhibited initiator diffusion and reaction in the PFDMA HIPEs as compared to EGDMA 
HIPEs.
193, 194
 This induction period decreased and the moduli slopes increased as 
initiator concentration was raised from 0.5 to 1.0 wt%, suggesting increased 
polymerization rate.
195
 This was attributed to increased initiation sites leading to more 
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chains growing simultaneously and causing chain molecular weight to increase more 
rapidly.  
 
Table 4.1. The effect of macromer and initiator chemistry on average gel fractions, pore 
diameters, and interconnect diameters of various polyHIPE formulations. 
Material 
Redox 
Initiator 
(wt%) 
Gel Fraction 
(%) 
Pore 
Diameter 
(µm) 
Interconnect 
Diameter 
(µm) 
EGDMA 0.5 86.1 ± 2.8 27 ± 12 * 3 ± 2 
 
1.0 89.1 ± 0.5 20 ± 10 3 ± 1 
 
5.0 89.0 ± 1.0 19 ± 12 3 ± 1 
BDMA 0.5 85.8 ± 0.4 14 ± 6 3 ± 1 
 
1.0 89.3 ± 0.4 14 ± 6 3 ± 1 
 
5.0 92.1 ± 0.3 13 ± 7 † 2 ± 1 
PFDMA 0.5 77.9 ± 1.7 5 ± 3 ‡ 1 ± 1 
 
1.0 81.0 ± 0.8 6 ± 3 1 ± 1 
 
5.0 85.6 ± 0.8 6 ± 3 1 ± 1 
  
 
  
Material 
TMA:BPO 
(wt%:wt%) 
Gel Fraction 
(%) 
Pore 
Diameter 
(µm) 
Interconnect 
Diameter 
(µm) 
EGDMA 0.5:1.0 87.8 ± 0.7 19 ± 8 3 ± 1 
 
1.0:1.0 89.1 ± 0.5 20 ± 10 ● 3 ± 1 
 
5.0:1.0 86.5 ± 1.9 17 ± 11 2 ± 1 
*: P <0.001 compared to EGDMA 1.0 and 5.0 wt% pore sizes 
†: P <0.05 compared to BDMA 0.5 and 1.0 wt% pore sizes 
‡: P <0.01 compared to PFDMA 1.0 and 5.0 wt% pore sizes 
●: P <0.01 compared to 0.5:1.0 and 5.0:1.0 TMA:BPO pore sizes 
 
Gel fraction (Table 4.1) was utilized to compare extent of network formation in 
polyHIPEs after 24 hr of curing and ranged from 78 to 92% for all compositions, Table 
4.1. As expected, increasing initiator concentration correlated with increased gel 
fraction. PFDMA gel fraction increased the most from 78 to 86%. BDMA gel fraction 
also increased significantly with higher initiator concentrations (86 to 92%); whereas, 
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EGDMA gel fractions only increased from 86 to 89%. Both EGDMA and BDMA had 
significantly higher gel fractions than the corresponding PFDMA polyHIPEs, likely due 
to steric hindrance and reduced radical diffusion associated with its higher molecular 
weight. Additionally, highly crosslinked microgels could form and begin to stearically 
hinder further crosslinking, increasing network defects and free-ends.
193
 Overall, these 
polyHIPEs showed excellent network formation that was further enhanced at higher 
initiator concentration. 
4.3.3 Effect of Redox Initiator Concentration and Storage on Pore 
Architecture The impact of the rapid, redox-initiated cure on polyHIPE micro-
architecture was examined to ensure retention of desirable pore size and interconnection. 
EGDMA polyHIPEs possessed the largest pore diameters (Table 4.1, Figure 4.3), 
almost double the size of BDMA and quadruple the size of PFDMA pores at each 
initiator concentration. Traditionally, pore size has been used as a marker of emulsion 
stability with smaller pore size indicating enhanced stability and reduced droplet 
coalescence prior to the gel point.
67, 114
 In this study, increasing pore size correlated with 
decreasing HIPE viscosity: PFDMA (11.0 Pa*s), BDMA (0.464 Pa*s) and EGDMA 
(0.343 Pa*s). This was consistent with the previous literature reports of increased 
emulsion viscosity impeding droplet coalescence and resulting in smaller pores.
183
 
Despite differences between materials, scanning electron micrographs revealed that 
average pore and interconnect diameter were not affected by redox initiator 
concentration for most materials. The 0.5% EGDMA was the exception with an average 
pore size of 26 µm, significantly larger than the 1.0 and 5.0% polyHIPEs (20 µm) and 
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indicative that some amount of coalescence occurred prior to the gel point. The rapid 
cure of both the 1.0 and 5.0 wt% EGDMA polyHIPEs reduced droplet coalescence and 
thus no change in pore size was observed.  
 
 
 
Figure 4.3. Representative SEMs illustrating the effect of initiator concentration on pore 
architecture of EGDMA (A, B, C), BDMA (D, E, F), and PFDMA (G, H, I) polyHIPEs. 
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Figure 4.4. Representative SEMs of PFDMA polyHIPEs after storing unpolymerized 
HIPEs at 4 °C for up to 6 months. 
 
 
Although there are no clear targets for ideal pore diameters to regenerate tissues, 
these pore sizes are relatively small compared to the general goal of >100 µm; however, 
recent studies indicate that <40 µm pores improve regeneration.78, 85 We have 
demonstrated previously that emulsion composition and processing can be modified to 
increase or decrease pore diameter but this was not the focus of this study.
67, 111, 157, 158
 
BDMA and EGDMA polyHIPEs possessed pore diameters up to 60 µm when cured via 
thermal initiation (data not shown). We hypothesized that the use of the static mixing 
head in this study decreased pore size by imparting extra shear forces on the emulsion 
and further breaking droplets down to smaller diameters. Therefore, use of a large 
diameter mixing head should minimize the impact on pore diameter for all materials and 
compositions tested.  
A crucial element of the double-barrel system is that the two HIPEs can be stored 
separately until needed, and the shelf-life can be further extended by storing at reduced 
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temperatures. PFDMA HIPEs were stored at 4 °C with samples removed and cured to 
examine any effect of storage on pore size indicating droplet coalescence or phase 
separation over time. No significant change in pore architecture was observed over a 
period of 6 months (Figure 4.4). This same technique could be used with any emulsion, 
but is especially useful for these solvent-free polyHIPEs that could encapsulate live cells 
or other biological therapeutics which could then be cryogenically stored without losing 
efficacy. Also, this method could facilitate scale-up with a central facility making the 
emulsion-filled syringes and transported to facilities where needed. 
 
 
Figure 4.5. The effect of initiator concentration on compressive modulus (A) and 
strength (B) for each material. One composition had large regions of uncured material 
and was not tested, denoted with X. 
 
0
10
20
30
40
50
60
0.5 1.0 5.0
C
o
m
p
re
s
s
iv
e
 
M
o
d
u
lu
s
 (
M
P
a
)
wt% Redox Initiator
EGDMA
BDMA
PFDMA
0
1
2
3
4
5
0.5 1.0 5.0
C
o
m
p
re
s
s
iv
e
 
S
tr
e
n
g
th
 (
M
P
a
)
wt% Redox Initiator
EGDMA
BDMA
PFDMA
†,• 
 
 
 : P <0.01 compared to all BDMA polyHIPEs 
†:   < .      p                  p         
‡:   < .      p                  p         
•:   < .      p             .     p         
○: P <0.01 compared to all 1.0 wt% polyHIPEs 
◊: P <0.01 compared to all 5.0 wt% polyHIPEs 
  
  
 ◊ 
†,○ 
†◊ 
  
  
 ◊ 
†,○ 
†◊ 
†,• 
B) PolyHIPE Compressive Strength 
A) PolyHIPE Compressive Modulus 
‡ 
‡◊ 
‡ 
‡◊ 
 85 
 
4.3.4 Effect of Redox Initiator Concentration on Compressive Properties 
Compressive modulus and strength are clinically important for bone grafts in stabilizing 
defects. Increased defect stability would reduce the necessity for immobilization and 
allow for earlier loading which has established benefits in stimulating bone 
regeneration.
196
 Although the polyHIPEs set within several minutes, specimens were 
sectioned after a 24 hour cure for further characterization. Compressive modulus and 
strength increased as redox initiator concentration increased for all materials tested, 
Figure 4.5. BDMA was significantly stiffer and stronger than both EGDMA and 
PFDMA for each concentration tested. These differences in strength were more 
pronounced than the modulus, with even the weakest BDMA (0.5 wt% initiator) having 
a higher yield strength than all but the strongest EGDMA and PFDMA polyHIPEs (5.0 
wt% initiator). The 0.5 wt% PFDMA samples were not tested in compression because 
they possessed large regions of uncured HIPE (reflected in their lower gel fraction). We 
hypothesize that the high viscosity of PFDMA decreased mixing efficiency of the two 
HIPEs and limited radical diffusion resulting in regions of uncured HIPEs. This was not 
observed in the 1.0 or 5.0% PFDMA HIPEs due to the higher concentration of initiator 
which limited the role of radical diffusion throughout the material. A longer static 
mixing head may eliminate the uncured regions in the 0.5% redox PFDMA. 
Representative loading curves are presented in Figure 4.6. EGDMA polyHIPEs were 
brittle and reduced to a compacted powder after compressive testing; whereas, both 
BDMA and PFDMA retained their dimensions. Toughness for all materials appeared to 
 86 
 
increase at higher initiator concentrations with 5 wt% redox BDMA and PFDMA 
specimens showing no signs of brittle fracture.  
 
 
Figure 4.6. Representative compressive loading curves for each material and initiator 
concentration. 
 
 
These porous materials approach the compressive properties of cancellous bone 
when matched by density, indicating the potential to mechanically stabilize the defect 
and elicit the appropriate mechanical cues to regenerate bone.
2, 34, 197
 Furthermore, some 
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studies have shown that the mechanical properties required to trigger bone formation 
may be much lower than those of fully matured bone tissue.
189
 In addition, the redox 
initiator system in these studies resulted in a rapid maturation of mechanical properties 
as compared to thermal initiation alone. Previously, the compressive modulus and 
strength of PFDMA polyHIPEs thermally cured with 5 wt% BPO increased over a 2 
week incubation at 37 °C, Figure 4.7. In that time, modulus increased from 8.5 to 43 
MPa and strength from 0.4 to 3 MPa. In contrast, the 5 wt% redox PFDMA polyHIPEs 
achieved similar properties within 24 hr of incubation and remained constant for the 2 
weeks tested. As such, the redox system could potentially be used as an immediate 
fixation device and/or allow patients to begin loading the injury site more quickly which 
can improve patient outcomes.
196
  
 
 
Figure 4.7. The effect of incubation for 1 and 14 days at 37 °C on PFDMA polyHIPE 
compressive (A) modulus and (B) strength. 
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4.3.5 Effect of TMA:BPO Ratio on PolyHIPE Properties The ratio of reductant 
to oxidant was also investigated to decouple the effects of rapid curing rates from 
increased initiator concentration. As expected, increasing the relative amount of TMA to 
BPO resulted in decreased work and set times, 90 to 30 seconds and 2.5 to 1 minute, 
respectively (Figure 4.8A). It should be noted that the 5.0 wt% TMA:1.0 wt% BPO 
HIPE set before testing could begin (< 20 seconds). We hypothesize that increasing the 
relative amount of TMA increases its availability to react with BPO, resulting in faster 
radical production and initiation. Other researchers have shown similar results with 
BPO/TMA systems and identified the formation of the BPO-TMA complex as the rate 
limiting step in radical production.
198, 199
 As such, the faster initiation would allow the 
HIPEs to form a network more quickly and increase the cure rate. The compressive data 
collected after 24 hours indicated that redox initiator ratio had little to no effect on 
compressive modulus and strength (Figure 4.8B, 4.8C). There was also minimal effect 
on pore architecture. Average pore diameter varied slightly as the relative amount of 
TMA was increased, but no clear trend was observed. The 1.0:1.0 ratio had the largest 
average pore diameter (20 µm) with 0.5 and 5.0:1.0 slightly smaller at 19 and 17 µm, 
respectively. Although statistically significant, these differences are small and overall 
pore architecture is similar between the compositions. 
 
 89 
 
 
Figure 4.8. The effect of increasing TMA: BPO ratio in EGDMA polyHIPEs on: 
(A) work and set times, (B) compressive modulus, and (C) compressive strength. 
 
 
Overall, these results demonstrate that the polyHIPE work and set time can be 
tuned independently from other polyHIPE properties (compressive modulus and 
strength, pore and interconnect diameter) with small variations in the reductant:oxidant 
ratio. For biomedical devices, especially tissue engineered grafts, this provides 
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researchers a route to preserve graft physical properties and cytocompatibility while 
optimizing work and set time to meet physician preferences. 
 
4.4  Conclusions 
This study demonstrates the benefits of redox-initiated polyHIPEs delivered 
using double-barrel syringes as tissue engineered bone grafts. Redox initiation reduced 
work and set times from hours to minutes matching current products like PMMA bone 
cement. These reduced cure times were also achieved with lower concentrations of total 
initiator that may enhance material cytocompatibility. Increasing redox initiator 
concentration increased compressive modulus and strength with minimal impact on pore 
architecture. Further modulation of the reductant:oxidant ratio decoupled set time from 
compressive modulus and strength allowing for increased tunability of future scaffold 
properties. The use of the double-barrel syringe permitted the emulsions to be stored for 
months at reduced temperatures and then undergo rapid on-demand curing upon 
injection due to mixing of the two components. Overall, the methodology developed in 
these studies facilitates clinical translation of this technology by providing new graft 
materials with improved attributes that maintain similar handling and deployment of 
traditional PMMA bone cements.  
  
 91 
 
CHAPTER V 
POLYHIPE MICROSPHERES FOR CONTROLLED RELEASE OF GROWTH 
FACTORS  
 
5.1 Introduction 
Bone grafting techniques have improved rates of healing and bone regeneration, 
but some cases require additional aid to induce calcification and neovascularization.
200, 
201
 Growth factors such as bone morphogenetic protein-2 (BMP-2), are used to enhance 
bone regeneration in many surgeries but are expensive and can have dangerous side 
effects.
202, 203
 The INFUSE bone graft is one FDA approved product comprised of a 
collagen sponge imbued with an excess of BMP-2, 1000X the amount naturally found in 
vivo.
204
 Despite the large amount of BMP-2, studies have found the INFUSE graft to 
offer little improvement over other methods with an expected success rate of 57.1% 
compared to 56.7% without using BMP-2 
205
. This is hypothesized to be a result of poor 
growth factor retention, up to 50% of BMP-2 released in the first 24 hours
206
, 
discharging expensive and potent growth factor into the body, potentially calcifying 
adjacent soft-tissue. Further, the amount of BMP-2 required to keep later dosages in the 
effective range increases treatment costs by over $10,000. A new material with sustained 
release of lower dosages up to 21 days could maximize regeneration while reducing both 
cost and health risks.
204
 
A variety of different systems have been studied including hydrogels, 
nanoparticles, and microparticles.
204
 Recently, these systems have been investigated as 
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additives to tissue engineered scaffolds as a means to induce or control bioactivity. 
Although hydrogels can be used to encapsulate drugs and cells, they typically have weak 
mechanical properties which limits their use as a component in load bearing devices 
because they can act as stress concentrators in a graft and result in brittle failure under 
physiological loading.
207
 Typical hydrogel mesh sizes limit the diffusion of large 
proteins out of the matrix to degradation rates, further limiting the specific molecules 
used.
208
 Emulsification-evaporation methods can be used to produce nano- or 
microparticles with tunable porosities and sizes. These particles are usually injected but 
can also be integrated with tissue grafts to allow for site specific delivery 
209
 and their 
tunability allows for fine control over the drug release profile. However, these systems 
require a relatively large amount of solvent, limiting which proteins can be encapsulated 
or requires them to be loaded post-fabrication, reducing encapsulation efficiency.
210
 A 
tunable and solvent-free system would broaden the number of potential proteins and 
decrease fabrication costs associated with using organic solvents. Additionally, this type 
of system could be added to a tissue engineered graft to improve treatment effectiveness 
and reduce healthcare costs to the patient. 
We propose using the polyHIPE system developed in our laboratory to generate 
microspheres that are solvent-free, high porosity, and tunable.
157, 158
 Additionally, these 
microspheres’ pore architecture and material composition would match our injectable 
scaffolds’, theoretically eliminating concerns of stress concentrators and thus retaining 
favorable mechanical properties. Using known principles, particle and pore size could be 
adjusted to tune encapsulation efficiency and release profiles. Furthermore, the solvent-
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free fabrication allows growth factors to be encapsulated in the initial steps which should 
hypothetically increase encapsulation efficiency over other techniques. The porous 
structure would allow large proteins such as BMP-2 to percolate through the polyHIPE 
microspheres slowly and maintain effective concentrations only at the site of injury, 
preventing risks associated with excess growth factors.
208
 
In this study, porous polyHIPE microspheres were chosen for use as a drug 
delivery system. This system is fabricated using emulsion templating without solvent to 
ensure biocompatibility and improve drug encapsulation efficiency. The effect of 
different fabrication parameters on particle size and pore diameter were investigated. 
One candidate composition was then selected to demonstrate proof of concept as an 
rhBMP-2 delivery system. 
 
5.2 Materials and Methods 
5.2.1 Materials Polyglycerol polyricinoleate (PGPR 4125) was donated by 
Paalsgard. All other chemicals were purchased and used as received from Sigma Aldrich 
unless otherwise noted. 
5.2.2 Macromer Filtration Macromer purchased from Sigma Aldrich was 
purified to remove inhibitor prior to use. Ethyleneglycol dimethacrylate (EGDMA) was 
filtered through an aluminum oxide column to remove monomethyl ether hydroquinone. 
5.2.3 PolyHIPE Fabrication Primary HIPEs were fabricated using a FlackTek 
Speedmixer DAC 150 FVZ-K according to a protocol adapted from Moglia et al.
157
 
Briefly, EGDMA was mixed with PGPR (10, 20, or 30 wt% of the macromer) and 2 
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wt% of the organically soluble photoinitiatior, 2,2-Dimethoxy-2-phenylacetophenone 
(DMPA), prior to emulsification. Once thoroughly mixed, an aqueous solution 
containing calcium chloride (1 wt%) was then added to the organic phase (75% v) in 3 
additions and mixed at 500 rpm for 2.5 minutes each.  
5.2.4 Microsphere Fabrication Microspheres were fabricated via a fluidics 
double emulsion technique (w/o/w) adapted from Gokmen et al., Figure 5.1.
211
 The 
primary HIPE was injected drop wise (KD Scientific-100 Infusion Pump) into an 
external aqueous phase containing 3 wt% poly(vinyl alcohol) (Harvard PHD 2000 
Infusion Pump) and passed through UV excitation (UVP High Performance 
Transilluminator 365 nm) for a duration of 2.5 minutes to initiate polymerization. Three 
sets of fabrication parameters were used to obtain distinct particle diameter profiles 
ranging from 300-800 microns, summarized in Table 5.1. Microspheres with 800 
micron diameter were made using a 27G blunt needle with a HIPE injection rate of 0.20 
mL h-
1
 and the external phase was pumped at 1.2 ml min
-1
 using 1.59 mm ID Tygon 
tubing. 500 µm microspheres were made by increasing the external flow rate to 5.6 ml 
min
-1
. The 300 µm spheres were made with a blunted 30G needle and a HIPE injection 
rate of 1.0 mL h
-1
, and the continuous phase was pumped at 6.0 ml min
-1
 using 0.79 mm 
ID Tygon tubing. Collected microspheres were filtered using vacuum aspiration and 
dried in vacuo for a minimum of 24 hours.  
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Figure 5.1. Schematic of microsphere fabrication. HIPE is injected through a needle 
parallel to the flow of 3 wt% PVA solution and polymerized via UV irradiation. 
Polymerized particles are collected and filtered prior to use. 
 
 
Table 5.1. Summary of microsphere fabrication parameters. 
Tubing 
Diameter 
(mm) 
HIPE 
Injection Rate 
(mL/hr) 
Needle Size 
(gauge) 
Aqueous Flow 
Rate (mL/min) 
Particle 
Diameter 
(µm) 
0.8 1.0 30 6.0 260 ± 30 
1.6 1.0 27 5.6 460 ± 40 
1.6 0.2 27 1.2 750 ± 40 
 
 
5.2.5 rhBMP-2 PolyHIPE Microsphere Fabrication Similar to the standard 
polyHIPE fabrication, an organic phase is made of 500 mg EGDMA, 150 mg PGPR, and 
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10 mg DMPA. Then, 5000 ng rhBMP-2 (E. coli expressed, R&D systems) is added to 
1.5 mL of deionized water to make the aqueous phase. The two phases are mixed in the 
same procedure as standard HIPEs. These rhBMP-2 HIPEs were made into ~800 µm 
microspheres following the same procedures outlined above. 
5.2.6 Loading Efficiency of rhBMP-2 Microspheres Loading efficiency of 
rhBMP-2 loaded microspheres was determined by crushing the microspheres and 
incubating in the presence of 3 ml deionized water with agitation for 15 hours in a 15 ml 
centrifuge tube. The tube was spun down at 3500 rpm for 5 min to pellet the crushed 
particles and the aqueous phase removed. The pellet was reagitated with 1 ml deionized 
water on a vortexer and separated like before. Protein concentration was determined with 
CBQCA (Sigma Aldrich) and fluorescence measured with a plate reader (Tecan Infinite 
200 Pro) using a 7-point calibration curve. From this concentration, the concentration of 
rhBMP-2 successfully encapsulated in the particles was calculated and compared to the 
theoretical maximum based on initial HIPE concentration. 
5.2.7 SEM Analysis Average particle, pore and interconnect diameter of varying 
compositions was determined using SEM (JOEL 6500). PolyHIPE microspheres were 
subjected to vacuum drying to remove water prior to characterization. A minimum of ten 
particles were coated with gold, imaged, and particle diameter measured. Pore size 
measurements were completed on five particles using the first ten pores that crossed the 
median of each 500X magnification micrograph. Average pore sizes for each polyHIPE 
microsphere composition are reported (n=50).  
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5.3 Results and Discussion 
5.3.1 Microsphere Fabrication Microspheres were made with a fluidics setup 
inspired by Gokmen et al. because of the resultant monodisperse particle diameters it 
produced.
211
 Reviews by Christopher and Anna, and Gokmen and Du Prez summarize 
the breadth of work done to understand microfluidic systems that is beyond this study’s 
scope, especially on droplet formation.
212, 213
 Using the principles outlined in these 
reviews, monodisperse particles were fabricated with tunable diameters ranging from 
200-800 µm (Table 5.1, & Figure 5.2) and pore sizes from 10-30 µm (Figure 5.3). The 
tunability of the system is ideal for the laboratory setting, allowing facile adjustment of 
microparticle properties from minor changes to the process. This solvent-free setup is 
also a favorable method to pursue at scale because it allows for facile incorporation of 
cells and other biological agents directly into the microparticles. 
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Figure 5.2. (A) The effect of external phase flow rate on average particle size with 
(B) representative SEM data. 
 
 
 
 
Figure 5.3. (A) The effect of HIPE PGPR concentration on average particle pore size 
with (B) representative SEM data. 
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Continuous phase flow velocity and droplet phase viscosity were two of the most 
important factors contributing to droplet size, shape, and uniformity.
212, 213
 These 
qualities dictate the shear forces at the injection site and cause droplets to “drip” from 
the needle, typically in spheres. EGDMA was chosen for the HIPEs because of their low 
viscosity, necessary to form uniform droplets in the aqueous continuous phase. Balance 
between the continuous and droplet phase flow rates maintained efficient and 
monodisperse droplet size, as outlined by Cramer et al.
214
 Excessive droplet flow rates 
resulted in “jetting” from the needle tip which forms small and variable droplets. Most of 
these relationships hold true when the Reynolds number is <<1, indicating laminar flow, 
and explains why the smaller tubing was used to achieve particle diameters below 500 
µm.
212
  
The inherent tunability of the initial w/o HIPE allowed for control of 
microsphere pore architecture independent of particle diameter. An interconnected pore 
structure was formed by selecting an organically soluble photo initiator and it is 
theoretically possible to instead form a closed pore microsphere by switching to an 
aqueous initiator system or decreasing internal water volume.
158
 Pore diameter is 
dependent on surfactant concentration with increased amounts causing decreased 
interfacial energy between the water and organic phases, thereby allowing surface area 
between the phases to increase which manifests as smaller internal droplet sizes and thus 
smaller pores.
67, 111, 157
 This phenomenon was observed here with pore size decreasing 
from 20 to 5 µm as PGPR concentration was increased from 10 to 30 wt%, Figure 5.3. 
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Independent control of both particle diameter and pore structure is ideal for 
controlling drug release profiles, critical for optimizing future therapies. Tortuosity is a 
unit-less measure of the fluid path length through the porous medium relative to the end-
to-end path length.
175
 Tortuosity increases with a decrease in pore size and results in a 
decreased diffusion gradient between the microsphere center and edge, decreasing drug 
release rate.
129
 The same principle allows path length (i.e. release rate) to be controlled 
by changing particle diameter, with larger particles releasing slower than similar small 
particles.
215
 
Burst release occurs when a relatively large portion of drug releases immediately 
after deployment. Considering the price of effective drugs and growth factors, this type 
of release phenomenon is widely considered a waste of resources therapeutically and 
economically
216
 Smaller particles have higher aspect ratios and are more prone to burst 
release kinetics because their increased surface area allows for relatively more 
drug/protein to quickly diffuse away from the particle surface.
216, 217
 Finally, slow drying 
of particles can cause the encapsulated drug to concentrate near the particle surface and 
increase burst release, but freeze-drying has been shown to completely prevent this 
effect.
218
 All of these factors must be considered in future protein release studies. 
Finally, the pore structures obtained are identical to monolithic forms of 
EGDMA polyHIPEs, potentially yielding a continuous polymeric structure with no 
stress concentrators that can result from additives. An initial study of polyHIPE 
compressive modulus and strength after adding 1 wt% microparticles showed no 
statistical difference from the control scaffold (Figure 5.4). Although future studies with 
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increased amounts of microspheres need to be conducted, this supports the hypothesis 
that their common pore structure will mitigate any negative effects on mechanical 
properties. These studies should also account for different particle and pore size to fully 
understand their effects. 
 
 
Figure 5.4. Effect of microsphere incorporation on scaffold compressive modulus and 
strength. 
 
 
5.3.2 rhBMP-2 Encapsulation in PolyHIPE Microspheres These particles’ 
effectiveness as a therapy relies on their ability to encapsulate and protect drugs and 
growth factors. To this end, rhBMP-2 was dissolved into the aqueous phase of the HIPE 
and encapsulated into microspheres with a diameter of ~800 µm and average pore size of 
14 µm. CBQCA determined an encapsulation efficiency of 73 ± 3% compared to theory. 
Many microparticles are fabricated using the emulsion-solvent evaporation method 
which can have encapsulation efficiencies as low as 15% during crosslinking and 
purification.
210
 Subject to specific methods used, retained proteins can be inactivated via 
mixing with organic solvents and extreme heat.
219, 220
 The method utilized here 
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crosslinks within minutes at room temperature and eliminates the need for purification 
because it is solvent-free, theoretically increasing encapsulation efficiency and 
protecting the rhBMP-2. Encapsulation efficiency could be improved by further 
decreasing pore size, fabricating particles with a closed shell, or increasing the 
concentration of the external aqueous phase. These methods would work by decreasing 
the rate of diffusion by lengthening the path length, decreasing coefficient of diffusion, 
or decreasing the concentration gradient.
217, 221
 
 
5.4 Conclusions 
 This study describes a method of producing tunable microspheres with 
theoretically high encapsulation efficiency and bioactivity retention that can be utilized 
to deliver site specific therapy in bone fusion or regeneration. The solvent-free nature of 
this method allowed for safe and efficient microsphere fabrication and protein retention, 
reducing fabrication costs and the amount of growth factor needed. Independent control 
of particle and pore geometry was demonstrated using the principles of emulsion 
templating and microfluidics, which should facilitate gradual release of rhBMP-2 over 
several weeks and increase treatment effectiveness while simultaneously reducing the 
risk of side effects.  
These microspheres can be utilized in combination with tissue engineered 
scaffolds to promote regeneration of complex tissues by loading with various drugs or 
cells, without negatively impacting scaffold mechanical properties. Control of 
microsphere pore architecture can be matched to the scaffold and minimize the impact 
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on composite mechanical properties, a critical feature for load-bearing applications. The 
interconnected porous structure of these microspheres is more favorable for therapeutic 
release of large proteins like IgG which are too large to diffuse readily through 
hydrogels.  
Studies are underway to evaluate protein bioactivity retention and release profiles 
over time as a function of particle and pore geometry. Microsphere osteoinductivity will 
be compared to a short “burst” of protein using hMSCs and ALP production. These 
microparticles are promising drug-delivery vehicles to enhance bioactivity of bone grafts 
without sacrificing mechanical properties. Their high loading efficiency and tunable 
release rates can potentially reduce the amount of drug needed to regenerate damaged 
bone, eliminate side effects, and decrease health care costs. 
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CHAPTER VI 
CONCLUSIONS 
 
6.1 Summary 
In this body of work, a variety of emulsion templated materials were developed 
for use as injectable scaffolds to further tissue engineering therapies. Current treatment 
options rely on donor tissue or poorly matched synthetic materials that later require 
revision treatments. Injectable systems are advantageous in tissue repair because of their 
ability to space-fill irregular defects resulting from injury, deformity, or tumor resection 
without the need for expensive fabrication to shape or custom-build devices. We have 
demonstrated that these unique porous scaffolds can space-fill irregular tissue defects, 
rapidly polymerize at body temperature, and possess appropriate and tunable mechanical 
properties. Emulsion compositions were designed to eliminate the toxic solvents 
commonly used to fabricate biodegradable polyHIPEs without sacrificing high porosity 
and mechanical properties. First, surfactant chemical structure was studied to elucidate 
new structure-property relationships affecting emulsion formation and resultant pore 
structures. A variety of methacrylate and isocyanate polymers were utilized to facilitate 
rapid scaffold polymerization at body temperature and maintain cytocompatibility. 
Varying polymer composition resulted in tunable scaffold mechanical properties similar 
to bone and soft tissues. Use of redox initiation dramatically reduced cure times from 
hours to minutes and improved compressive properties without compromising pore 
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architecture. These studies demonstrated the ability of emulsion templated scaffolds to 
improve upon current scaffold materials used to treat injuries. 
The principles learned in developing these scaffolds were also used to create 
porous polyHIPE microspheres which could potentially increase graft bioactivity. 
Growth factors like rhBMP-2 are commonly used to improve bone regeneration in vivo, 
but the excessive dosages have caused their cost and safety to be questioned by many 
researchers. An improved drug delivery system could decrease the required amount and 
thereby reduce treatment cost and side effects. These microspheres possessed the same 
porous structure and material properties as the scaffolds but could be easily loaded with 
drugs and growth factors to promote and guide tissue regeneration. Microspheres loaded 
with a small amount of rhBMP-2 exhibited a high encapsulation efficiency of 73%. In 
future studies, these particles can be incorporated into the scaffolds to guide cell 
differentiation and tissue regeneration directly at the site of injury.  
In summary, we have developed a library of injectable porous materials that can 
be used to improve tissue regeneration. Furthermore, the emulsion chemistry structure-
property relationships explored here can be used in designing future polyHIPEs for 
tissue engineering or other applications. 
 
6.2 Significance of Work 
Chapter II described the fabrication and development of the first solvent-free and 
biodegradable polyHIPE. PFDMA’s highly reactive methacrylate end-groups and a low 
molecular weight resulted in a low-viscosity emulsion that cured at body temperature, 
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and ultimately opened up the possibility of incorporating living cells or proteins inside 
the emulsions. Prior to this, the majority of polyHIPEs used styrene/divinylbenzene 
systems which were not degradable, and any biodegradable polymers required solvents 
to reduce their viscosity and allow emulsification which did not allow for an injectable 
system or cell encapsulation. Additionally, the effect of hydrogen bonding sites in 
surfactant chemical structures on emulsion stability was discussed for the first time. 
Surfactant selection has previously been accomplished by utilizing the HLB method to 
narrow down choices, and then trial-and-error to find the best one. With thousands of 
possible surfactants to choose from, this process was time consuming and wasteful. The 
new selection criteria is based on molecular hydrophobicity predictions and key 
surfactant structure features provided a rational selection methodology for new 
biodegradable formulations. Indeed, we have used this method to select new macromer 
chemistries with a 100% success rate. 
The PUU scaffolds produced in Chapter III were the first injectable polyMIPEs 
to have elastomeric properties. In contrast to the first generation PFDMA polyHIPEs that 
were rigid and brittle, these materials were pliable and exhibited elastic recovery close to 
100% after large strains. This demonstrated that injectable scaffolds could be applied to 
treat both hard and soft tissues. Another advantage of the PUU system was the increased 
porosity caused by carbon dioxide blowing during polymerization, enhancing the 
emulsion’s space-filling properties, and resulting in large interconnected pores which 
can theoretically increase nutrient flux over non-porous soft-tissue scaffolds. 
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The double-barrel syringe storage and delivery system developed in Chapter IV 
solved two future obstacles to clinical translation. The first generation polyHIPEs 
developed in Chapter II required up to 2 hours to cure and had to be made shortly before 
use. Surgeons would not be able to “close-up” a patient until the scaffold had hardened 
and leaving incisions open for 2 hours would likely be put patients at an unacceptably 
high risk for infection. Additionally, surgeons would have been required to make the 
emulsions prior to the procedure which could take up to 30 minutes and user-specific 
handling could affect the final scaffold properties. This study determined that pre-cured 
emulsions could be stored for up to 6 months at 4 °C prior to use without any significant 
effect on pore structure, allowing HIPEs to be made uniformly at a central plant and then 
shipped to clinics in pre-packaged syringes. The first generation polyHIPEs also relied 
on thermal initiation to polymerize, and increasing cure temperature would decrease set 
time but put the patient at risk of acute tissue necrosis. The use of redox pair initiators 
dramatically decreased cure time from hours to minutes for PFDMA, EGDMA, and 
BDMA polyHIPEs without increasing the scaffold’s curing exotherm. The double-barrel 
syringe system permitted HIPEs to be safely stored until needed and cure rapidly on-
demand comparable to current materials such as PMMA bone cement. Furthermore, this 
system could be applied to large scale with two emulsion streams mixing just prior to 
mold filling, and used in fabricating any porous media with temperature sensitive 
components. 
Finally, chapter V demonstrated another use of the emulsion templated 
polyHIPEs to improve the bioactivity of the load-bearing scaffolds. Here, HIPE droplets 
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were made via a double emulsion process adapted from microfluidics fabrication 
techniques. Typically this process and all others to develop drug eluting microspheres 
require solvents and thus purification before use. Our system is solvent-free, which 
eliminates the need for purification and thus reduces manufacturing costs. Additionally, 
drugs and growth factors can be added to the aqueous phase of the initial emulsion 
instead of being added later. Both of these advantages result in higher theoretical loading 
efficiencies and bioactivity retention over traditional drug-loaded microsphere 
fabrication techniques. 
 In summary, these studies have resulted in a solvent-free method to fabricate a 
variety of porous materials that can be used to advance tissue engineering. Beyond tissue 
engineering, these studies have also investigated the relationships between surfactant 
chemical structures and polymer chemistry on emulsion formation and resultant material 
properties, specifically in solvent-free systems which had not been studied before. 
 
6.3 Challenges and Future Directions 
These studies lay the foundation for a successful and effective tissue engineered 
scaffold, but much work still needs to done and questions answered. Several methods to 
tune pore size have been presented, most notably through controlling surfactant 
concentration and mixing speeds. However, the changes remained on the order of tens of 
microns and it would be ideal to increase that range to 100 µm or greater. A class of 
surfactant termed “defoamers” has been used extensively in the production of PU foams 
to facilitate cell collapse in polymer-air foams. Typically a defoamer would 
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counterbalance another surfactant in order to stabilize pores up to a certain size but cause 
the collapse of larger ones. Previously, calcium stearate was investigated to increase 
thermally initiated PFDMA polyHIPEs but it often caused complete collapse before the 
emulsion could polymerize. Attempting to add the defoamer closer to the gel point was 
slightly more successful but resulted in a heterogeneous pore structure. With the 
introduction of redox initiation and its shorter cure times, calcium stearate should be 
reevaluated as a possible means to increase pore size. A small amount of calcium 
stearate suspended in water could be added while the redox HIPEs are mixed, promoting 
droplet coalescence until the gel point is reached and pore structure set. These tests 
should be run with either EGDMA or BDMA because their decreased viscosity and 
larger pore sizes would magnify any observable changes. Alternatively, incorporating 
small amphiphilic molecules such as PEG 600 has been shown to increase droplet 
coalescence, and thus pore and interconnect size. The amphiphile is hypothesized to 
increase water droplet size (and thus pore diameter) in a similar manner as Ostwald 
ripening. The amphiphile is thought to increase water molecule transport through the 
uncured polymer film separating suspended droplets, increasing average droplet size by 
causing some to expand and others to shrink. Either of these approaches may yield an 
increased pore and interconnect size, but any new components would have to be 
evaluated for cytocompatibility as well their effect on mechanical properties. 
In addition to increasing pore and interconnect sizes, there is the need to 
decouple the two features. Until now, emulsion destabilization has been the pursued 
method of increasing either but always affects both. Therefore, increasing pores will 
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usually increase interconnect size. This is an acceptable trade-off for the near future, but 
there may come a time where it would be ideal to keep one property constant while 
modifying the other. Interconnects form as a result of polymer film shrinkage during 
polymerization, and typically the thinnest film occurs where two droplets are tangent to 
each other. Very large interconnects have been achieved in classic 
styrene/divinylbenzene polyHIPEs because these systems also incorporated solvent. 
During polymerization, the solvent would become increasingly insoluble in the polymer 
and aggregate to the cell walls between droplets. Upon drying, the solvent would be 
removed leaving large interconnects between pores. This exact mechanism is not 
possible in the solvent-free systems described here but it could potentially be mimicked 
using a semi-miscible or rapidly degrading monomer. A minute amount of low 
molecular weight polyanhydride without reactive endgroups could be mixed with a 
reactive macromer such as EGDMA. Upon initiation, EGDMA would begin to crosslink 
and potentially separate from the anhydride monomers which could form a film between 
droplets. Anhydride bonds degrade rapidly in the presence of water; our lab has 
observed degradation beginning within minutes of exposure. This could mimic the effect 
seen in solvent containing styrene systems and potentially provide a way to 
independently tune interconnect and pore size. 
The porous microspheres are a promising method to impart bioactivity into the 
polyHIPE scaffolds. Although this first formulation successfully incorporated rhBMP-2, 
higher encapsulation efficiencies are desired. The rhBMP-2 is hypothesized to be lost 
during microsphere fabrication due to diffusion between the relatively high 
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concentration of rhBMP-2 in the microsphere and the dilute external aqueous phase. 
Fabrication of closed pore microspheres would stop this diffusion and theoretically 
increase encapsulation efficiency. Upon degradation, the pore walls would open or 
become more permeable to rhBMP-2 and release would begin. Decreasing internal water 
volume and making polyMIPEs is one method to decrease pore interconnectivity and 
requires no new formulations. Alternatively, use of an aqueous phase initiator has been 
shown to promote close pore formation in polyHIPEs. 
With a closed pore microsphere system, degradation would have to be quick and 
tunable to control growth factor release. Unfortunately, EGDMA’s high crosslink 
density makes it a slow degrading polymer. Recently, thiol-ene crosslinking chemistries 
have been explored for future polyHIPE formulations and show increased degradation 
rates proportional to thiol content. These thiol-ene emulsions could be used to make 
closed pore microspheres with controllable degradation, hypothetically increasing 
encapsulation efficiency and release kinetics.  
Finally, these scaffolds have been designed and tested in the lab and their in vitro 
properties are being studied concurrently, but they must be tested in vivo to truly 
advance the knowledge of graft performance. The load-bearing nature of these scaffolds 
should require a study on changes in mechanical properties during any in vivo studies, 
specifically testing changes in modulus, strength, and fatigue. While simple hydrolytic 
degradation has been evaluated via mass loss under accelerated conditions, it should also 
result in decreased compressive modulus and strength. The damaged tissue is 
hypothesized to regenerate which may alleviate any loss in modulus and strength. 
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Therefore, it may be telling to implant pre-formed, cylindrical specimens into rat ulnar 
defects. These defects remain relatively unloaded, mitigating any fatigue or creep/stress-
relaxation that could affect the implants. Then at set times, explanting scaffolds and 
subjecting them to 3-point bending tests to calculate changes in modulus, strength, or 
fatigue strength compared to day 0 properties. These results could be compared with 
accompanying radiographs or CT scans to measure bone growth and related to 
restoration of function.  
Although there are many studies remaining before these devices can be used in 
the clinic, this system offers potential for an off-the-shelf treatment to improve tissue 
regeneration over current methods. The studies proposed would further improve the 
knowledge of polyHIPE interconnect formation and in vivo scaffold performance. 
  
 113 
 
REFERENCES 
 
 
1. Wang, X.; Shen, X.; Li, X.; Mauli Agrawal, C., Age-related changes in the 
collagen network and toughness of bone. Bone 2002, 31, (1), 1-7. 
2. Karageorgiou, V.; Kaplan, D., Porosity of 3D biomaterial scaffolds and 
osteogenesis. Biomaterials 2005, 26, 5474-5491. 
3. Chen, G.; Ushida, T.; Tateishi, T., Development of biodegradable porous 
scaffolds for tissue engineering. Materials Science and Engineering: C 2001, 17, (1-2), 
63-69. 
4. Yang, S.; Leong, K. F.; Du, Z.; Chua, C. K., The design of scaffolds for use in 
tissue engineering. Part I: Traditional factors. Tissue Engineering 2001, 7, (6), 679-89. 
5. Alila Medical Media, Bone structure. www.shutterstock.com. 
6. Biewener, A. A., Musculoskeletal design in relation to body size. Journal of 
Biomechanics 1991, 24, Supplement 1, (0), 19-29. 
7. Zioupos, P.; Currey, J. D., Changes in the stiffness, strength, and toughness of 
human cortical bone with age. Bone 1998, 22, (1), 57-66. 
8. Taylor, D., Fatigue of bone and bones: An analysis based on stressed volume. 
Journal of Orthopaedic Research 1998, 16, (2), 163-169. 
9. Freyman, T. M.; Yannas, I. V.; Gibson, L. J., Cellular materials as porous 
scaffolds for tissue engineering. Progress in Materials Science 2001, 46, (3-4), 273-282. 
10. Bhatia, S. N.; Chen, C. S., Tissue engineering at the micro-scale. Biomedical 
Microdevices 1999, 2, (2), 131-144. 
11. Busby, W.; Cameron, N. R.; Jahoda, C. A. B., Tissue engineering matrixes by 
emulsion templating. Polymer International 2002, 51, 871-881. 
12. Harris, L. D.; Kim, B.-S.; Mooney, D. J., Open pore biodegradable matrices 
formed with gas foaming. Journal of Biomedical Materials Research 1998, 42, (3), 396-
402. 
13. Kim, T. K.; Yoon, J. J.; Lee, D. S.; Park, T. G., Gas foamed open porous 
biodegradable polymeric microspheres. Biomaterials 2006, 27, 152-159. 
 114 
 
14. Pham, Q. P.; Sharma, U.; Mikos, A. G., Electrospinning of polymeric nanofibers 
for tissue engineering applications: a review. Tissue Engineering 2006, 12, (5), 1197-
1211. 
15. Rose, F. R. A. J.; Oreffo, R. O. C., Bone tissue engineering: hope vs hype. 
Biochemical and Biophysical Research Communications 2002, 292, (1), 1-7. 
16. Hacker, M.; Ringhofer, M.; Appel, B.; Neubauer, M.; Vogel, T.; Young, S.; 
Mikos, A. G.; Blunk, T.; Gopferich, A.; Schulz, M. B., Solid lipid templating of 
macroporous tissue engineering scaffolds. Biomaterials 2007, 28, (24), 3497-3507. 
17. Mistry, A. S.; Cheng, S. H.; Yeh, T.; Christenson, E.; Jansen, J. A.; Mikos, A. G., 
Fabrication and in vitro degradation of porous fumarate-based polymer/alumoxane 
nanocomposite scaffolds for bone tissue engineering. Journal of Biomedical Materials 
Research, Part A 2009, 89A, (1), 68-79. 
18. Gailani, G.; Benalla, M.; Mahamud, R.; Cowin, S. C.; Cardoso, L., Experimental 
determination of the permeability in the lacunar-canalicular porosity of bone. Journal of 
Biomechanical Engineering 2009, 131, (10), 101007-7. 
19. Ruckenstein, E., The concentrated emulsion approach to toughened polymer 
composites: a review. Polymer Composites 1997, 18, (3), 320-331. 
20. Konttinen, Y. T.; Zhao, D.; Beklen, A.; Ma, G.; Takagi, M.; Kivela-Rajamaki, 
M.; Ashammakhi, N.; Santavirta, S., The microenvironment around total hip 
replacement prostheses. Clinical Orthopaedics and Related Research 2005, 28-38. 
21. Artico, M.; Ferrante, L.; Pastore, F. S.; Ramundo, E. O.; Cantarelli, D.; 
Scopelliti, D.; Lannetti, G., Bone autografting of the calvaria and craniofacial skeleton: 
historical background, surgical results in a series of 15 patients, and review of the 
literature. Surgical Neurology 2003, 60, 71-79. 
22. Chen, J.; Horan, R. L.; Bramono, D.; Moreau, J. E.; Wang, Y.; Geuss, L. R.; 
Collette, A. L.; Volloch, V.; Altman, G. H., Monitoring mesenchymal stromal cell 
developmental stage to apply on-time mechanical stimulation for ligament tissue 
engineering. Tissue Engineering 2006, 12, (11), 3085-3095. 
23. Hemmrich, K.; von Heimburg, D.; Rendchen, R.; Di Bartolo, C.; Milella, E.; 
Pallua, N., Implantation of preadipocyte-loaded hyaluronic acid-based scaffolds into 
nude mice to evaluate potential for soft tissue engineering. Biomaterials 2005, 26, (34), 
7025-7037. 
24. Amsden, B., Curable, biodegradable elastomers: emerging biomaterials for drug 
delivery and tissue engineering. Soft Matter 2007, 3, 1335-1348. 
 115 
 
25. Chandrashekar, N.; Mansouri, H.; Slauterbeck, J.; Hashemi, J., Sex-based 
differences in the tensile properties of the human anterior cruciate ligament. Journal of 
Biomechanics 2006, 39, (16), 2943-2950. 
26. Akizuki, S.; Mow, V. C.; Müller, F.; Pita, J. C.; Howell, D. S.; Manicourt, D. H., 
Tensile properties of human knee joint cartilage: I. Influence of ionic conditions, weight 
bearing, and fibrillation on the tensile modulus. Journal of Orthopaedic Research 1986, 
4, (4), 379-392. 
27. Samartzis, D.; Shen, F. H.; Matthews, D. K.; Yoon, S. T.; Goldberg, E. J.; An, H. 
S., Comparison of allograft to autograft in multilevelanterior cervical discectomy and 
fusion with rigid plate fixation. The Spine Journal 3, (6), 451-459. 
28. Chau, A.; Mobbs, R., Bone graft substitutes in anterior cervical discectomy and 
fusion. European Spine Journal 2009, 18, (4), 449-464. 
29. Liu, X.; Ma, P. X., Polymeric scaffolds for bone tissue engineering. Annals of 
Biomedical Engineering 2004, 32, (3), 477-486. 
30. Mikos, A. G.; Temenoff, J. S., Formation of highly porous biodegradable 
scaffolds for tissue engineering. Electronic Journal of Biotechnology 2000, 3, (2), 114-
119. 
31. Costantino, P. D.; Hiltzik, D.; Govindaraj, S.; Moche, J., Bone healing and bone 
substitutes. Facial Plastic Surgery 2002, 18, 13-26. 
32. Seal, B. L.; Otero, T. C.; Panitch, A., Polymeric biomaterials for tissue and organ 
regeneration. Materials Science and Engineering 2001, R34, 147-230. 
33. Mercuri, L. G.; Giobbie-Hurder, A., Long-term outcomes after total alloplastic 
temporomandibular joint reconstruction following exposure to failed materials. Journal 
of Oral and Maxillofacial Surgery 2004, 62, 1088-1096. 
34. Svaldi-Muggli, D.; Burkoth, A. K.; Anseth, K. S., Crosslinked polyanhydrides 
for use in orthopaedic applications: degradation behavior and mechanics. Journal of 
Biomedical Materials Research 1999, 46, 271-278. 
35. Peter, S. J.; Kim, P.; Yasko, A. W.; Yaszemski, M. J.; Mikos, A. G., Crosslinking 
characteristics of an injectable poly(propylene fumarate)/β-tricalcium phosphate paste 
and mechanical properties of the crosslinked composite for use as a biodegradable bone 
cement. Journal of Biomedical Materials Research 1999, 44, 314-321. 
36. Peter, S. J.; Lu, L.; Kim, D. J.; Mikos, A. G., Marrow stromal osteoblast function 
on a poly(propylene fumarate)/β-tricalcium phosphate biodegradable orthopaedic 
composite. Biomaterials 2000, 21, 1207-1213. 
 116 
 
37. Peter, S. J.; Nolley, J. A.; Widmer, M. S.; Merwin, J. E.; Yaszemski, M. J.; 
Yasko, A. W.; Engel, P. S.; Mikos, A. G., In vitro degradation of a poly(propylene 
fumarate)/β-tricalcium phosphate composite orthopaedic scaffold. Tissue Engineering 
1995, 1, 41-52. 
38. Burdick, J. A.; Anseth, K. S., Photoencapsulation of osteoblasts in injectable 
RGD-modified PEG hydrogels for bone tissue engineering. Biomaterials 2002, 23, 
4315-4323. 
39. Fromstein, J. D.; Woodhouse, K. A., Elastomeric biodegradable polyurethane 
blends for soft tissue applications. Journal Of Biomaterials Science. Polymer Edition 
2002, 13, (4), 391-406. 
40. Fisher, J. P.; Holland, T. A.; Dean, D.; Engel, P. S.; Mikos, A. G., Synthesis and 
properties of photocross-linked poly(propylene fumarate) scaffolds. Journal Of 
Biomaterials Science. Polymer Edition 2001, 12, (6), 673-687. 
41. Timmer, M. D.; Horch, A. R.; Ambrose, C. G.; Mikos, A. G., Effect of 
physiological temperature on the mechanical properties and network structure of 
biodegradable poly(propylene fumarate)-based networks. Journal Biomaterial Science 
Polymer Edition 2003, 14, (4), 369-382. 
42. Ergun, A.; Yu, X.; Valdevit, A.; Ritter, A.; Kalyon, D. M., In vitro analysis and 
mechanical properties of twin screw extruded single-layered and coextruded 
multilayered poly(caprolactone) scaffolds seeded with human fetal osteoblasts for bone 
tissue engineering. Journal of Biomedical Materials Research Part A 2011, 99A, (3), 
354-366. 
43. Gogolewski, S.; Gorna, K.; Turner, A. S., Regeneration of bicortical defects in 
the iliac crest of estrogen-deficient sheep, using new biodegradable polyurethane bone 
graft substitutes. Journal of Biomedical Materials Research 2006, 77A, (4), 802–810. 
44. Guan, J.; Fujimoto, K. L.; Sacks, M. S.; Wagner, W. R., Preparation and 
characterization of highly porous, biodegradable polyurethane scaffolds for soft tissue 
applications. Biomaterials 2005, 26, (18), 3961-3971. 
45. Jabbari, E.; Wang, S.; Lu, L.; Gruetzmacher, J. A.; Ameenuddin, S.; Hefferan, T. 
E.; Currier, B. L.; Windebank, A. J.; Yaszemski, M. J., Synthesis, material properties, 
and biocompatibility of a novel self-cross-linkable poly(caprolactone fumarate) as an 
injectable tissue engineering scaffold. Biomacromolecules 2005, 6, (5), 2503-2511. 
46. Pêgo, A. P.; Poot, A. A.; Grijpma, D. W.; Feijen, J., Biodegradable elastomeric 
scaffolds for soft tissue engineering. Journal of Controlled Release 2003, 87, (1-3), 69-
79. 
 117 
 
47. Schmedlen, R.; Masters, K.; West, J., Photocrosslinkable polyvinyl alcohol 
hydrogels that can be modified with cell adhesion peptides for use in tissue engineering. 
Biomaterials 2002, 23, 4325-4332. 
48. Tai, H.; Sergienko, A.; Silverstein, M. S., High internal phase emulsion foams: 
copolymers and interpenetrating polymer networks. Polymer Engineering and Science 
2001, 41, (9), 1540-1552. 
49. Christenson, E.; Anseth, K.; van den Beucken, J.; Chan, C.; Ercan, B.; Jansen, J.; 
Laurencin, C.; Li, W.; Murugan, R.; Nair, L.; Ramakrishna, S.; Tuan, R.; Webster, T.; 
Mikos, A., Nanobiomaterial applications in orthopedics. Journal of Orthopaedic 
Research 2007, 25, (1), 11-22. 
50. Langer, R.; Vacanti, J. P., Tissue engineering. Science 1993, 260, (5110), 920-
926. 
51. Kenley, R.; Yim, K.; Abrams, J.; Ron, E.; Turek, T.; Marden, L.; Hollinger, J., 
Biotechnology and bone graft substitutes. Pharmaceutical Research 1993, 10, (10), 
1393-1401. 
52. Sikavitsas, V. I.; Temenoff, J. S.; Mikos, A. G., Biomaterials and bone 
mechanotransduction. Biomaterials 2001, 22, (19), 2581-2593. 
53. Cameron, N. R.; Sherrington, D. C.; Albiston, L.; Gregory, D. P., Study of the 
formation of the open-cellular morphology of poly(styrene/divinylbenzene) polyHIPE 
materials by cryo-SEM. Colloid and Polymer Science 1996, 274, 592-595. 
54. Akay, G.; Birch, M. A.; Bokhari, M. A., Microcellular polyHIPE polymer 
supports osteoblast growth and bone formation in vitro. Biomaterials 2004, 25, 3991-
4000. 
55. Hayman, M. W.; Smith, K. H.; Cameron, N. R.; Przyborskia, S. A., Growth of 
human stem cell-derived neurons on solid three-dimensional polymers. Journal of 
Biochemical and Biophysical Methods 2005, 62, 231-240. 
56. Busby, W.; Cameron, N. R.; Jahoda, C. A. B., Emulsion-derived foams 
(polyHIPEs) containing poly(ε-caprolactone) as matrixes for tissue engineering. 
Biomacromolecules 2001, 2, (1), 154-164. 
57. Barbetta, A.; Dentini, M.; Zannoni, E. M.; De Stefano, M. E., Tailoring the 
Porosity and Morphology of Gelatin-Methacrylate PolyHIPE Scaffolds for Tissue 
Engineering Applications. Langmuir 2005, 21, (26), 12333-12341. 
 118 
 
58. Barbetta, A.; Dentini, M.; De Vecchis, M. S.; Filippini, P.; Formisano, G.; 
Caiazza, S., Scaffolds based on biopolymeric foams. Advanced Functional Materials 
2005, 15, (1), 118-124. 
59. Cameron, N. R.; Barbetta, A.; Cooper, S. J., High internal phase emulsions 
(HIPEs) containing divinylbenzene and 4-vinylbenzyl chloride and the morphology of 
the resulting PolyHIPE materials. Chemical Communications 2000, 221–222. 
60. Bokhari, M. A.; Birch, M. A.; Akay, G., Polyhipe polymer: a novel scaffold for 
in vitro bone tissue engineering. Experimental Medical Biology: Tissue Engineering, 
Stem Cells, and Gene Therapies 2003, 534, 247-254. 
61. Hayman, M. W.; Smith, K. H.; Cameron, N. R.; Przyborski, S. A., Enhanced 
neurite outgrowth by human neurons grown on solid three-dimensional scaffolds. 
Biochemical and Biophysical Research Communications 2004, 314, (2), 483-488. 
62. Cameron, N. R.; Sherrington, D. C.; Ando, I.; Kuroso, H., Chemical modification 
of monolithic poly(styrene/divinylbenzene) polyHIPE materials. Journal of Material 
Chemistry 1996, 6, 719-726. 
63. Williams, J. M.; Wrobleski, D. A., Spatial distribution of the phases in water-in-
oil emulsions. Open and closed microcellular foams from cross-linked polystryene. 
Langmuir 1988, 4, (3), 656-662. 
64. Cameron, N. R.; Sherrington, D. C., Synthesis and characterisation of poly(aryl 
ether sulfone) polyHIPE materials. Macromolecules 1997, 30, 5860-5869. 
65. Lumelsky, Y.; Silverstein, M., Biodegradable porous polymers through emulsion 
templating. Macromolecules 2009, 42, 1627-1633. 
66. Youssef, C.; Backov, R.; Treguer, M.; Birot, M.; Deleuze, H., Preparation of 
amazingly hard polyHIPE material from a direct emulsion. Materials Research Society 
Symposium 2010, 1269, 1-6. 
67. Williams, J. M.; Gray, A. J.; Wilkerson, M. H., Emulsion stability and rigid 
foams from styrene or divinylbenzene water-in-oil emulsions. Langmuir 1990, 6, 437-
444. 
68. Yaszemski, M. J.; Payne, R. G.; Hayes, W. C.; Langer, R.; Mikos, A. G., 
Evolution of bone transplantation: molecular, cellular and tissue strategies to engineer 
human bone. Biomaterials 1996, 17, (2), 175-185. 
69. Bennett, S.; Connolly, K.; Lee, D. R.; Jiang, Y.; Buck, D.; Hollinger, J. O.; 
Gruskin, E. A., Initial biocompatibility studies of a novel degradable polymeric bone 
substitute that hardens in situ. Bone 1996, 19, (1, Supplement 1), S101-S107. 
 119 
 
70. Hafeman, A. E.; Li, B.; Yoshii, T.; Zienkiewicz, K.; Davidson, J. M.; Guelcher, 
S. A., Injectable biodegradable polyurethane scaffolds with release of platelet-derived 
growth factor for tissue repair and regeneration. Pharmaceutical Research 2008, 25, 
(10), 2387-2399. 
71. Lewandrowski, K. U.; Gresser, J. D.; Bondre, S.; Silva, A. E.; Wise, D. L.; 
Trantolo, D. J., Developing porosity of poly(propylene glycol-co-fumaric acid) bone 
graft substitutes and the effect on osteointegration: a preliminary histology study in rats. 
Journal Of Biomaterials Science. Polymer Edition 2000, 11, (8), 879-889. 
72. Takahashi, Y.; Tabata, Y., Effect of the fiber diameter and porosity of non-
woven PET fabrics on the osteogenic differentiation of mesenchymal stem cells. Journal 
of Biomaterials Science-Polymer Edition 2004, 15, (1), 41-57. 
73. Kuboki, Y.; Jin, Q.; Kikuchi, M.; Mamood, J.; Takita, H., Geometry of Artificial 
ECM: Sizes of Pores Controlling Phenotype Expression in BMP-Induced Osteogenesis 
and Chondrogenesis. Connective Tissue Research 2002, 43, (2-3), 529-534. 
74. Jin, Q. M.; Takita, H.; Kohgo, T.; Atsumi, K.; Itoh, H.; Kuboki, Y., Effects of 
geometry of hydroxyapatite as a cell substratum in BMP-induced ectopic bone 
formation. Journal of Biomedical Materials Research 2000, 52, (4), 841-851. 
75. Liu, L.-S.; Thompson, A. Y.; Heidaran, M. A.; Poser, J. W.; Spiro, R. C., An 
osteoconductive collagen/hyaluronate matrix for bone regeneration. Biomaterials 1999, 
20, (12), 1097-1108. 
76. Tsuruga, E.; Takita, H.; Itoh, H.; Wakisaka, Y.; Kuboki, Y., Pore Size of Porous 
Hydroxyapatite as the Cell-Substratum Controls BMP-Induced Osteogenesis. Journal of 
Biochemistry 1997, 121, (2), 317-324. 
77. Kuboki, Y.; Jin, Q.; Takita, H., Geometry of carriers controlling phenotypic 
expression in BMP-induced osteogenesis and chondrogenesis. The Journal Of Bone And 
Joint Surgery. American Volume 2001, 83-A Suppl 1, (Pt 2), S105-S115. 
78. Hulbert, S. F.; Young, F. A.; Mathews, R. S.; Klawitter, J. J.; Talbert, C. D.; 
Stelling, F. H., Potential of ceramic materials as permanently implantable skeletal 
prostheses. Journal of Biomedical Materials Research 1970, 4, 433-456. 
79. Fisher, J. P.; Vehof, J. W. M.; Dean, D.; van der Waerden, J. P. C. M.; Holland, 
T. A.; Mikos, A. G.; Jansen, J. A., Soft and hard tissue response to photocrosslinked 
poly(propylene fumarate) scaffolds in a rabbit model. Journal of Biomedical Materials 
Research 2002, 59, (3), 547-556. 
 120 
 
80. Kujala, S.; Ryhänen, J.; Danilov, A.; Tuukkanen, J., Effect of porosity on the 
osteointegration and bone ingrowth of a weight-bearing nickel–titanium bone graft 
substitute. Biomaterials 2003, 24, (25), 4691-4697. 
81. Kruyt, M. C.; de Bruijn, J. D.; Wilson, C. E.; Oner, F. C.; van Blitterswijk, C. A.; 
Verbout, A. J.; Dhert, W. J. A., Viable osteogenic cells are obligatory for tissue-
engineered ectopic bone formation in goats. Tissue Engineering 2003, 9, (2), 327-336. 
82. Itoh, M.; Shimazu, A.; Hirata, I.; Yoshida, Y.; Shintani, H.; Okazaki, M., 
Characterization of CO3Ap-collagen sponges using X-ray high-resolution 
microtomography. Biomaterials 2004, 25, (13), 2577-2583. 
83. Chu, T. M. G.; Orton, D. G.; Hollister, S. J.; Feinberg, S. E.; Halloran, J. W., 
Mechanical and in vivo performance of hydroxyapatite implants with controlled 
architectures. Biomaterials 2002, 23, (5), 1283-1293. 
84. Klawitter, J. J.; Hulbert, S. F., Application of porous ceramics for the attachment 
of load bearing internal orthopedic applications. Journal of Biomedical Materials 
Research 1971, 5, (6), 161-229. 
85. Madden, L. R.; Mortisen, D. J.; Sussman, E. M.; Dupras, S. K.; Fugate, J. A.; 
Cuy, J. L.; Hauch, K. D.; Laflamme, M. A.; Murry, C. E.; Ratner, B. D., Proangiogenic 
scaffolds as functional templates for cardiac tissue engineering. Proceedings of the 
National Academy of Sciences 2010, 107, (34), 15211-15216. 
86. Roy, T. D.; Simon, J. L.; Ricci, J. L.; Rekow, E. D.; Thompson, V. P.; Parsons, J. 
R., Performance of degradable composite bone repair products made via three-
dimensional fabrication techniques. Journal of Biomedical Materials Research Part A 
2003, 66A, (2), 283-291. 
87. Schultz, R. J.; Johnston, A. D.; Krishnamurthy, S., Thermal effects of 
polymerization of methyl-methacrylate on small tubular bones. International 
Orthopaedics 1987, 11, (3), 277-282. 
88. Stankus, J. J.; Guan, J.; Wagner, W. R., Fabrication of biodegradable elastomeric 
scaffolds with sub-micron morphologies. Journal of Biomedical Materials Research 
Part A 2004, 70A, (4), 603-614. 
89. Day, R. M.; Boccaccini, A. R.; Maquet, V.; Shurey, S.; Forbes, A.; Gabe, S. M.; 
Jérôme, R., In vivo characterisation of a novel bioresorbable poly(lactide-co-glycolide) 
tubular foam scaffold for tissue engineering applications. Journal of Materials Science: 
Materials in Medicine 2004, 15, (6), 729-734. 
 121 
 
90. Barralet, J. E.; Grover, L.; Gaunt, T.; Wright, A. J.; Gibson, I. R., Preparation of 
macroporous calcium phosphate cement tissue engineering scaffold. Biomaterials 2002, 
23, (15), 3063-3072. 
91. Marshall, A. J.; Ratner, B. D., Quantitative characterization of sphere-templated 
porous biomaterials. AIChE Journal 2005, 51, (4), 1221-1232. 
92. Lin-Gibson, S.; Cooper, J. A.; Landis, F. A.; Cicerone, M. T., Systematic 
investigation of porogen size and content on scaffold morphometric parameters and 
properties. Biomacromolecules 2007, 8, (5), 1511-1518. 
93. Barbetta, A.; Massimi, M.; Conti Devirgiliis, L.; Dentini, M., Enzymatic cross-
linking vs radical polymerization in the preparation of gelatin polyHIPEs and their 
performances as scaffolds in the culture of hepatocytes. Biomacromolecules 2006, 7, 
(11), 3059-3068. 
94. Bokhari, M. A.; Akay, G.; Zhang, S.; Birch, M. A., The enhancement of 
osteoblast growth and differentiation in vitro on a peptide hydrogel—polyHIPE polymer 
hybrid material. Biomaterials 2005, 26, 5198-5208. 
95. Gunn, J.; Turner, S.; Mann, B., Adhesive and mechanical properties of hydrogels 
influence neurite extension. Journal of Biomedical Materials Research 2004, 72A, (1), 
91-97. 
96. Hahn, M. S.; Taite, L. J.; Moon, J. J.; Rowland, M. C.; Ruffino, K. A.; West, J. 
L., Photolithographic patterning of polyethylene glycol hydrogels. Biomaterials 2006, 
27, (12), 2519-2524. 
97. Kretlow, J. D.; Mikos, A. G., From material to tissue: Biomaterial development, 
scaffold fabrication, and tissue engineering. AIChE Journal 2008, 54, (12), 3048-3067. 
98. Park, S.; Lee, S.; Kim, W., Fabrication of hydrogel scaffolds using rapid 
prototyping for soft tissue engineering. Macromolecular Research 2011, 19, (7), 694-
698. 
99. Hearon, K.; Singhal, P.; Horn, J.; Small, W.; Olsovsky, C.; Maitland, K. C.; 
Wilson, T. S.; Maitland, D. J., Porous shape-memory polymers. Polymer Reviews 2013, 
53, (1), 41-75. 
100. Neuss, S.; Blomenkamp, I.; Stainforth, R.; Boltersdorf, D.; Jansen, M.; Butz, N.; 
Perez-Bouza, A.; Knüchel, R., The use of a shape-memory poly(ε-
caprolactone)dimethacrylate network as a tissue engineering scaffold. Biomaterials 
2009, 30, (9), 1697-1705. 
 122 
 
101. Thornton, A. J.; Alsberg, E.; Albertelli, M.; Mooney, D. J., Shape-defining 
scaffolds for minimally invasive tissue engineering. Transplantation 2004, 77, (12), 
1798-1803. 
102. Zhang, D.; Petersen, K. M.; Grunlan, M. A., Inorganic–organic shape memory 
polymer (SMP) foams with highly tunable properties. ACS Applied Materials & 
Interfaces 2012, 5, (1), 186-191. 
103. De Nardo, L.; Bertoldi, S.; Tanzi, M. C.; Haugen, H. J.; Farè, S., Shape memory 
polymer cellular solid design for medical applications. Smart Materials and Structures 
2011, 20, (3), 035004. 
104. Barby, D.; Haq, Z., European Patent 0,060,138 (to Unilever). 1982. 
105. Christenson, E. M.; Hiltner, A.; Anderson, J. M., Biodegradation mechanism of 
polyurethane elastomers. Corrossion Engineering Science and Technology 2007, 42, (4), 
312-323. 
106. Umez-Eronini, N. O.; Collins, A.; Neal, D. E., Optimisation of bladder stromal 
culture on polyHIPE European Cells and Materials 2002, 4, (2), 77-78. 
107. Tai, H.; Sergienko, A.; Silverstein, M., Organic-inorganic networks in foams 
from high internal phase emulsion polymerizations. Polymer 2001, 42, 4473-4482. 
108. Lepine, O., Preparation of macrocellular PU–PS interpenetrating networks. 
Polymer 2005, 46, 9653–9663. 
109. David, D.; Silverstein, M., Porous polyurethanes synthesized within high internal 
phase emulsions (HIPEs). Journal of Polymer Science: Part A: Polymer Chemistry 
2009, 47, 9. 
110. Bokhari, M.; Carnachan, R. J.; A., P. S.; Cameron, N. R., Emulsion-templated 
porous polymers as scaffolds for three dimensional cell culture: effect of synthesis 
parameters on scaffold formation and homogeneity. Journal of Materials Chemistry 
2007, 17, 4088–4094. 
111. Williams, J. M., High internal phase water-in-oil emulsions: influence of 
surfactants and cosurfactants on emulsion stability and foam quality. Langmuir 1991, 7, 
1370-1377. 
112. Menner, A.; Bismarck, A., New evidence for the mechanism of the pore 
formation in polymerising high internal phase emulsions or why polyHIPEs have an 
interconnected pore network structure. Macromolecular Symposia 2006, (242), 19-24. 
 123 
 
113. Mercier, A.; Deleuzea, H.; Mondain-Monval, O., Preparation and 
functionalization of (vinyl)polystyrene polyHIPEs. Short routes to binding functional 
groups through a dimethylene spacer. Reactive & Functional Polymers 2000, 46, 67–79. 
114. Christenson, E. M.; Soofi, W.; Holm, J. L.; Cameron, N. R.; Mikos, A. G., 
Biodegradable fumarate-based polyHIPEs as tissue engineering scaffolds. 
Biomacromolecules 2007, 8, 3806-3814. 
115. Lumelsky, Y.; Lalush-Michael, I.; Levenberg, S.; Silverstein, M., A degradable, 
porous, emulsion-templated polyacrylate. Journal of Polymer Science Part A: Polymer 
Chemistry 2009, 47, (24), 7043-7053. 
116. Lumelsky, Y.; Zoldan, J.; Levenberg, S.; Silverstein, M. S., Porous 
polycaprolactone-polystyrene semi-interpenetrating polymer networks synthesized 
within high internal phase emulsions. Macromolecules 2008, 41, 1469-1474. 
117. Carnachan, R. J.; Bokhari, M.; Przyborski, S. A.; Cameron, N. R., Tailoring the 
morphology of emulsion-templated porous polymers. Soft Matter 2006, 2, 608-616. 
118. Hainey, P.; Huxham, I. M.; Rowatt, B.; Sherrington, D. C., Synthesis and 
ultrastructural studies of styrene-divinylbenzene polyHIPE polymers. Macromolecules 
1991, 24, (1), 117-121. 
119. Porter, B. D.; Oldham, J. B.; He, S. L.; Zobitz, M. E.; Payne, R. G.; An, K. N.; 
Currier, B. L.; Mikos, A. G.; Yaszemski, M. J., Mechanical properties of a 
biodegradable bone regeneration scaffold. Journal of Biomechanical Engineering 2000, 
122, (3), 286-288. 
120. Wolfe, M. S.; Dean, D.; Chen, J. E.; Fisher, J. P.; Han, S.; Rimnac, C. M.; Mikos, 
A. G., In vitro degradation and fracture toughness of multilayered porous poly(propylene 
fumarate)/β-tricalcium phosphate scaffolds. Journal of Biomedical Materials Research 
2002, 61, (1), 159-164. 
121. Burdick, J. A.; Padera, R. F.; Huang, J. V.; Anseth, K. S., An investigation of the 
cytotoxicity and histocompatibility of in situ forming lactic acid based orthopedic 
biomaterials. Journal of Biomedical Materials Research 2002, 63, (5), 484-491. 
122. Burdick, J. A.; Frankel, D.; Dernell, W. S.; Anseth, K. S., An initial investigation 
of photocurable three-dimensional lactic acid based scaffolds in a critical-sized cranial 
defect. Biomaterials 2003, 24, (9), 1613-1620. 
123. Lin, A. S. P.; Barrows, T. H.; Cartmell, S. H.; Guldberg, R. E., 
Microarchitectural and mechanical characterization of oriented porous polymer 
scaffolds. Biomaterials 2003, 24, (3), 481-489. 
 124 
 
124. Borden, M.; El-Amin, S. F.; Attawia, M.; Laurencin, C. T., Structural and human 
cellular assessment of a novel microsphere-based tissue engineered scaffold for bone 
repair. Biomaterials 2003, 24, (4), 597-609. 
125. Ruckenstein, E.; Li, H., Rubber toughened styrene/methyl methacrylate/butyl 
methacrylate composites by the concentrated emulsion pathway. Journal of Applied 
Polymer Science 1994, 54, (5), 561-568. 
126. Ruckenstein, E.; Li, H., Toughened polystyrene composites by the concentrated 
emulsion pathway. Journal of Applied Polymer Science 1994, 52, (13), 1949-1958. 
127. Silverstein, M. S.; Tai, H.; Sergienko, A.; Lumelsky, Y.; Pavlovsky, S., 
PolyHIPE: IPNs, hybrids, nanoscale porosity, silica monoliths and ICP-based sensors. 
Polymer 2005, 46, 6682–6694. 
128. Despois, J.-F.; Mortensen, A., Permeability of open-pore microcellular materials. 
Acta Materialia 2005, 53, (5), 1381-1388. 
129. Botchwey, E. A.; Dupree, M. A.; Pollack, S. R.; Levine, E. M.; Laurencin, C. T., 
Tissue engineered bone: Measurement of nutrient transport in three-dimensional 
matrices. Journal of Biomedical Materials Research Part A 2003, 67A, (1), 357-367. 
130. Malachanne, E.; Dureisseix, D.; Cañadas, P.; Jourdan, F., Experimental and 
numerical identification of cortical bone permeability. Journal of Biomechanics 2008, 
41, (3), 721-725. 
131. Baroud, G.; Falk, R.; Crookshank, M.; Sponagel, S.; Steffen, T., Experimental 
and theoretical investigation of directional permeability of human vertebral cancellous 
bone for cement infiltration. Journal of Biomechanics 2004, 37, (2), 189-196. 
132. Menner, A.; Powell, R.; Bismarck, A., A new route to carbon black filled 
polyHIPEs. Soft Matter 2006, 2, 337–342. 
133. Wu, R.; Menner, A.; Bismarck, A., Tough interconnected polymerized medium 
and high internal phase emulsions reinforced by silica particles. Journal of Polymer 
Science Part A: Polymer Chemistry 2010, 48, 1979-1989. 
134. Mistry, A.; Pham, Q.; Schouten, C.; Yeh, T.; Christensen, E.; Mikos, A.; Jansen, 
J., In vivo bone biocompatibility and degradation of porous fumarate-based 
polymer/alumoxane nanocomposites for bone tissue engineering. Journal of Biomedical 
Materials Research Part A 2010, 92A, (2), 451-462. 
135. ASTM, C. D. o. P., Standard test method for compressive properties of rigid 
cellular plastics (D 1621-04a). 2004, (D 1621-04a). 
 125 
 
136. Molinspiration, Interactive logP calculator. www.molinspiration.com. 
137. Cameron, N. R.; Barbetta, A., The influence of porogen type on the porosity, 
surface area and morphology of poly(divinylbenzene) polyHIPE foams. Journal of 
Materials Chemistry 2000, 10, 2466-2471. 
138. Cohen, N.; Silverstein, M., Synthesis of emulsion-templated porous 
polyacrylonitrile and its pyrolysis to porous carbon monoliths. Polymer 2011, 52, 282-
287. 
139. Patrick, C. W., Tissue engineering strategies for adipose tissue repair. The 
Anatomical Record 2001, 263, (4), 361-366. 
140. Dhandayuthapani, B.; Yoshida, Y.; Maekawa, T.; Kumar, D. S., Polymeric 
scaffolds in tissue engineering application: a review. International Journal of Polymer 
Science 2011, 2011. 
141. Hodde, J., Naturally occuring scaffolds for soft tissue repair and regeneration. 
Tissue Engineering 2002, 8, (2), 295-308. 
142. Butler, D. L.; Goldstein, S. A.; Guilak, F., Functional tissue engineering: the role 
of biomechanics. Journal of Biomechanical Engineering 2000, 122, (6), 570-575. 
143. Kim, B.-S.; Mooney, D. J., Scaffolds for engineering smooth muscle under cyclic 
mechanical strain conditions. Journal of Biomechanical Engineering 2000, 122, (3), 
210-215. 
144. Kim, B.-S.; Nikolovski, J.; Bonadio, J.; Mooney, D. J., Cyclic mechanical strain 
regulates the development of engineered smooth muscle tissue. Nature Biotechnology 
1999, 17, (10), 979-983. 
145. Andrew A, B., Musculoskeletal design in relation to body size. Journal of 
Biomechanics 1991, 24, Supplement 1, (0), 19-29. 
146. Spaans, C. J.; de Groot, J. H.; Dekens, F. G.; Pennings, A. J., High molecular 
weight polyurethanes and a polyurethane urea based on 1,4-butanediisocyanate. Polymer 
Bulletin 1998, 41, (2), 131-138. 
147. Guan, J.; Sacks, M. S.; Beckman, E. J.; Wagner, W. R., Biodegradable poly(ether 
ester urethane)urea elastomers based on poly(ether ester) triblock copolymers and 
putrescine: synthesis, characterization and cytocompatibility. Biomaterials 2004, 25, (1), 
85-96. 
148. Lee, S.-H.; Kim, B.-S.; Kim, S. H.; Choi, S. W.; Jeong, S. I.; Kwon, I. K.; Kang, 
S. W.; Nikolovski, J.; Mooney, D. J.; Han, Y.-K.; Kim, Y. H., Elastic biodegradable 
 126 
 
poly(glycolide-co-caprolactone) scaffold for tissue engineering. Journal of Biomedical 
Materials Research, Part A 2003, 66A, (1), 29-37. 
149. Rouwkema, J.; Rivron, N. C.; van Blitterswijk, C. A., Vascularization in tissue 
engineering. Trends in Biotechnology 2008, 26, (8), 434-441. 
150. Benhardt, H.; Sears, N.; Touchet, T.; Cosgriff-Hernandez, E., Synthesis of 
collagenase-sensitive polyureas for ligament tissue engineering. Macromolecular 
Bioscience 2011, 11, (8), 1020-1030. 
151. Courtney, T.; Sacks, M. S.; Stankus, J.; Guan, J.; Wagner, W. R., Design and 
analysis of tissue engineering scaffolds that mimic soft tissue mechanical anisotropy. 
Biomaterials 2006, 27, (19), 3631-3638. 
152. Landers, R.; Pfister, A.; Hübner, U.; John, H.; Schmelzeisen, R.; Mülhaupt, R., 
Fabrication of soft tissue engineering scaffolds by means of rapid prototyping 
techniques. Journal of Materials Science 2002, 37, (15), 3107-3116. 
153. Landers, R.; Hübner, U.; Schmelzeisen, R.; Mülhaupt, R., Rapid prototyping of 
scaffolds derived from thermoreversible hydrogels and tailored for applications in tissue 
engineering. Biomaterials 2002, 23, (23), 4437-4447. 
154. Chen, J.; Park, H.; Park, K., Synthesis of superporous hydrogels: Hydrogels with 
fast swelling and superabsorbent properties. Journal of Biomedical Materials Research 
1999, 44, (1), 53-62. 
155. Dumas, J. E.; Prieto, E. M.; Zienkiewicz, K. J.; Guda, T.; Wenke, J. C.; Bible, J. 
E.; Holt, G. E.; Guelcher, S., Balancing the rates of new bone formation and polymer 
degradation enhances healing of weight-bearing allograft/polyurethane composites in 
rabbit femoral defects. Tissue Engineering: Part A 2013. 
156. Duggan, M.; Rago, A.; Sharma, U.; Zugates, G.; Freyman, T.; Busold, R.; 
Caulkins, J.; Pham, Q.; Chang, Y.; Mejaddam, A.; Beagle, J.; Velmahos, G.; deMoya, 
M.; Zukerberg, L.; Ng, T. F.; King, L. D. R., Self-expanding polyurethane polymer 
improves survival in a model of noncompressible massive abdominal hemorrhage. 
Journal of Trauma- Injury, Infection, and Critical Care 2013, 74, (6), 1462-1467. 
157. Moglia, R. S.; Holm, J. L.; Sears, N. A.; Wilson, C. J.; Harrison, D. M.; Cosgriff-
Hernandez, E., Injectable polyHIPEs as high-porosity bone grafts. Biomacromolecules 
2011, 12, (10), 3621-3628. 
158. Robinson, J. L.; Moglia, R. S.; Stuebben, M. C.; McEnery, M. A. P.; Cosgriff-
Hernandez, E., Achieving interconnected pore architecture in injectable polyHIPEs for 
bone tissue engineering. Tissue Engineering: Part A 2014, 20, (5-6), 1103-1112. 
 127 
 
159. Barbetta, A.; Cameron, N. R., Morphology and surface area of emulsion-derived 
(PolyHIPE) solid foams prepared with oil-phase soluble porogenic solvents: Span 80 as 
surfactant. Macromolecules 2004, 37, 3188-3201. 
160. Muschenborn, A.; Ortega, J.; Szafron, J.; Szafron, D.; Maitland, D., Porous 
media properties of reticulated shape memory polymer foams and mock embolic coils 
for aneurysm treatment. Biomedical Engineering OnLine 2013, 12, (1), 1-13. 
161. Geertsma, J., Estimating the coefficient of inertial resistance in fluid flow 
through porous media. SPE Journal 1974, 14, (5), 445-450. 
162. Hafeman, A. E.; Davidson, J. M.; Guelcher, S. A., Effects of polyol, isocyanate, 
and additives on poly(ester urethane)urea scaffolds: material and in vivo histological 
properties. PMSE Preprints 2007, 97, 546. 
163. Hafeman, A. E.; Zienkiewicz, K. J.; Carney, E.; Litzner, B.; Stratton, C.; Wenke, 
J. C.; Guelcher, S. A., Local delivery of tobramycin from injectable biodegradable 
polyurethane scaffolds. Journal of Biomaterials Science, Polymer Edition 2010, 21, (1), 
95-112. 
164. Garrett, P. R., Defoaming: Theory and Industrial Applications. Marcel Dekker, 
Inc.: New York, 1993. 
165. Dumas, J. E.; Davis, T.; Holt, G. E.; Yoshii, T.; Perrien, D. S.; Nyman, J. S.; 
Boyce, T.; Guelcher, S. A., Synthesis, characterization, and remodeling of weight-
bearing allograft bone/polyurethane composites in the rabbit. Acta Biomaterialia 2010, 
6, (7), 2394-2406. 
166. Etter, M. C., Hydrogen bonds as design elements in organic chemistry. Journal 
of Physical Chemistry 1991, 95, (12), 4601-4610. 
167. Christenson, E. M.; Anderson, J. M.; Hiltner, A.; Baer, E., Relationship between 
nanoscale deformation processes and elastic behavior of polyurethane elastomers. 
Polymer 2005, 46, (25), 11744-11754. 
168. Gogolewski, S., Selected topics in biomedical polyurethanes. A review. Colloid 
and Polymer Science 1989, 267, (9), 757-785. 
169. Mullins, L.; Tobin, N., Theoretical model for the elastic behavior of filler-
reinforced vulcanized rubbers. Rubber Chemistry and Technology 1957, 30, (2), 555-
571. 
170. Qi, H. J.; Boyce, M. C., Stress–strain behavior of thermoplastic polyurethanes. 
Mechanics of Materials 2005, 37, (8), 817-839. 
 128 
 
171. Yeh, F.; Hsiao, B. S.; Sauer, B. B.; Michel, S.; Siesler, H. W., In-situ studies of 
structure development during deformation of a segmented poly(urethane−urea) 
elastomer. Macromolecules 2003, 36, (6), 1940-1954. 
172. Hammond, P. T.; Nallicheri, R. A.; Rubner, M. F., An examination of the strain-
induced orientation of hard segment domains in 4,4′-methylenebis(phenyl isocyanate)-
based polyurethane-diacetylene segmented copolymers. Materials Science and 
Engineering: A 1990, 126, (1–2), 281-287. 
173. Saraf, H.; Ramesh, K. T.; Lennon, A. M.; Merkle, A. C.; Roberts, J. C., 
Mechanical properties of soft human tissues under dynamic loading. Journal of 
Biomechanics 2007, 40, (9), 1960-1967. 
174. Gao, J.; Crapo, P. M.; Wang, Y., Macroporous elastomeric scaffolds with 
extensive micropores for soft tissue engineering. Tissue Engineering 2006, 12, (4), 917-
25. 
175. Bear, J., Dynamics of fluids in porous media. Reprint ed.; American Elsevier 
Publishing Co.: New York, 2013. 
176. Lage, J., The fundamental theory of flow through permeable media from Darcy 
to turbulence. Transport phenomena in porous media 1998, 2. 
177. Dybbs, A.; Edwards, R. V., A new look at porous media fluid mechanics — 
Darcy to turbulent. In Fundamentals of Transport Phenomena in Porous Media, Bear, J.; 
Corapcioglu, M. Y., Eds. Springer Netherlands: 1984; Vol. 82, pp 199-256. 
178. Scheidegger, A. E., The physics of flow through porous media. University of 
Toronto Press: Toronto; Buffalo [N.Y.], 1974. 
179. Tanzi, M. C.; Verderio, P.; Lampugnani, M. G.; Resnati, M.; Dejana, E.; Sturani, 
E., Cytotoxicity of some catalysts commonly used in the synthesis of copolymers for 
biomedical use. Journal of Materials Science: Materials in Medicine 1994, 5, (6-7), 393-
396. 
180. Middleton, J. C.; Tipton, A. J., Synthetic biodegradable polymers as orthopedic 
devices. Biomaterials 2000, 21, (23), 2335-2346. 
181. Peter, S. J.; Miller, M. J.; Yasko, A. W.; Yaszemski, M. J.; Mikos, A. G., 
Polymer concepts in tissue engineering. Journal of Biomedical Materials Research 
1998, 43, (4), 422-427. 
182. Hou, Q.; De Bank, P. A.; Shakesheff, K. M., Injectable scaffolds for tissue 
regeneration. Journal of Materials Chemistry 2004, 14, 1915-1923. 
 129 
 
183. Butler, R.; Hopkinson, I.; Cooper, A. I., Synthesis of porous emulsion-templated 
polymers using high internal phase CO2-in-water emulsions. Journal of the American 
Chemical Society 2003, 125, (47), 14473-14481. 
184. Wu, R.; Menner, A.; Bismarck, A., Macroporous polymers made from medium 
internal phase emulsion templates: Effect of emulsion formulation on the pore structure 
of polyMIPEs. Polymer 2013, 54, (21), 5511-5517. 
185. He, S.; Timmer, M. D.; Yaszemski, M. J.; Yasko, A. W.; Engel, P. S.; Mikos, A. 
G., Synthesis of biodegradable poly(propylene fumarate) networks with poly(propylene 
fumarate)±diacrylate macromers as crosslinking agents and characterization of their 
degradation products. Polymer 2001, 42, 1251-1260. 
186. Foudazi, R.; Gokun, P.; Feke, D. L.; Rowan, S. J.; Manas-Zloczower, I., 
Chemorheology of poly(high internal phase emulsions). Macromolecules 2013. 
187. Mason, T. G.; Lacasse, M.-D.; Grest, G. S.; Levine, D.; Bibette, J.; Weitz, D. A., 
Osmotic pressure and viscoelastic shear moduli of concentrated emulsions. Physical 
Review E 1997, 56, (3), 3150-3166. 
188. Stryker, HydroSet injectable HA bone substitute. www.stryker.com.  
189. Temenoff, J. S.; Mikos, A. G., Injectable biodegradable materials for orthopedic 
tissue engineering. Biomaterials 2000, 21, 2405-2412. 
190. Farrar, D. F.; Rose, J., Rheological properties of PMMA bone cements during 
curing. Biomaterials 2001, 22, (22), 3005-3013. 
191. Parallax Medical, Bone cement. www.parallaxmed.com  
192. McMahon, S.; Hawdon, G.; Bare, J.; Sim, Y.; Bertollo, N.; Walsh, W. R., 
Thermal necrosis and PMMA – A cause for concern? Journal of Bone & Joint Surgery, 
British Volume 2012, 94-B, (SUPP XXIII), 64. 
193. Chiu, Y. Y.; Lee, L. J., Microgel formation in the free radical crosslinking 
polymerization of ethylene glycol dimethacrylate (EGDMA). I. Experimental. Journal of 
Polymer Science Part A: Polymer Chemistry 1995, 33, (2), 257-267. 
194. Goodner, M. D.; Bowman, C. N., Modeling primary radical termination and its 
effects on autoacceleration in photopolymerization kinetics. Macromolecules 1999, 32, 
(20), 6552-6559. 
195. Van Assche, G.; Verdonck, E.; Van Mele, B., Interrelations between mechanism, 
kinetics, and rheology in an isothermal cross-linking chain-growth copolymerisation. 
Polymer 2001, 42, (7), 2959-2968. 
 130 
 
196. Munin, M. C.; Rudy, T. E.; Glynn, N. W.; Crossett, L. S.; Rubash, H. E., Early 
inpatient rehabilitation after elective hip and knee arthroplasty. JAMA 1998, 279, (11), 
847-852. 
197. Coombes, A. G. A.; Meikle, M. C., Resorbable synthetic polymers as 
replacements for bone graft. Clinical Materials 1994, 17, (1), 35-67. 
198. Sideridou, I. D.; Achilias, D. S.; Karava, O., Reactivity of benzoyl 
peroxide/amine system as an initiator for the free radical polymerization of dental and 
orthopaedic dimethacrylate monomers: effect of the amine and monomer chemical 
structure. Macromolecules 2006, 39, (6), 2072-2080. 
199. Pryor, W. A.; Hendrickson Jr, W. H., The mechanism of radical production from 
the reaction of N,N-dimethylaniline with benzoyl peroxide. Tetrahedron Letters 1983, 
24, (14), 1459-1462. 
200. Carlisle, E.; Fischgrund, J. S., Bone morphogenetic proteins for spinal fusion. 
The Spine Journal 2005, 5, (6, Supplement), S240-S249. 
201. Giannoudis, P. V.; Tzioupis, C., Clinical applications of BMP-7 - The UK 
perspective. Injury-International Journal of the Care of the Injured 2005, 36, 47-50. 
202. Paramore, C. G.; Lauryssen, C.; Rauzzino, M.; Wadlington, V. R.; Palmer, C.; 
Brix, A.; Cartner, S. C.; Hadley, M., The safety of OP-1 for lumbar fusion with 
decompression - a canine study. Neurosurgery 1999, 44, (5), 1151-1155. 
203. Walker, D. H.; Wright, N. M., Bone morphogenetic proteins and spinal fusion. 
Neurosurgical Focus 2002, 13, (6), 1-13. 
204. Bessa, P. C.; Casal, M.; Reis, R. L., Bone morphogenetic proteins in tissue 
engineering: the road from laboratory to clinic, part II (BMP delivery). Journal of Tissue 
Engineering and Regenerative Medicine 2008, 2, (2-3), 81-96. 
205. Fauber, J. Spinal fusion device:  a bone of contention for FDA. 
http://www.medpagetoday.com/Surgery/Orthopedics/21908  
206. Geiger, M.; Li, R. H.; Friess, W., Collagen sponges for bone regeneration with 
rhBMP-2. Advanced Drug Delivery Reviews 2003, 55, (12), 1613-1629. 
207. Chung, H. J.; Park, T. G., Surface engineered and drug releasing pre-fabricated 
scaffolds for tissue engineering. Advanced Drug Delivery Reviews 2007, 59, (4–5), 249-
262. 
208. Brazel, C. S.; Peppas, N. A., Mechanisms of solute and drug transport in 
relaxing, swellable, hydrophilic glassy polymers. Polymer 1999, 40, (12), 3383-3398. 
 131 
 
209. Mainardes, R. M.; Silva, L. P., Drug delivery systems: past, present, and future. 
Current Drug Targets 2004, 5, (5), 449-455. 
210. Basmanav, B. F.; Kose, G. T.; Hasirci, V., Sequential growth factor delivery 
from complexed microspheres for bone tissue engineering. Biomaterials 2008, 29, (31), 
4195-4204. 
211. Gokmen, M. T.; Van Camp, W.; Colver, P. J.; Bon, S. A. F.; Du Prez, F. E., 
Fabrication of porous "clickable" polymer beads and rods through generation of high 
internal phase emulsion (HIPE) droplets in a simple microfluidic device. 
Macromolecules 2009, 42, (23), 9289-9294. 
212. Christopher, G.; Anna, S., Microfluidic methods for generating continuous 
droplet streams. Journal of Physics D: Applied Physics 2007, 40, (19), R319. 
213. Gokmen, M. T.; Du Prez, F. E., Porous polymer particles—A comprehensive 
guide to synthesis, characterization, functionalization and applications. Progress in 
Polymer Science 2012, 37, (3), 365-405. 
214. Cramer, C.; Fischer, P.; Windhab, E. J., Drop formation in a co-flowing ambient 
fluid. Chemical Engineering Science 2004, 59, (15), 3045-3058. 
215. Klose, D.; Siepmann, F.; Elkharraz, K.; Krenzlin, S.; Siepmann, J., How porosity 
and size affect the drug release mechanisms from PLGA-based microparticles. 
International Journal of Pharmaceutics 2006, 314, (2), 198-206. 
216. Yeo, Y.; Park, K., Control of encapsulation efficiency and initial burst in 
polymeric microparticle systems. Archives of Pharmacal Research 2004, 27, (1), 1-12. 
217. Jiang, G.; Thanoo, B. C.; DeLuca, P. P., Effect of osmotic pressure in the solvent 
extraction phase on BSA release profile from PLGA microspheres. Pharmaceutical 
Development and Technology 2002, 7, (4), 391-399. 
218. Huang, X.; Brazel, C. S., On the importance and mechanisms of burst release in 
matrix-controlled drug delivery systems. Journal of Controlled Release 2001, 73, (2–3), 
121-136. 
219. Timasheff, S. N., Protein-solvent interactions and protein conformation. 
Accounts of Chemical Research 1970, 3, (2), 62-68. 
220. Yano, K.; Hoshino, M.; Ohta, Y.; Manaka, T.; Naka, Y.; Imai, Y.; Sebald, W.; 
Takaoka, K., Osteoinductive capacity and heat stability of recombinant human bone 
morphogenetic protein-2 produced by Escherichia coli and dimerized by biochemical 
processing. Journal of Bone and Mineral Metabolism 2009, 27, (3), 355-363. 
 132 
 
221. Yang, Y.-Y.; Chung, T.-S.; Ping Ng, N., Morphology, drug distribution, and in 
vitro release profiles of biodegradable polymeric microspheres containing protein 
fabricated by double-emulsion solvent extraction/evaporation method. Biomaterials 
2001, 22, (3), 231-241. 
222. Moglia, R. S.; Robinson, J. L.; Muschenborn, A. D.; Touchet, T. J.; Maitland, D. 
J.; Cosgriff-Hernandez, E., Injectable polyMIPE scaffolds for soft tissue regeneration. 
Polymer 2014, 55, (1), 426-434. 
 
 
  
 133 
 
APPENDIX I 
INTERPENETRATING POLYMER NETWORK POLYHIPES 
 
A.1 Introduction 
Due to their porous structure and composition of acrylic polymer, polyHIPEs 
typically behave as weak brittle materials. This limits their usefulness in a variety of 
fields, specifically tissue engineering as brittle fracture would cause catastrophic graft 
failure and reinjury. The polyHIPEs discussed previously in Chapters 2 and 3 
demonstrate that mechanical response can be tuned by material composition, from weak 
elastomeric foams to rigid structures approaching cancellous bone. Obtaining a tough 
injectable polyHIPE, having both strength and some elasticity, would be advantageous 
over current materials. 
Composites materials are hybrids of two or more different components which act 
synergistically to produce unique properties distinct from either component alone. 
Interpenetrating polymer networks (IPNs) are one type of composite material used to 
combine the properties of two or more disparate polymer networks in order to improve 
either: chemical, electrical, or mechanical properties. IPNs and semi-IPN polyHIPEs are 
typically fabricated one network at a time in a two-step reaction but this cannot be done 
in situ, and thus cannot be injectable.
125, 126
  
We propose to use the more recent one-pot approach which has been used to 
toughen polyHIPEs by combining brittle and flexible polymers and polymerized via 
separate routes.
1, 48, 127
 Here, a brittle EGDMA network will be combined with the 
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elastomeric PUUs studied in Chapter III. These networks will be crosslinked into two 
distinct but physically entangled networks simultaneously because the methacrylated 
monomers undergo radical chain growth while PUs are crosslink via step growth 
polymerization of isocyanates. Tuning the IPN component ratios should allow for the 
creation a library of toughened scaffolds with a wide range of various compressive 
moduli and strength that can match a variety of bodily tissues. 
In this study, two different PUU prepolymers were combined with EGDMA 
alone and together to form IPN polyHIPE scaffolds. The concentration of linear PCL-DI 
and branched PCL-TI was varied and their effects on resultant pore structures, gel 
fractions, and compressive properties evaluated. Finally, EGDMA content was kept 
constant and the ratio of PCL-DI:PCL-TI varied to investigate effects of PUU crosslink 
density on overall scaffold performance. 
 
A.2 Materials and Methods 
A.2.1 Materials Polyglycerol polyricinoleate (PGPR 4125) was donated by 
Paalsgard. All other chemicals were purchased and used as received from Sigma Aldrich 
unless otherwise noted. 
A.2.2 EGDMA Filtration EGDMA purchased from Sigma Aldrich was purified 
to remove inhibitor prior to use. The macromer was filtered through an aluminum oxide 
column to remove monomethyl ether hydroquinone. The purified product was stored at 4 
°C under a nitrogen blanket until used for HIPE fabrication. 
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A.2.3 PCL-Isocyanate Synthesis Isocyanate functionalized prepolymers were 
synthesized in bulk following the same procedure used in Moglia et al.
222
 Briefly, 
polycaprolactone (PCL) diol or triol (530, 900 Mn respectively) was heated with 50°C 
air and added dropwise to a reaction flask charged with hexamethylene diisocyanate 
(HDI, 2.02 x mol diol, 9.00 x mol triol). The reaction was heated to 80 °C for 90-120 
minutes and reaction progress was monitored with FTIR spectroscopy every 30 minutes 
until complete. The product was washed with hexane to remove excess HDI and dried 
under vacuum overnight. The final products were colorless liquids with a viscosity 
similar to honey. The prepolymer structure was confirmed using 
1
H NMR (300 MHz, 
CdCl3): PCL-diisocyanate (PCL-DI) δ 1.33-1.47 (m, 8H), 1.52 (q, 4H), 1.60-1.75 (m, 
8H), 2.30-2.40 (m, 4H), 3.18 (s, 2H), 3.33 (q, 2H), 3.70-3.73 (m, 2H), 4.09 (t, 4H), 4.24-
4.27 (m, 2H), 4.77 (s, 1H). PCL-triisocyanate (PCL-TI) δ 0.91(t, 3H), 1.33-1.52 (m, 8H), 
1.60-1.75 (m, 8H), 2.31-2.38 (m, 4H), 3.18 (s, 2H), 3.33 (m, 2H), 4.04-4.11 (m, 4H), 
4.74 (s, 1H).  
A.2.4 PolyHIPE Fabrication HIPEs were fabricated using a FlackTek 
Speedmixer DAC 150 FVZ-K according to a protocol adapted from Moglia et al.
157
 
Briefly, EGDMA was combined with varied amounts of PCL-DI (10, 20, and 30 wt%), 
PCL-TI (10, 20, and 30 wt%), or a blend of both (5 wt% DI:15 wt% TI, 10 wt% DI:10 
wt% TI, 15 wt% DI:5 wt% TI). This solution was mixed with 10 wt% PGPR 4125 and a 
1 wt% benzoyl peroxide (BPO) prior to emulsification. A second mixture consisting of 
an identical macromer solution, 10 wt% PGPR, and 1 wt% trimethylaniline (TMA) was 
also combined prior to emulsification. An aqueous solution of calcium chloride (1 wt%) 
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was then added to the organic phases (75% v) in 3 additions and mixed at 500 rpm for 
2.5 minutes each. HIPEs were placed in double barrel syringe and the two emulsions 
mixed upon injection using a static mixing head (5 mL syringe with 3 cm straight mixer, 
Sulzer Mixpac K-System). HIPEs were then placed in a 37°C bath for 48 hr to allow for 
complete polymerization. 
A.2.5 SEM Analysis PolyHIPEs were dried in vacuo for 24 hr to remove water 
prior to characterization. Average pore and interconnect size of varying compositions 
was determined using scanning electron microscopy (SEM, Phenom Pro). Circular 
specimens from each polyHIPE composition were sectioned into quarters, fractured at 
the center, and imaged in a rastor pattern yielding five images. Pore size measurements 
were completed on the first ten pores that crossed the median of each 2000x 
magnification micrograph. Average pore sizes for each polyHIPE composition are 
reported (n=150). A statistical correction was calculated to account for the random 
fracture plane through spherical voids and pores, 2/ .
159
 Average diameter values were 
multiplied by this correction factor resulting in a more accurate pore diameter.  
A.2.6 Mechanical Testing PolyHIPE compressive properties were investigated 
as a function of composition using an Instron 3300, equipped with a 1000-N load cell. 
ASTM D1621-04a was utilized to determine the compressive modulus and strength of 
the polyHIPEs.
135
 Each polyHIPE specimen was sectioned into three discs (15mm 
diameter, 5 mm thick) using an Isomet® saw and compressed to 50% strain at 50 µm/s. 
The compressive modulus was calculated from the slope of the linear region after 
correcting for zero strain and the compressive strength was identified as the stress at the 
3
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yield point or 10% strain, whichever occurred first. Reported moduli and strength data 
were averages of 3 specimens for each composition tested. 
A.2.7 Gel Fraction Gel fraction was measured gravimetrically to evaluate the 
extent of network formation. After curing for 48 hr, polyHIPE samples were sectioned 
into 15mm by 1 mm discs. Each specimen was vacuum dried for 48 hr, incubated 48 hr 
in 100X dichloromethane at 37 °C, and vacuum dried again until a constant mass was 
achieved. The final weight divided by the initial weight was assessed as the gel fraction. 
Fourier transform infrared spectroscopy (FTIR) was used to assess the composition of 
gel fraction extracts. 
A.2.8 Statistical Analysis The data are displayed as mean ± standard deviation 
for each composition. A Student’s t test was performed to determine any statistically 
significant differences between compositions. All tests were carried out at a 95% 
confidence interval (p < 0.05). 
 
A.3 Results and Discussion 
A.3.1 Pore Structure-Varied PCL Content Increasing PCL content in the 
EGDMA polyHIPEs decreased average pore sizes, as shown in Figure A.1 and Table 
A.1. PCL-TI had the greatest effect with the 10, 20, and 30 wt% scaffolds exhibiting 17, 
13, and 7 µm pores respectively. PCL-DI caused a similar but less drastic decrease in 
pore size with the 10, 20, and 30 wt% scaffolds possessing 15, 12, and 11 µm pores. 
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Figure A.1. Representative SEM images of IPN polyHIPE composition on pore 
structure. (A) 100% EGDMA control, (B & E) 10 wt% PCL 90 wt% EGDMA, (C & F) 
20 wt% PCL 80 wt% EGDMA, (D & G) 30 wt% PCL 70 wt% EGDMA. Images H-J 
demonstrate the effort of varied PCL-DI:PCL-TI with a constant 80 wt% EGDMA: (H) 
5 wt%:15 wt%, (I) 10 wt%:10 wt%, (J) 15 wt%:5 wt%. 
 
 
Interconnect size decreased slightly with increasing PCL content, but both 10 
wt% compositions had larger interconnects than the EGDMA control. All of the IPN 
interconnects were approximately 1/4
th
 their corresponding pore size, larger than the 
EGDMA control’s 1/7th ratio. This can be interpreted as an increase in pore 
interconnectedness and is visible in Figure A-1. The increased interconnectivity may be 
a result of CO2 blowing from the isocyanates reacting with water to form urea bonds.
109, 
222
 Previously, this reaction caused an increase in pore size for PUU polyMIPEs.
222
 Here, 
the redox polymerization of the EGDMA macromer likely set the emulsion geometry 
within minutes, faster than CO2 was formed. We hypothesize that the CO2 pressure 
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increased in the water-filled pores, until an escape path was formed via interconnected 
pores to the scaffold surface. During this pressure build-up, the polymerized regions of 
cell walls would easily resist deformation, focusing the pressure to less-cured regions 
between adjacent pores. This focusing may have exerted enough force on polymer 
wall/film to expand the interconnect size. 
 
 
Table A.1. Effect of IPN polyHIPE composition on average pore and interconnect size. 
Material 
% PCL 
(wt%) 
Average 
Pore (µm) 
Average 
Interconnect (µm) 
EGDMA Control 0   20 ± 10 * 3 ± 1 
PCL-DI 10   15 ± 5 †‡ 4 ± 2 
  20 12 ± 4 † 3 ± 1 
  30   11 ± 5 †● 3 ± 2 
PCL-TI 10  17 ± 6 ○‡ 4 ± 2 
  20 13 ± 4 ○ 3 ± 1 
  30     7 ± 5 ○● 2 ± 1 
DI:TI 5:15  9 ± 4 □ 3 ± 1 
  10:10 10 ± 4 □ 3 ± 1 
  15:5   15 ± 5 ◊□ 4 ± 2 
*: P <0.001 compared to all other pore sizes 
†: P <0.01 compared to all PCL-DI/EGDMA IPN pore sizes 
‡: P <0.001 compared to 10% PCL-DI/EGDMA and 10% PCL-TI/EGDMA IPN pore sizes 
●: P <0.001 compared to 30% PCL-DI/EGDMA and 30% PCL-TI/EGDMA IPN pore sizes 
○: P <0.001 compared to all PCL-TI/EGDMA IPN pore sizes 
◊: P <0.001 compared to 5% PCL-DI:15% PCL-TI/EGDMA & 10% PCL-DI:10% PCL-TI/EGDMA IPN 
pore sizes 
□: P <0.001 compared to 20% PCL-DI/EGDMA and 20% PCL-TI/EGDMA IPN pore sizes 
 
 
There is no simple explanation for the decrease in pore size with increasing PCL 
content, and further testing would be required to pinpoint the responsible mechanism. 
The first possibility is that increasing PCL content caused increases to organic phase 
viscosity, and this phenomenon was observed qualitatively during polyHIPE fabrication. 
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Increased organic phase viscosity would inhibit droplet coalescence prior to cure and 
result in smaller average pore sizes. Alternatively, increasing PCL content also raises the 
macromer phase hydrophobicity, evaluated here via LogP. Previously, increasing 
hydrophobicity has been linked to increased pore sizes caused by emulsion 
destabilization.
56, 111, 157, 222
 However, there is likely an optimum hydrophobicity 
associated with each macromer-surfactant system. The closer to the optimum value, the 
more stable the emulsion will be resulting in smaller water droplets and thus pores 
diameters. Further studies carefully controlling both macromer viscosity and 
hydrophobicity are required, in addition to testing with varied surfactants to truly explain 
these results. 
Finally, the amount of PCL-DI relative to PCL-TI was varied and increasing this 
ratio resulted in an increase in average pore diameter and interconnect size, matching the 
sizes for the 10 wt% PCL-DI/90 wt% EGDMA polyHIPE. This result further supports 
the theory of an optimum hydrophobicity because it follows the same trend seen when 
increasing PCL concentration. PCL-TI is more hydrophobic than PCL-DI and thus 
would raise the overall macromer hydrophobicity more dramatically than PCL-DI alone, 
driving it towards optimum values and creating smaller pores. 
A.3.2 Gel Fraction Gel fraction was measured to evaluate PUU network 
formation, and the results are summarized in Figure A.2. The EGDMA control had a gel 
fraction of 90%, an acceptable value considering the surfactant is expected to elute out 
and would account for 10% of scaffold weight. All PCL-TI compositions showed similar 
high gel fractions around 90%, statistically similar to the control EGDMA material. 
 141 
 
Conversely, the PCL-DI at 10 wt% had a gel fraction of 90% but decreased to 82 and 
79% for the 20 and 30 wt% PCL-DI formulations. FTIR analysis of the extraction 
solutions confirms the presence of PCL-DI for each the 10, 20, and 30 wt% samples, 
signifying that those materials are likely semi-IPNs with linear PUU chains physically 
entangled within the EGDMA network. This is expected due to the inability of PCL-DI 
to form covalent crosslinks and to instead grow linearly in molecular weight. 
Furthermore, FTIR of the PCL-TI specimens revealed only the presence of 
unfunctionalized PCL-triol, characterized the lack of urethane or urea associated peaks, 
and no traces of PCL urethane-ureas. Considering the functionalization of the PCL-TI 
was ~85%, some unfunctionalized species are expected but rare as it is more likely that 
molecules would functionalize at least 1 or 2 of the available alcohol groups. This 
implies that the PCL-TI forms full IPNs even at 10 wt% concentrations. 
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Figure A.2. Effect of IPN polyHIPE composition on gel fraction. 
 
 
Varying the ratio of PCL-DI:PCL-TI had little effect on gel fraction, except for 
the 20% DI:0% TI (discussed above) which showed significantly lower gel fraction than 
the others. This is the only composition of the set without any ability to form covalent 
crosslinks and thus was expected to form only a semi-IPN. This data shows that even as 
little as 5% PCL-TI crosslinker and 15% PCL-DI is enough to form a fully crosslinked 
PUU network. 
While this data can be used to infer whether full or semi-IPNs have been created, 
more extensive work would need to be done. For example, if a linear polymer’s 
molecular weight increased enough it would be difficult to remove from a crosslinked 
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polymer network. Although it would not truly be an IPN, it could behave like one due to 
the number of chain entanglements. Alternatively, Lumelsky et al. reported that excess 
PCL began to phase separate from the acrylate network to form phase separated regions 
of their material with vastly different properties.
116
 If the individual components have 
sufficiently different Tg’s, DSC or DMA can be used to measure phase mixing.116 
A.3.3 Mechanical Response PolyHIPE modulus and strength decreased as PCL 
content was increased, Figure A.3. The control EGDMA polyHIPE possessed a 
modulus of ~20 MPa and strength ~1.4 MPa. The modulus for PCL-DI IPNs decreased 
to 15 MPa for 10 wt% and ~6 MPa for the 30 wt% compositions respectively. Similarly, 
strength decreased to 0.8 and 0.5 for the 10 and 30 wt% PCL-DI IPNs. PCL-TI 
containing polyHIPEs exhibited lower average moduli than their PCL-DI equivalent, but 
similar strengths at 10 and 20 wt% concentrations.   
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Figure A.3. Effect of PCL-DI and –TI content on IPN polyHIPE compressive (A) 
modulus and (B) strength. 
 
 
Varying the ratio of PCL-DI:PCL-TI had very little effect on compressive 
properties with the exception of the 20% DI:0% TI which was significantly lower than 
the rest, Figure A.4. Unlike the others, the 20% DI:0% TI polyHIPE was the only semi-
IPN in the set with no ability to form a covalently crosslinked PUU network. Without 
the second network to help resist strain, overall crosslink density decreased and therefore 
behaved as expected. 
 
0
5
10
15
20
25
PCL-DI PCL-TI
C
o
m
p
re
s
s
iv
e
 
M
o
d
u
lu
s
 (
M
P
a
)
PCL Content
(wt%)
0%
10%
20%
30%
0
0.5
1
1.5
2
PCL-DI PCL-TI
C
o
m
p
re
s
s
iv
e
 
S
tr
e
n
g
th
 (
M
P
a
)
PCL Content
(wt%)
0%
10%
20%
30%
  : P <0.05 compared to all other polyHIPEs 
†:   < .      p                     L-DI 
‡:   < .      p                     L-TI 
●: P <0.05 compared to 30% PCL-DI and 30% PCL-TI 
B) Varied PCL Content 
A) Varied PCL Content 
  
  
†● 
†● 
‡● 
‡● 
  
 145 
 
 
Figure A.4. Effect of PCL-DI:PCL-TI ratio on IPN polyHIPE compressive (A) modulus 
and (B) strength, with 80 wt% EGDMA. 
 
 
In the PUU polyMIPEs from Chapter III, PCL-DI scaffolds exhibited an 
increased modulus and strength due to hydrogen bonding forming physical crosslinks 
between chains which increased effective crosslink density and thus mechanical 
properties. In this redox system, the EGDMA network forms much faster than the PUU 
and possibly prevents the chain reorganization necessary to create secondary bonds, 
yielding a weaker and more pliable material. 
Increasing PCL content was expected to decrease compressive modulus because 
overall crosslink density is decreasing, especially for the PCL-DI only IPNs. Volume 
that had been taken up by highly crosslinked EGDMA was replaced by the pliable and 
elastomeric PUUs. Figure A.5 shows representative compression curves for each 
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material, and both the PCL-DI and –TI materials show a broadening and disappearing of 
the yield point with increasing PCL content. These materials behave less like the brittle 
EGDMA polyHIPEs and start to resemble the response associated with the pure PUU 
polyMIPEs.
222
 While the decrease in strength is apparent in these plots, the 20% PCL-TI 
remains an anomaly and exhibits higher strengths than the EGDMA control at strains 
greater than 20%. This behavior indicates an increase in mechanical toughness, or 
resistance to brittle fracture. While toughness could not be measured directly in 
compression, all of the IPN polyHIPEs were noticeably less brittle during handling, and 
fractured into larger and fewer pieces with increasing PCL content. 
IPNs are typically stronger than semi-IPNs because of increased crosslink 
density leading to more entanglements between the two networks. There is usually some 
compromise between individual network properties, but Lepine et al. and Lumelsky et 
al. saw the greatest improvement in mechanical properties after crosslinking the two 
materials into the same graft-co-polymer network.
108, 116
 Therefore, future studies should 
investigate changing endgroups between the two macromers to facilitate formation of a 
single graft-co-polymer network with both rigid and elastomeric components. 
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Figure A.5. Representative compression curves for (A) PCL-DI/EGDMA, (B) PCL-
TI/EGDMA, and (C) DI:TI/EGDMA IPN polyHIPEs. 
 
 
A.4 Conclusions 
In conclusion, this data shows that combining the PUU prepolymers and rigid 
EGDMA is a viable method to achieve mechanical properties in between the two types 
of scaffolds. Here, a range of material modulus, strength, and elasticity were be created 
by varying polymer concentration, without sacrificing injectability. Previously, IPN 
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fabrication required a two-step process, making the first network and then swelling it in 
a solvent/component B mixture to make the IPN. This method requires no solvent to 
make the IPN and is a one-step process, reducing fabrication costs and time. 
However, these IPNs did not increase the fracture toughness of the brittle 
EGDMA polyHIPEs, and the only composition which did sacrificed too much in terms 
of modulus and strength. Therefore, alternative options to increase toughness should be 
considered. 
 
 
 
